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  Histone deacetylase inhibitors (HDIs) are a novel class of chemotherapeutics that have 
potent anti-proliferative and cytotoxic properties in many cancer-derived cell lines.  Research has 
demonstrated that these compounds can activate genes such as the cell cycle inhibitor p21
WAF1
, 
while repressing the SRC and MYC proto-oncogenes.  To investigate the effects of several HDI 
compounds in a panel of breast cancer-derived cell lines, a reverse transcriptase qPCR (RT-
qPCR) and immuno-blotting approach was used.  These compounds corresponded to various 
classes of these therapeutic drugs, and include Trichostatin A (TSA), Apicidin, Entinostat and 
Mocetinostat, while the cell lines were representative of the heterogeneity of breast cancer.  It 
was hypothesised that while these drugs demonstrate similar cellular responses such as enhanced 
histone acetylation, cytotoxicity and p21
WAF1 
induction, they have different effects on their ability 
to repress genes.  Using qPCR techniques, the expression of the p21
WAF1
, SRC and MYC was 
analysed following HDI treatment in four cell lines.  SRC repression were observed in all cell 
lines following TSA and Apicidin treatment, whereas the effects of Entinostat and Mocetinostat 
were more diverse; these compounds had no effect or induced expression of SRC in T47D, 
Hs578T and HCC-1419 cell lines while repressing expression in the BT-474 cell line.  The 
expression of MYC was down-regulated with TSA only in T47D and BT474 cell lines, while 
Apicidin, Entinostat and Mocetinostat induced expression in all cell lines.  However, these four 
inhibitors induced p21
WAF1
 while exhibiting cytotoxicity and histone acetylation.  In addition, it 
has been illustrated in the literature that RNA polymerase II-transcribed miRNA can be 
epigenetically modulated by chromatin-remodelling drugs.  Therefore, the expression of tumour 
suppressor miRNA was analysed following drug treatment, and it was observed that HDIs up-
regulated the expression of certain miRNAs in a cell-specific manner.  miR-129-5p was induced 
with TSA and Entinostat in the T47D cell line, while miR-424 increased following TSA, 
Entinostat and Mocetinostat treatment in T47D and Hs578T cell lines.  In addition, TSA induced 
expression of miR-9-3p in T47D, Hs578T and HCC-1419 cell lines.  It was further determined 
that induction of these miRNA genes down-regulated the protein and/or mRNA expression of 
their target genes.  The data presented in this thesis highlight the complex nature and the myriad 
effects of these inhibitors, and suggest that certain chemotherapeutics might have a clinical 
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1. REVIEW OF THE LITERATURE 
 
1.1 Introduction  
 
Malignancies can develop through dysfunctional cellular processes that result from 
inactivation of tumour suppressor genes and/or activation of oncogenes (Stearns et al., 2007; 
Podo et al., 2010).  These can arise through many processes, including epigenetic modifications 
such as promoter CpG methylation by DNA methyltransferases and imbalances in histone 
acetylation by histone acetyltransferases and histone deacetylases (HDACs).  The dysregulation 
of epigenetic mechanisms represents a level of gene control that can be exploited by chromatin-
remodelling chemotherapeutics.  Within Canada, it was estimated that ninety thousand women 
would develop cancer in 2014, with one in every nine women having a risk to develop breast 
cancer in their lifetimes (Canadian Cancer Statistics, 2014).  Histone deacetylase inhibitors 
(HDIs) are a novel class of chemotherapeutics that preferentially affect cancerous cells, leading 
to apoptosis, cell cycle arrest and differentiation (Mehnert et al., 2007; Ma et al., 2009; Wanczyk 
et al., 2011; Nebbioso et al., 2010).  It is traditionally thought that HDI treatment facilitates 
histone acetylation and transcriptional activation through inhibiting HDAC enzymes.  However, 
only a small fraction of genes are up-regulated in this manner; in fact, many genes are also 
repressed upon drug treatment (Van Lint et al., 1996; Gray et al., 2004; Marks et al., 2004; Peart 
et al., 2005; Ropero and Esteller, 2007; LeBonte et al., 2009; Halsall et al., 2012; Khan et al., 
2012).  The SRC and MYC proto-oncogenes are over-expressed in many cancers, including those 
of the breast (Escot et al., 1986; Wong et al., 1986; Dubik et al., 1987; Blanchard et al., 1988; 
Cartwright et al., 1989, 1990; Brunton et al., 1997; Iravani et al., 1998; Dehm and Bonham, 
2004; Alvarez et al., 2006; Chen and Olopade, 2008; Wheeler et al., 2009; Horiuchi et al., 2012), 
and are repressed following HDI treatment (Kostyniuk et al., 2002; Dehm and Bonham, 2004; 
Hirsch et al., 2006; Bonham and Beaton-Brown, unpublished data).  While these mechanisms are 
currently unknown, it likely involves the adoption of a promoter proximal paused state which is 
associated with the loss of histone H3 phosphorylation, recruitment of the negative elongation 
factor NELF and further de-phosphorylation of the CTD region of RNA polymerase II (RNA pol 
II) and loss of the complex from the gene body (Bonham and Beaton-Brown, unpublished data).  
Furthermore, cellular processes affected by HDIs are often myriad and cell-specific; for example, 
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certain chemical classes of HDIs affect cell cycle arrest and apoptosis in a differential manner.  In 
addition, only a small percentage of genes are similarly regulated by the same HDI (Halsall et al., 
2012; Chatterjee et al., 2013).  It has also been shown that microRNA (miRNA) transcribed by 
RNA pol II are induced or repressed following HDI administration (Lu et al., 2005; Scott et al., 
2006).  These non-coding miRNAs control numerous cellular processes important in the 
pathogenesis of many malignancies, including cancer (Iorio et al., 2005; Lu et al., 2005; Scott et 
al., 2006; Lowery et al., 2009).  The experiments presented in this thesis investigated differential 
HDI-mediated effects on histone acetylation, cell viability and gene expression in four breast 
cancer cell lines representative of the heterogenous nature of breast cancer.  Furthermore, the 
effects of these compounds upon miRNA expression and subsequently miRNA-mediated gene 
and protein regulation were explored.  The data presented demonstrate divergences between the 
effects of these drugs in diverse breast cancer subtypes.  This literature review briefly summarises 
vital aspects of the pathological and molecular subtypes of breast cancer and associated 
therapeutics.  The current knowledge of HDACs and HDIs are then reviewed, followed by a 
detailed background in the context of cancer and transcriptional control on p21
WAF1
 and the 
proto-oncogenes SRC and MYC.  Finally, miRNA and their associated cellular regulatory 
processes are discussed.   
  
1.2 Breast Cancer 
 
Malignant tumours arise through the accumulation of defects in cellular regulatory 
processes, including metabolic alteration, evasion of the cell cycle control checkpoints, faulty 
DNA repair mechanisms, apoptotic defects and invasive properties leading to metastasis.  These 
dysfunctional processes can result from the silencing and inactivation of tumour suppressor genes 
and/or the activation of oncogenes (Lengauer et al., 1998; Hanahan and Weinberg, 2000; 
Volgstein and Kinzler, 2004).  Multiple levels of inactivation and activation can arise through 
translocations, mutations, amplifications, deletions and/or epigenetic alterations, such as 
promoter methylation and/or chromatin remodelling via altered histone acetylation.  Epigenetic 
mechanisms represent an alternative method of gene control, which does not alter the nucleotide 
sequence.  The most commonly studied of these is the methylation of CpG dinucleotides in 
promoter regions, enzymatically carried out by DNA methyltransferases (DNMTs) in dividing 
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cells.  Another well-known epigenetic modulation is post-translational histone modifications, 
some of which are mediated by histone deacetylase (HDAC) enzymes (Lengauer et al., 1998; 
Hanahan and Weinberg, 2000; Volgstein and Kinzler, 2004; Stearns et al., 2007; Elias, 2010; 
Podo et al., 2010; Timp and Feinberg, 2013), which are the focus in a forthcoming section.   
  Breast carcinoma is considered a group of clinically and pathologically heterogeneous 
malignancies, and attempts to cluster these diseases into homogenous entities have only been 
partially successful (Elias, 2010).  Annually, over one and a half million women worldwide are 
diagnosed with breast tumours, and it has become the most common cancer in women 
(Bouchalova et al., 2009; Tate et al., 2012; Ferlay et al., 2015).  In a statistical report released by 
the Canadian Cancer Society, it was estimated that ninety thousand women developed cancer in 
2014, with twenty-six percent of these cases representing new diagnoses of breast cancer.  
Moreover, one in every nine women has the potential to develop the disease in their lifetime 
(Canadian Cancer Statistics, 2014).   
 
1.2.1 Pathological and Molecular Classes of Breast Cancer 
 
  There are two common histological categories of breast carcinoma, ductal and lobular 
(Bouchalova et al., 2009; Malhotra et al., 2010).  Lobular carcinomas develop from the lobules 
glands in the breast, whereas ductal carcinomas originate from the lactiferous ducts and are the 
most frequently diagnosed histological pattern.  Both ductal and lobular carcinomas can remain 
in situ or become invasive and migrate from their sites of origin.  In fact, invasive ductal 
carcinoma encompasses various subtypes, including medullary carcinoma, mucinous carcinoma 
and papillary carcinoma (Malhotra et al., 2010).   
  Breast cancers have historically been classified based on histological and morphological 
features, as well as by the ‘TNM’ system consisting of tumour size, lymph node status and 
metastatic occurrence.  Based on this classification, breast tumours were categorised into 
eighteen histological subtypes, which failed to form homogeneous clusters (Elston and Ellis, 
1993; Tavassoli and Devilee, 2003; Weigelt et al., 2008; de Ruijter et al., 2010; Malhotra et al., 
2010).  DNA microarray analysis has provided an additional method for breast cancer 
classification, based upon gene expression profiling of the transcriptome.  This has further 
illustrated its heterogeneous nature (Sorlie et al., 2001); gene expression profiling does not form 
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homogeneous clusters similar with the historical histo-morphological clustering.  Therefore, 
breast cancer is considered a heterogeneous disease with considerable phenotypic and genetic 
diversity (Perou et al., 2000; Sorlie et al., 2001; de Ruijter et al., 2010), several of which are 
discussed shortly.   
Following diagnoses, patient prognosis is determined based on several factors, such as 
tumour size and grade, lymph node metastases, vascular tumour invasion, amplification of the 
HER2/neu oncogene, and the presence or absence of oestrogen receptor-alpha (ERα) and 
progesterone receptor (PgR) (Table 1.1).  The most striking division of breast cancer is between 
the presence or absence of these hormone receptors; those breast cancers which are positive for 
ERα and PgR expression can be further divided into ‘luminal A’ and ‘luminal B’ based on the 
amplification of the erythroblastosis oncogene B2 (ERBB2) gene and its protein product, the 
human epidermal growth factor receptor 2 (HER2/neu).  Luminal A cancers have normal 
HER2/neu expression, whereas luminal B have enriched HER2/neu expression (Sorlie et al., 
2001, 2003; de Ruijter et al., 2011; Renoir, 2012).  In contrast, the basal subtype is most often 
triple-negative breast tumours and therefore lacks ERα and PgR expression, and HER2/neu is not 
amplified and/or over-expressed.  The last major subtype based on gene expression profiling is 
the HER2-amplified category, which is frequently negative for ERα and PgR expression but 
possesses amplified HER2/neu as the nomenclature suggests (Sorlie et al., 2001, 2003; Bertucci, 
2008; de Ruijter et al., 2010; Renoir, 2012).  In addition, certain oncogenic mutations have been 
shown to cluster with either ERα-positive or ERα-negative cancers, such as mutations in the 
PTEN and Rb1 tumour suppressors which associate with triple-negative breast cancers (Hu et al., 
2009; de Ruijter et al., 2010).  While these aforementioned divisions are beneficial for prognostic 
value, they also assist in determining clinical therapeutic options and predict patient response 
(Bouchalova et al., 2009; Renoir, 2012).   
 
1.2.2 Breast Cancer Therapy 
 
 The identification of the ERα and HER2/neu molecular markers has facilitated the 
movement toward personalised therapy targeted against ERα expression and HER2/neu 
amplification (Bouchalova et al., 2009; Podo et al., 2010; Renoir, 2012).  Personalised therapy 


















Table 1.1.  The common molecular subtypes of breast cancer.  Luminal A and B express the 
hormone receptors ERα and PgR, whereas expression is absent in basal and HER2-amplifed.  The 
HER2/neu protein and/or gene is amplified only in Luminal B and the HER2-amplified subtypes. 
 
 ERα and PgR HER2/neu 
Luminal A present normal 
Luminal B present amplified 
Basal absent normal 







to treat patients.  This method of treatment interferes with specific molecules highly expressed in 
the cancerous tissue and is relatively ineffective in normal cells (de Ruijter et al., 2010; Podo et 
al., 2010).  Numerous biomolecules such as metabolites, proteins and enzymes are considered 
candidate biomarkers in breast cancer pathogenesis.  The first personalised anti-hormonal 
therapies for breast cancer were targeted against ERα and/or PgR, whereas the identification of 
the HER2/neu gene was the first cytogenic marker (Bouchalova et al., 2009; Podo et al., 2010).  
The presence of ERα and PgR, and HER2/neu amplification are the subdivisions of breast cancer 
clinicians frequently employ, resulting in three main subtypes: ERα-positive, HER2-amplified 
and triple-negative.  These subtypes are further stratified based on their therapeutic potential and 
prognoses (Elias, 2010) and are briefly discussed below.  
 
1.2.2.1 ERα-Positive Breast Cancers 
 
In normal development, oestrogens control the physiological growth and differentiation of 
normal mammary tissue through the actions of the ERα and oestrogen receptor beta (ERβ).  
These are members of the nuclear receptor superfamily of transcription factors and possess a 
carboxy terminal ligand-binding domain necessary for activation and dimerisation.  In response 
to the presence of oestrogens, dimerisation results in a conformational change, allowing 
interaction with numerous transcription regulators.  These multi-protein complexes bind to ER-
responsive elements and alter chromatin structure, ultimately leading to altered gene expression 
(Jenuwein and Allis, 2001; Sommer and Fuqua, 2001; Margueron et al., 2004; Pathiraja et al., 
2010; Renoir, 2012). 
 Through the action of ERα and ERβ, oestrogens act as mitogens and control numerous 
cellular functions critical in hormone-responsive carcinogenesis (Henderson et al., 1982; Conzen 
2008; Cicatiello et al., 2010; Pathiraja et al., 2010).  While the function of ERβ in breast cancer 
progression is relatively unknown, the role of ERα has been extensively studied (Pathiraja et al., 
2010; Renoir, 2012).  Oestrogens alter gene expression in ERα-positive luminal A and luminal B 
cell lines (Cicatiello et al., 2010), and inhibiting these pathways is therapeutically beneficial 
(Cicatiello et al., 2010; de Ruijter et al., 2010).  In fact, signalling from ERα is one of the 
significant determinants of tumorigenesis in ERα-positive breast cancers, which accounts for 
approximately sixty-five to seventy percent of breast cancer diagnoses (Thomas et al., 2011). 
 7 
 
 With the advent of individualised therapy, these oestrogen-dependent, ERα-positive 
cancers can be treated with anti-hormonals (Swain et al., 2005; Goss et al., 2008; Thomas and 
Munster, 2009; de Ruijter et al., 2010; Podo et al., 2010; Sabnis et al., 2011; Thomas et al., 
2011).  The preferred treatment for hormone-sensitive cancers is targeting ERα through anti-
oestrogen molecules, although less than fifty percent of ERα-positive cases continually respond 
to endocrine therapy; de novo and acquired resistance occur in a quarter of ERα-positive tumours.  
This resistance is thought to result from transcriptional inactivation of ERα through mechanisms 
such as promoter methylation (Katzenellenbogen, 1991; Ottaviano et al., 1994; Thomas and 
Munster, 2009; Zilli et al., 2009; Pathiraga et al., 2010; Osborne et al., 2011; Retnoir, 2012).  
Tamoxifen, through its conversion to 4-hydroxytamoxifen, binds to ERα and competes with 
oestrogen binding, thus preventing ERα-dependent signalling.  This alters the expression of 
oestrogen-responsive genes and generally inhibits oestrogen-dependent cellular growth (Thomas 
and Munster, 2009; Thomas et al., 2011).  In addition, aromatase inhibitors can be exploited to 
reduce the synthesis of oestrogen from testosterone and androenedione through the activity of the 
enzyme aromatase (Pathiraja et al., 2010; Retnoir, 2012). 
  Several reports have indicated that ERα expression can be modulated through chromatin 
remodelling drugs such as DNA methyltransferases (DNMTs) and histone deacetylases (HDACs) 
(Yang et al., 2000; Keen et al., 2003; Yan et al., 2003; Stearns et al., 2007; Bicaku et al., 2008; 
Stark et al., 2013).  While HDACs in particular are reviewed in an upcoming section, it is 
interesting to note that HDAC inhibition may augment the cytotoxicity of anti-oestrogen 
treatment (Fan et al., 2008; Bicaku et al., 2008; Thomas et al., 2011).  Furthermore, in vitro cell 
line studies have illustrated HDAC inhibitors (HDIs) may in fact increase ERα mRNA expression 
in ERα-negative cells, an effect opposite to that observed within ERα-positive cells (Yang et al., 
2000; Keen et al., 2003; Bicaku et al., 2008; Fan et al., 2008; Thomas et al., 2011).  This 
inducing effect was also observed for PgR mRNA in ERα-negative cells, although functional 
ERα rather than HDI-dependent epigenetic mechanisms may be responsible (Keen et al., 2003; 
Fleury et al., 2008).  The alteration of histone acetylation is not the sole determinant of ERα 
expression however, and DNMT inhibitors (alone or in conjunction with an HDI) have also 
restored ERα levels and re-sensitised ERα-negative cell lines to endocrine therapy (Yan et al., 
2003).  In particular, synergistic treatments of Vorinostat, Trichostatin A (TSA) or Scriptaid with 
the DNMT inhibitor 5-aza-2’deoxycytidine (AZA) increased ERα mRNA expression in ERα-
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negative cell lines (Yang et al., 2000; Keen et al., 2003; Sharma et al., 2004; Jang et al., 2006; 
Stark et al., 2013).   
  Additionally, apoptotic processes are induced when breast cancer cell lines are co-treated 
with an HDI and tamoxifen, and thus HDAC inhibition has been considered a viable treatment 
option for ERα-positive cancers (Bicaku et al., 2008; Fan et al., 2008; Thomas et al., 2011).  
Furthermore, tamoxifen and Vorinostat have been used in combination to treat ERα-positive 
metastatic cancers and restored hormone sensitivity (Munster et al., 2009).  In fact, many clinical 
and pre-clinical studies involving DNMTs and/or HDIs in conjunction with endocrine therapies 
are currently in progress (Bicaku et al., 2008; Fan et al., 2008; Chavan and Somani, 2010; 
Pathiraga et al., 2010; Ferguson et al., 2011; Martinet and Bertrand, 2011; Thomas et al., 2011).  
HDI-mediated effects upon ERα and PgR expression, as well as general non-transcriptional 
effects, are discussed in greater detail in a forthcoming subsection. 
 
1.2.2.2 HER2/neu Amplified Breast Cancers 
 
  The receptor tyrosine kinase HER2/neu is amplified in approximately twenty-five to 
thirty percent of breast carcinomas and is generally indicative of poorer clinical outcomes, lower 
survival rates, increased metastasis and advanced tumour stage with aggressive phenotypes 
(Garcia et al., 1989; Chen et al., 2010; Tagliabue et al., 2010; Kodack et al., 2012).  A high 
incidence of brain metastases is associated with HER2-amplified cancers, likely due to the 
inability of therapeutics to cross the blood-brain barrier (Kodack et al., 2012). 
There are three homologous HER receptor tyrosine kinases (RTKs), HER1 (also known 
as the epidermal growth factor receptor [EGFR]) and HER3 and HER4.  These RTKs hetero- or 
homo-dimerise and autophosphorylate conserved tyrosine moieties to recruit downstream 
signalling proteins.  This enhances cellular proliferation through the induction of growth-
promoting genes.  HER2/neu is ligand-independent and hetero-dimerises with other HER family 
members in the absence of extracellular ligand, thus making it a potent oncogenic kinase (Sorlie 
et al., 2001; Hondermarck, 2003; Citri and Yarden, 2006; Chen et al., 2010). In fact, HER2/neu 
up-regulation is sufficient to induce tumorigenicity in a normal mammary epithelial cell line 
(Kim et al., 2009). 
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  While personalised therapy has lead to the treatment of ERα-positive cancers with anti-
oestrogens and aromatase inhibitors, HER2-amplified cancers can be targeted with trastuzumab, 
an antibody which targets the HER2/neu receptor (Swain et al., 2005; Goss et al., 2008; de 
Ruijter et al., 2010; Sabnis et al., 2011).  Otherwise known in the market as ‘Herceptin’, 
trastuzumab is a humanised monoclonal antibody that blocks HER2/neu activity by targeting the 
extracellular domain IV (Podo et al., 2010).  While trastuzumab has decreased breast cancer-
related mortality, a significant fraction of patients develop resistance or refractory disease, while 
those with brain metastatic disease are incurable.  A secondary avenue of therapy, the humanised 
monoclonal antibody pertuzumab (Perjeta), targets the dimerisation domain of HER2/neu.  This 
prevents dimerisation and has resulted in favourable patient prognosis in clinical trials.  In 
addition, trastuzumab and pertuzumab have exhibited promising results when used in conjunction 
(Piccart-Gebhart et al., 2005; Perez et al., 2011; Slamon et al., 2011; Lamond and Younis, 2014; 
O’Sullivan and O’Connolly, 2014). 
  Interestingly, synergistic treatment of HER2-positive cell lines with the sodium butyrate 
(NaB) and trastuzumab enhanced the anti-proliferative effects of the drugs.  This effect was 
insignificant in HER2-negative cell lines (Chen et al., 2007).  In addition, Vorinostat attenuated 
HER2/neu expression in HER2-positive breast cancer cell lines, and dual-treatment with 
trastuzumab further decreased cellular growth (Bali et al., 2005). 
 
1.2.2.3 Triple-Negative Breast Cancers 
 
 Similar to the HER2-amplified breast cancers, triple-negative account for fifteen to 
twenty percent of breast cancer diagnoses, and are frequently classified as high-grade invasive 
ductal carcinomas (Bouchalov et al., 2009; Elias, 2010).  Triple-negative cancers are often 
associated with an aggressive tumour phenotype and poor prognosis with higher distant 
recurrence rates and reduced overall survival (de Ruijter et al., 2010; Podo et al., 2010).  Patients 
presenting with triple-negative cancers are generally younger in age than those diagnosed with 
ERα-positive cancers, and generally have higher mortality rates.  In addition, there is a higher 
incidence of triple-negative cancers among those of African-American descent (Dent et al., 2007; 
Rakha et al., 2007; Bouchalov et al., 2009; Elias, 2010; Podo et al., 2010).   
While these cancers are often synonymous with the basal subtype, molecular analysis has 
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shown that these are two separate entities.  In general, the basal-like, triple-negative cancers 
present with more chromosomal losses and/or gains than the luminal subtypes (Podo et al., 
2010).  Cytogenetics have also revealed genomic fragile sites common in triple-negative breast 
cancers, such as amplification of the 8q24 and 17q12 loci, corresponding to the MYC and 
HER2/neu genes (Struski et al., 2002; Bouchalova et al., 2009).  MYC is a transcription factor 
thought to control approximately fifteen percent of human genes and its amplification is 
associated with poorer prognosis (Escot et al., 1986; Dubik et al., 1987; Garcia et al., 1989; Nass 
and Dickson, 1997; Levens, 2008; Chen and Olopade, 2008; Horiuchi et al., 2012).  In addition, 
ERα-negative breast cancers have been shown to have higher proliferative rates than ERα-
positive cancers, a characteristic which is often associated with MYC amplification (Wirapati et 
al., 2008).  MYC and its role in carcinogenesis are discussed in greater detail in an upcoming 
section.  In addition, expression of EGFR and mutations in PTEN were more common in triple-
negative breast cancers than other subtypes (Elias, 2010).  The association of mutations in the 
BRCA1 and BRCA2 genes in triple-negative cancers are of particular interest; these familial 
breast cancer predisposing genes are involved with DNA repair and can be exploited in breast 
cancer treatment (Podo et al., 2010). 
 Due to the lack of HER2/neu over-expression and absence of ERα and PgR, the antibody 
trastuzumab and endocrine therapies are unsuccessful in treating these breast cancers.  In 
addition, they currently lack targeted clinical therapies and are partially resistant to treatment.  
However, one avenue of therapy for these breast cancers are cytotoxic chemotherapies that 
induce DNA damage (Elias, 2010; Podo et al., 2010).  The mutation of BRCA1 previously 
mentioned to be correlated with the triple-negative subtype suggests that cisplatin and/or 
carboplatin are promising treatments for these breast cancers (Silver et al., 2010; Elias, 2010; 
Podo et al., 2010; Valero, 2014; von Minckwitz, 2014).  Cytotoxic therapies such as paclitaxel 
and cyclophosphamide have also shown favourable results against triple-negative cancers (Podo 
et al., 2010).  In addition, agents inhibiting the activity of tyrosine kinases such as pp60 c-Src 
have promising pre-clinical results in cancer treatments (Finn et al., 2007; Elias, 2010). 
In addition, the HDI panobinostat has been shown to be cytotoxic to triple-negative cell 
lines and able to reduce tumour growth in vivo.  This was associated with a partial mesenchymal-
to-epithelial transition in morphology, indicative of diminished invasive properties (Tate et al., 
2012).  However, while HDIs induce apoptosis and promote autophagy, cancer cells with 
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defective apoptotic systems can survive treatment (Shao et al., 2004).  Combining an autophagy 
inhibitor with panobinostat has demonstrated reduced tumour burden and increased survival in 
mouse xenograft models of triple-negative breast cancer (Rao et al., 2012).  Dual therapy of 
Vorinostat with a kinase inhibitor or receptor antagonist further potentiated anti-tumour effects of 
the chemotherapeutics, indicating novel therapeutic strategies involving HDAC inhibitors (Fiskus 
et al., 2012; Stark et al., 2013).  Furthermore, while triple-negative cancers remain difficult to 
treat due to a lack of targeted therapies, HDI treatment of ERα-negative cell lines and derived 
xenografts re-sensitise these tumours to hormone treatment.  This is partially through activating 
ERα expression, where anti-oestrogens and aromatase inhibitors are then rendered effective (Jang 
et al., 2004; Margueron et al., 2004; Li et al., 2010; Munster et al., 2011; Gryder et al., 2013; 




Although breast carcinoma related deaths have been decreasing since the 1980s, with the 
morality rate falling approximately 40%, it remains the second leading cause of cancer-related 
deaths among women in Canada (Canadian Cancer Statistics, 2014).  In the clinic, patient 
tumours are stratified according to their histolo-morphological features and gene expression 
patterns, and these subtypes determine clinical therapy and are able to predict patient outcome 
(Bouchalova et al., 2009; Podo et al., 2010; Renior 2012).  ERα-positive disease accounts for the 
majority of diagnoses, while HER2-amplified and triple-negative account for the remaining 
fifteen to twenty percent (Tagliabue et al., 2010; Thomas et al., 2011; Kodack et al., 2012).  
While ERα-positive and HER2-amplified tumours can be treated with anti-hormonals and 
receptor-targeted antibodies, personalised therapies remain ineffective against triple-negative 
cancers (de Ruijter et al., 2010; Podo et al., 2010; Sabnis et al., 2011; Thomas et al., 2011).  As 
previously mentioned, one mechanism by which ERα transcription is silenced in ERα-negative 
tumours is via histone modification and/or promoter methylation.  Histone acetylation is 
generally associated with active transcription, and manipulating the acetylation status is a viable 
therapeutic option for many cancers, as briefly highlighted (Yang et al., 2000; Keen et al., 2003; 
Jang et al., 2004; Sharma et al., 2006; Tsai and Baylin, 2011; Stark et al., 2013).  This dynamic 
process is controlled by a set of reciprocally-acting enzymes known as HDACs and histone 
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acetyltransferases (HATs), proteins which are frequently deregulated in numerous carcinomas, 
including those of the breast (Allfrey, 1964; Roth et al., 2001; Khorasanizadeh, 2004; Sjoblom et 
al., 2006; Ma et al., 2009; Bannister and Kouzarides, 2011; Wanczyk et al., 2011; Barneda-
Zahonero and Parra, 2012; Timp and Feinberg, 2013).  While examples of HDI administration in 
breast cancer have been described earlier, a more detailed analysis of the HDAC enzymes and the 
consequences of their inhibition follows.  
 
1.3 Histone Deacetylases 
 
In eukaryotic organisms, genomic DNA is packaged into highly structured chromatin 
fibres within the nucleus.  The main component of chromatin is the nucleosome, DNA segments 
of 147 base-pairs wrapped around the core histone octamer, which consists of two copies of 
histones H2A, H2B, H3 and H4 (Wolffe, 1994; Khorasanizadeh, 2004; Barneda-Zahonero and 
Parra, 2012).  The amino-terminal histone tails that extend from the nucleosomes are enriched 
with lysine moieties, and the positive charge facilitates histone-histone and/or histone-DNA ionic 
interactions (Hebbes et al., 1988; Ridsdale et al., 1990; Kelly and Cowley, 2013).  Epigenetic, 
post-translational histone modifications have the ability to modify these chromatin structures, 
subsequently controlling transcriptional activation or repression (Khorasanizadeh, 2004; Ropero 
and Esteller, 2007; Barneda-Zahonero and Parra, 2012).  These include the phosphorylation of 
serine or tyrosine residues, the methylation of arginines, and the ubiquitination, methylation, 
sumoylation or acetylation of lysines (Khorasanizadeh, 2004; Mehnert and Kelly, 2007; 
Bannister and Kouzarides, 2011; Barneda-Zahonero and Parra, 2012).   
Histone acetylation and deacetylation are reversible enzymatic reactions controlled by the 
reciprocally-acting histone acetyltransferases (HATs) and HDACs.  While HATs catalyse the 
addition of an acetyl group from acetyl-CoA to the epsilon-amino group of lysines, HDACs act to 
remove the acetyl group as an acetate molecule (Allfrey, 1964; Roth et al., 2001; 
Khorasanizadeh, 2004; Santos-Rosa et al., 2005; Bannister and Kouzarides, 2011; Barneda-
Zahonero and Parra, 2012).  This acetylation neutralises the positive charge of the lysine residue, 
minimising ionic interactions and resulting in a relaxed or ‘open’ chromatin conformation (called 
‘euchromatin’) that facilitates transcription factor binding (Felsenfeld, 1992; Wolffe, 1994; Ueda 
et al., 2006; Ropero and Esteller, 2007; Haberland et al., 2009; Wang et al., 2010; Barneda-
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Zahonero and Parra, 2012).  Histone acetylation also decreases association with the linker histone 
H1 (Kelly and Cowley, 2013) and forms a binding site for bromodomain-containing proteins 
(Halsall et al., 2012; Kelly and Cowley, 2013); therefore, acetylation is generally associated with 
transcriptionally active genomic regions.  A condensed or ‘closed’ chromatin conformation, 
referred to as ‘heterochromatin’, is associated with higher nucleosome density.  This prevents the 
formation of pre-initiation complexes and access to transcriptional machinery and is thus 
associated with inactive genes (Felsenfeld, 1992; Wolffe, 1994; Ropero and Esteller, 2007; 
Haberland et al., 2009; Barneda-Zahonero and Parra, 2012; Halsall et al., 2012; Timp and 
Feinberg, 2013).  The proteins which modify chromatin structure are generally known as 
‘writers’ of histone acetylation, whereas proteins which recognise these chromatin markers are 
referred to as ‘readers’.  For instance, the acetylation of histone H3 lysine 9 (H3K9Ac) and the 
tri-methylation of histone H3 lysine 3 (H3K4me
3) ‘written’ by HAT enzymes are associated with 
active transcription.  These chromatin marks are then ‘read’ by the bromodomain-containing 
proteins and/or transcription factors to result in transcriptional activation (Ropero and Esteller, 
2007; Tsai and Baylin, 2011; Marmorstein and Zhou, 2014). 
In addition to their effects on histone deacetylation, HDACs also remove acetyl groups 
from lysine residues on an ever-increasing amount of non-histone cytosolic and nuclear proteins.  
Currently, approximately 1700 of these proteins have been identified, and a single protein could 
have two or more lysines potentially targeted for acetylation (Kim et al., 2006; Peng and Seto, 
2011; Barneda-Zahonero and Parra, 2012; Kelly and Cowley, 2013).  Due to this, HATs and 
HDACs are becoming more known as lysine acetyltransferases (KATs) and lysine deacetylases 
(KDACs) in the literature (Roth et al., 2001; Santos-Rosa et al., 2005; Allis et al., 2007), but will 
be referred to as ‘HATs’ and ‘HDACs’ in the forthcoming sections.  Furthermore, histone 
acetylation is also associated with chromatin assembly, DNA damage response and 
recombination (Vidanes et al., 2005; Polo et al., 2005; Ropero and Esteller, 2007).  These non-
histone targets and physiological effects of HDACs are discussed following a brief introduction 
into the mechanistic action and biology of HDAC enzymes. 
 
1.3.1 Mechanisms of HDAC Action and Structural Classes of HDACs 
 
Currently, there are eighteen human HDAC enzymes divided into four categories based 
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on their sequence homology to yeast HDACs, as well as their catalytic mechanisms (Figure 1.1).  
Classes I, II and IV require a zinc divalent cation (Zn
2+
) for their deacetylase activity, while the 
third class requires nicotine adenine dinucleotide (NAD
+
) for catalysis (Thiagalingam et al., 
2003; Ropero and Esteller, 2007; Xu et al., 2007; Schrump, 2009; Wanczyk et al., 2011).  The 
Zn
2+
-dependent HDACs have an active site with adjacent histidine and aspartate residues, a 
tyrosine (or histidine) residue and a Zn
2+ 
ion (Bressi et al., 2007; Delcuve et al., 2013).  HDACs 
exert their effects through nucleophilic attack of a zinc-activated H2O molecule on the carbonyl 
carbon of the substrate acetyl group, resulting in an oxyanion intermediate.  The negative charge 
of the intermediate is stabilised through interactions of the Zn
2+ 
ion and the tyrosine at the active 
site.  The resulting acetate molecule and de-acetylated lysine protein substrate are produced by 
proton transfer (Finnin et al., 1999; Vannini et al., 2007; Shuetz et al., 2008). 
 
1.3.2 Structural Classes of HDACs 
 
The class I HDACs (1, 2, 3 and 8) share sequence homology to the yeast transcriptional 
regulator Rpd3.  They are ubiquitously expressed in all tissues and predominantly localised to the 
nucleus, with the exception of the nuclear and cytosolic HDAC3 (Yang et al., 2002; Mehnert and 
Kelly, 2007; Khan and La Thangue, 2012).  Class I HDACs possess a nuclear localisation signal 
and are low molecular weight molecules, between 22 kDa and 55 kDa (Mehnert and Kelly, 2007; 
Khan and La Thangue, 2012).  They have the highest catalytic rates and share similar protein 
structures, containing a conserved deacetylase domain, an amino-terminal extension and a 
carboxy-terminal extension (Yang et al., 2008; Nebbioso et al., 2010; Segre et al., 2011; 
Wanczyk et al., 2011; Barneda-Zahonero and Parra, 2012; Kelly and Cowley, 2013); in 
particular, HDACs 1 and 2 share 83% sequence identity between them, while HDAC3 only 
shares 53% identity to HDACs 1 and 2 (Kelly and Cowley, 2013), containing a variable carboxy 
terminal region non-homologous to other HDACs.  (Karagianni and Wong, 2007).  Interestingly, 
this region is also required for its deacetylase activity (Yang et al., 2002). 
The class II HDACs are based on their domain organisation and sequence similarity to the 
yeast protein Hda1, and are further divided according to their structures and 
compartmentalisation into subgroup IIa (HDACs 4, 5, 7 and 9) and subgroup IIb (HDACs 6 and 
10) (Grozinger et al., 1999; Bieliauskas and Pflum, 2008; Schrump, 2009; Nebbioso et al., 2010; 











Figure 1.1.  Schematic representations of the structures and cellular localisations of the 
human histone deacetylase enzymes.  The ubiquitous class I HDACs (1, 2, 3 and 8) share 
structural homology to the yeast transcriptional regulator Rpd3 and are located in the cytoplasm 
and/or nucleus.  The tissue-specific class II HDACs are homologous to the yeast protein Hda1 
and are further divided based on domain organisation into class IIa (HDACs 4, 5, 7, and 9) and 
class IIb (HDACs 6 and 10).  The primary structure and organisation of the HDAC enzymes are 





Contrary to the class I HDACs, the class II enzymes exhibit tissue-specificity, with expression in 
the heart, liver and/or kidney, and are involved with differentiation and developmental processes 
(Bannister and Kouzarides, 2011; Barneda-Zahonero and Parra, 2012).  These are higher 
molecular weight molecules, between 120 kDa and 135 kDa (Egger et al., 2004; Laird, 2005; 
Mehnert and Kelly, 2007), and shuttle between the nucleus and cytoplasm, with subgroup IIa 
possessing a nuclear localisation signal while subgroup IIb lacks this domain (Khan and La 
Thangue, 2012).  The negligible catalytic activity of the class II HDACs is likely due to the 
histidine substitution at their active site, rather than the tyrosine residue present in the class I 
HDACs.  The class II enzymes have therefore been classified as ‘pseudo-enzymes’ and could 
function in non-enzymatic cellular roles (Lahm et al., 2007; Yang et al., 2008; Parra and Verdin, 
2010; Barneda-Zahonero and Parra, 2012; Sun et al., 2013).  It is also thought that any detectable 
deacetylase activity is due to their interaction with HDAC3 in co-repressor complexes (Fischel et 
al., 2002; Sun et al., 2013), discussed in further detail below.  Despite this, these HDACs have a 
conserved catalytic deacetylase domain and an amino-terminal domain containing a regulatory 
serine residue that undergoes phosphorylation (Yang et al., 2008; Parra and Verdin, 2010; 
Barneda-Zahonero and Parra, 2012; Kelly and Cowley, 2013).  HDACs 6 and 10 of subgroup IIb 
are unique in their structures in that they contain a second homologous deacetylase domain 
(Hubbert et al., 2002; Zou et al., 2006; Yang et al., 2013).  Additionally, HDAC6 contains a 
carboxy-terminal ubiquitin-binding zinc finger domain and a nuclear export signal (Seigneur-
Berny et al., 2001; Khan and La Thangue, 2012; Yang et al., 2013), and HDAC7 has an HDAC-
specific zinc binding motif neighbouring the active site.  It is likely that this domain functions in 
substrate recognition and protein-protein interactions (Schuetz et al., 2008).   
 The last Zn
2+
-dependent class of HDACs is class IV, which contains only HDAC11.  It 
shares conserved residues between both class I and II HDACs (Haberland et al., 2009; Barneda-
Zahonero and Parra, 2012) and resides in the cytoplasm and nucleus (Kawaguchi et al., 2003; Liu 
et al., 2008; Yang and Seto, 2008; Khan and La Thangue, 2012).  There has been little research 
into the function of HDAC11, but it is highly expressed in a tissue-specific manner, particularly 
in the kidney, brain and heart (Gao et al., 2002; Liu et al., 2008; Villagra et al., 2009).   
Class III HDACs (SIRT 1 through SIRT 7) are structurally homologous to the yeast Sir2 
protein and, as mentioned previously, require NAD
+
 rather than Zn
2+ 
for catalysis.  Due to this 
difference in co-factor dependency, the class III HDACs are insensitive to HDI-mediated 
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inhibition (Dockmanovic et al., 2007) and will not be discussed in detail in this review.     
 
1.3.3 Multi-Protein HDAC Co-Repressor Complexes 
 
Class I and II HDACs cannot directly bind to DNA and are likely inactive without their 
activating partners.  They exist in large multi-protein co-repressor complexes known as Sin3, 
NuRD (nucleosome remodelling and deacetylating), CoREST (co-repressor for element-1-
silencing transcription factor), and NCoR/SMRT (nuclear receptor co-repressor/silencing 
mediator of retinoic and thyroid receptors), depending on the HDAC present (Zhang et al., 1999; 
Goodson et al., 2005; Ropero and Esteller, 2007; Perissi et al., 2010; Kelly and Cowley, 2013; 
Sun et al., 2013).  HDACs 1 and 2 can form hetero- or homo-dimers (Luo et al., 2009; Delcuve et 
al., 2013) and are subunits within Sin3, NuRD and CoREST (Figure 1.2 A)  (Yang and Seto 
2008; Barneda-Zahonero and Parra, 2012), whereas HDAC3 dimerises with the class II HDACs 
and is found within the NCoR/SMRT complex (Figure 1.2 B) (Li et al., 2000).  The co-repressor 
complex(es) associated with HDAC8 have yet to be identified (Barneda-Zahonero and Parra, 
2012).   
These multi-protein complexes are then targeted to chromatin by transcription factors 
such as p53, GATA4, E2F, pRb and/or STAT3 (Marks et al., 2004; Drummond et al., 2005; Lin 
et al., 2006; Liu et al., 2006; Mehnert and Kelly, 2007; Delcuve et al., 2013) and/or chromatin-
altering enzymes (Zhang et al., 1999; Ropero and Esteller, 2007; Kelly and Cowley, 2013).  In 
addition, methylated DNA can recruit HDAC complexes through methyl-binding proteins in 
order to repress gene expression (Jones et al., 1998; Nan et al., 1998; Ropero and Esteller, 2007).  
Interestingly, several nuclear receptors can form co-repressor complexes with HDACs in the 
absence of ligands, and can further influence gene expression (Lin et al., 2006). 
These co-repressor complexes have diverse multi-protein components that dictate their 
functional activities (Table 1.2).  The Sin3 co-repressor complex has deacetylase activity, and 
additional proteins associated with the Sin3 complex include SAP18, SAP30L, Ing2 and 
RbAp46/48 (Hayakawa et al., 2011; Hurst et al., 2012; Delcuve et al., 2013).  The NuRD 
complex consists of protein components such as RbAp46/47, p66α/β, MBD2, MTA1/2/3 and 
LSD1.  This co-repressor has lysine deacetylation and ATP-dependent helicase activities, carried 










Figure 1.2.  Schematic representation of histone deacetylases and their associated co-
repressor complexes.  (A) HDACs 1 and 2 form hetero- or homo-dimers within the Sin3, NuRD 
and CoREST complexes and (B) HDAC3 complexes with NCoR/SMRT.  Shown are the various 
protein subunits currently known to form the complexes; the HDACs are indicated by their 
numbers in the blue colour and those associated with helicase or demethylation activity are 













Table 1.2.  The co-repressor complexes and their associated HDAC and protein subunits.  
HDAC 1 and 2 form hetero- or homo-dimers within the Sin3, NuRD and CoREST complexes, 
and HDAC3 forms a complex with NCoR/SMRT.  The four co-repressor complexes have 
deacetylation activity while NuRD and CoREST also have helicase and demethylation activity, 
respectively. 
 
Co-Repressor Complex HDAC Subunits Function(s) 
Sin3  1/2  SAP18  




NuRD  1/2  RbAp46/47 
 p66α/β 
 MBD2 




CoREST  1/2  LSD1 











2007; Wang et al., 2009; Decluve et al., 2013).  The CoREST complex has deacetylase and 
demethylase activity, and includes the LSD1, HMG20B and PHF21A proteins (Lakowski et al., 
2006).  The proteins associated with the HDAC3-containing complex NCoR/SMRT include 
TBL1 and GPS-2.  This complex functions mainly in deacetylation (Li et al., 2000; Karagianni 
and Wong, 2007). 
HDAC3 is unique in that it requires the deacetylase activating domain (DAD) of the 
NCoR/SMRT complex for enzymatic activity (Guenther et al., 2001; Sun et al., 2013), and this 
interaction is dependent upon an inositol tetraphosphate (IP4) molecule (Watson et al., 2012).  
Due to the association of class II HDACs with HDAC3, and their deficient catalytic activity, it 
has recently been suggested that they potentially have a role in protein scaffolding rather than 
deacetylation (Schapira, 2011; Sun et al., 2013).  In addition to the canonical co-repressor HDAC 
complexes, HDACs have also been found to be present in many other complexes.  For example, 
SHMP is a complex consisting of HDAC1, Sin3B, MRG15 and PHF12, and is associated with 
the gene coding region during transcription (Jelinic et al., 2011; Delcuve et al., 2013).   
 
1.3.3.1 HDAC Co-Repressor Regulation 
 
The activities of HDAC-containing complexes can be regulated through subcellular 
localisation and post-translational modifications.  Phosphorylation of HDAC1 at serines 393, 421 
and 423, and HDAC2 serines 394, 422 and 424 are required to form co-repressor complexes 
(Tsai et al., 2002), and the acetylation of HDAC1 at lysine 432 inhibits the activity of HDAC1-
containing dimers.  For instance, the protein kinase CK2 has been found to be associated with the 
Sin3 and NuRD complexes and act to maintain the phosphorylation state of HDACs 1 and 2 for 
catalytic function (Luo et al., 2009; Spiegel et al., 2012; Delcuve et al., 2013).  Additionally, the 
ubitiquination of HDACs 1 and 2 can lead to their degradation (Segre et al., 2011).  Likewise, 
serine 424 phosphorylation on HDAC3 by CK2 stimulates its activity, while an additional level 
of regulation comes through its cytoplasmic or nuclear localisation mediated by the CRM1-
pathway (Yang et al., 2002; Zhang et al., 2005; Karagianni and Wong, 2007; Yao and Yang, 
2011).  It has also been shown that protein phosphatase 4 (PP4) is associated with the 
NCoR/SMRT complex and contributes to HDAC3 regulation (Zhang et al., 2005). 
In addition, the class II HDACs can be regulated through their subcellular localisation.  
 21 
 
Phosphorylated HDACs 4 and 5 associate with the regulatory protein 14-3-3, which then blocks 
their nuclear translocation from the cytoplasm (Nishino et al., 2008).  This prevents their binding 
to the HDAC3-containing co-repressor complexes and reduces their transcriptional activity 
(Grozinger et al., 1999; Nishino et al., 2008)  In addition, protein phosphatase 2A (PP2A) can 
dephosphorylate HDAC4 and expose its nuclear localisation signal (Paroni et al., 2008; Nishino 
et al., 2008). 
 
1.3.4 Physiological and Cellular Functions of HDACs 
 
Diverse HDAC physiological and cellular functions (Table 1.3), as well as the importance 
of co-repressor binding, have been illustrated in knock-down and/or knock-out analyses in 
Drosophila, yeast and mice (Yang and Seto, 2008; Haberland et al., 2009; Kelly and Cowley, 
2013).  The focus of this section will be on mammalian HDACs.  HDAC enzymes have been 
implicated in many cellular processes, including transcription, elongation, splicing, mRNA 
stability and mitosis (Lagger et al., 2002; Kelly and Cowley, 2013).  The class I HDACs mainly 
function in cell survival and cellular growth.  For instance, knocking out HDAC1 in cell lines 
negatively influences proliferation and up-regulates cyclin-dependent kinase inhibitors.  
Furthermore, despite high structural similarity between the enzymes, HDAC2 and HDAC3 could 
not rescue the impaired phenotype, highlighting their unique roles (Lagger et al., 2002). 
  The majority of in vivo research has centred on the developmental roles of the class I 
HDACs, particularly HDAC1 and HDAC2.  Despite their high sequence similarity, murine 
models indicate that they possess non-redundant cellular functions that are critical for embryonic 
development and cardiovascular health (Haberland et al., 2009; Kelly and Cowley, 2013).  The 
deletion of hdac1 in mice results in embryonic lethality, and it is therefore thought to be involved 
in embryogenesis and cardiac development (Lagger et al., 2002; Zupkovitz et al., 2010), whereas 
conditional knock-out of both hdac1 and hdac2 alleles impairs neural tissue development 
(Montgomery et al., 2009; Chen et al., 2011).  In addition, histones H3 and H4 were hypo-
acetylated in hdac-null embryos, and hdac1 deletion in embryonic stem cells enhances expression 




 (Lagger et al., 2002).  
Furthermore, deletion of HDAC3 is embryonically lethal in mouse models (Bhaskara et al., 2008; 







Table 1.3.  The cellular and physiological functions of HDACs.  Indicated are select cellular 
and physiological functions for the class I (HDACs 1, 2, 3 and 8), class IIa (HDACs 4, 5, 7 and 
9), class IIb (HDACs 6 and 10) and the class IV (HDAC11).  Further listed are the knock-out 
phenotypes observed in mouse studies. 
 
 HDAC   Cellular  





Class I  1   gene activation embryogenesis  
cardiogenesis  
embryonic lethality 
impaired neural tissue  
     development 
  2   gene activation embryogenesis  
cardiogenesis  
 
impaired neural tissue  
     development 
cardiac abnormalities 
  3   cell cycle arrest 
  DNA repair  
  mitosis 
  apoptosis 
-- embryonic lethality 
 
  8   -- -- -- 
Class IIa  4    gene expression cardiogenesis -- 
  5   angiogenesis -- 
  7    apoptosis angiogenesis -- 
  9    angiogenesis -- angiogenic abnormalities  
cardiac abnormalities 
Class IIb  6    cellular growth 
   apoptosis 
   chaperone 
   autophagy 
   protein degradation 
angiogenesis -- 
  10    autophagy -- -- 







  Knock-out studies in mice have also illustrated that HDACs 1 and 2 can regulate gene 
expression in both a positive and negative manner (Zupkovitz et al., 2006; Yamaguchi et al., 
2010; Kelly and Cowley, 2013).  Chromatin immuno-precipitation (ChIP) partnered with high-
throughput sequencing (ChIP-Seq) indicated that these HDACs associate with transcriptionally 
active genomic regions (Wang et al., 2009).  It is speculated that this counteracts the activity of 
HATs and RNA pol II in a dynamic, cyclic process of gene inactivation and activation (Kelly and 
Cowley, 2013).  Silencing and/or knock-down of hdac1 and hdac2 in cell lines demonstrate 
reduced proliferation and increased expression of p21
WAF1
 in vitro (Wilting et al., 2010; 
Yamaguchi et al., 2010; Zupkovitz et al., 2010; Kelly and Cowley, 2013). 
  In addition, knocking down expression of HDAC3 in cells leads to cell cycle arrest, 
impaired DNA repair responses and apoptotic dysregulation (Bhaskara et al., 2008; Barneda-
Zahonero and Parra, 2012; Khan and La Thangue, 2012; Reichert et al., 2012).  As previously 
mentioned, HDAC3 requires the DAD domain of NCoR/SMRT and an IP4 molecule for its 
deacetylation activity.  Interestingly, mouse models with knock-in mutations that obliterate these 
interactions are able to live to adulthood.  Mutational analysis has also demonstated that HDAC3 
deacetylase activity is not required; this suggests that the NCoR/SMRT and HDAC3 complex 
also functions independently of its deacetylation activity (Sun et al., 2013; You et al., 2013).    
  While the majority of research has investigated the function of class I HDACs, murine 
models indicate that class II HDACs are involved in muscle and neuronal differentiation, 
adipogenic gene regulation and angiogenic processes (Nebbioso et al., 2010).  HDAC9 knock-out 
in transgenic mice can lead to increased cardiac growth (Zhang et al., 2002) and angiogenic 
abnormalities, such as decreased retina vascularisation and reduced blood flow (Kaluza et al., 
2013).  It has further been illustrated that HDAC4 through HDAC7 are negative regulators of 
angiogenic processes (Vega et al., 2004; Urbich et al., 2009; Khan and La Thangue, 2012; 
Kaluza et al., 2013), while HDAC7 can also negatively regulate apoptosis (Dequiedt et al., 
2003).  Furthermore, through their interaction with the PPARγ signalling pathway, the class II 
HDACs have been implicated in heart and adipose tissue development in vivo (Nebbioso et al., 
2010).  Interestingly, both HDAC2- and HDAC9-deficient mice present with cardiac 




  Through its ubiquitin-binding zinc finger domain, HDAC6 functions in numerous cellular 
processes, including proliferation, apoptosis, chaperone functions, autophagy, and the ubiquitin-
proteosomal and misfolded protein degradation systems.  These functions are likely achieved 
through interaction with ubiquitin mediated by the ubiquitin-binding domain (Rubinsztein et al., 
2006; Olzmann et al., 2007; Lee et al., 2010; Peng and Seto, 2011; Yang et al., 2013).  In 
addition to cancer, HDAC6 has also been implicated in many neurological and protein 
conformational disorders, many of which harbour abnormal pathways such as protein degradation 
and autophagy (Yang et al., 2013). 
  Histone deacetylases have many physiological roles, and while the activities of some 
enzymes are redundant, the importance of HDAC activity in the organism is highlighted by in 
vivo knock-out and/or knock-down studies (Yang et al., 2008; Haberland et al., 2009; Kelly and 
Cowley, 2013).  It is also interesting to note that HDACs function independently of their 
deacetylase activity, further highlighting their complicated roles in transcription and cellular 
homeostasis (Sun et al., 2013; You et al., 2013).  Contributing to their complicated and robust 
nature is their ability to deacetylate non-histone proteins (Kim et al., 2006; Choudhary et al., 
2009), prompting a movement in the literature to renaming them as ‘lysine deacetylases’ 
(KDACs).  While histones were considered the central substrates for these enzymes, their non-
histone targets and activities are seemingly just as vital (Gregoretti et al., 2004; Dockmanovic et 
al., 2007; Xu et al., 2007). 
 
1.3.5 Non-Histone Targets of HDACs 
 
Phylogenetic analysis has demonstrated that HDAC enzymes predate histone proteins 
(Gregoretti et al., 2004) and are conserved in many species (Yu et al., 2008; Zhang et al., 2009; 
Wang et al., 2010), hence, it is unsurprising that there has been increasing evidence that they 
target non-histone proteins.  Protein acetylation is one of the most common post-translational 
modifications which affect protein regulation.  As previously indicated, the first acetylated 
proteins identified were histones and subsequently twenty-seven years later, the responsible 
enzymes were discovered and named after their common substrates (Inoue and Fujimoto, 1969; 
Taunton et al., 1996; Yao and Yang, 2011).  There are approximately 1700 proteins which can be 
acetylated and deacetylated by HDACs.  These include cytoplasmic proteins and nuclear 
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transcription factors, such as p53, GATA4, ERα, E2F1 and NF-κB (Kim et al., 2006; Choudhary 
et al., 2009; Peng and Seto, 2011; Kelly and Cowley, 2013).   
The acetylation of lysines offers an additional layer of protein regulation and affects 
protein stability, cellular localisation, and protein-DNA or protein-protein interactions (Singh et 
al., 2010).  While the deacetylation of transcription factors can indirectly influence transcriptional 
regulation, the deacetylation of non-histone proteins can exert physiological effects that are 
independent to transcription.  These include apoptosis, cell cycle progression, autophagy, cell 
motility, chaperone functions and differentiation.  Many of these biological processes can be 
controlled via HDACs in both non-transcriptional and transcriptional manners (Ropero and 
Esteller, 2007; Kaluza et al., 2013), and certain processes are highlighted in further detail. 
The first non-histone target identified for HDAC enzymes was the p53 tumour suppressor 
protein (Gu and Roeder, 1997).  It contains many potential lysine sites that can be targeted for 
acetylation by at least HDACs 1, 2 and 3 (Juan et al., 2000; Wang et al., 2003; Luo et al., 2004; 
Zeng et al., 2006; Karagianni and Wong, 2007; Ropero and Esteller, 2007).  Following DNA 
damage, p53 is stabilised through acetylation by the p300/CBP acetyltransferase, thereby 
increasing its DNA binding capability and activating p53-responsive target genes.  This 
ultimately leads to cell cycle arrest and apoptosis.  Thus, HDAC-mediated deacetylation 
decreases p53 protein stability and diminishes DNA binding, resulting in cell cycle arrest and 
apoptotic inhibition (Juan et al., 2000; Luo et al., 2000).  For instance, it has been illustrated in 
MCF-7 breast cancer-derived cell lines that HDAC2 functions in the p53 pathway.  Silencing 
HDAC2 induced p53-dependent and p53-independent senescence and cell cycle arrest at the G1 
phase.  HDAC2 negatively regulates p53-dependent transcriptional activity, and knocking down 
HDAC2 increases p53-binding to promoters.  Furthermore, MYC expression was also down-
regulated in a p53-dependent manner (Harms and Chen, 2007). 
STAT1 deacetylation prevents the phosphorylation required for its nuclear translocation 
and DNA binding (Kramer et al., 2009).  In addition, the STAT1 transcription factor is 
deacetylated to destabilise its homo- and hetero-dimerisation ability (Yuan et al., 2005).  Despite 
their classification of pseudo-enzymes (Fischel et al., 2002; Lahm et al., 2007; Yang et al., 2008; 
Parra and Verdin, 2010; Sun et al., 2013), class II HDAC4 and HDAC7 can deacetylate p53, 
RUNX (runt domain transcription factor)-2 and HIF-1α (hypoxia inducible factor 1α).  However, 
this is likely due to their association with HDAC3 (Yao and Yang, 2011).  It is also interesting to 
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note that HDAC3 is recruited to and associated with chromosomes during mitotic division (Li et 
al., 2006; Karagianni and Wong, 2007).  Furthermore, HDAC3 is critical for the kinetochore-
microtubule formation and the assembly of mitotic spindles (Ishii et al., 2008), and is required to 
deacetylate histone H3 lysine 4 (H3K4) during sister chromatid attachment (Eot-Houllier et al., 
2008).  It is thought that the mitotic defects mediated by HDAC3 are independent of histone 
acetylation.  In Drosophila, it has been shown that the centromere has a high concentration of tri-
methylated histone H3 lysine 9 (H3K9me
3
), likely due to HDAC3 inhibition and its non-
acetylated functions (Warrener et al., 2010). 
In an additional non-transcriptional mechanism, the deacetylation of the apoptotic 
regulator Ku70 interferes with its ability to bind BAX, thus inhibiting apoptosis (Yamaguchi et 
al., 2009).  While SIRT1, a class III HDAC, is thought to be the main deacetylase responsible 
(Cohen et al., 2004), HDACs belonging to class I can also act upon Ku70 (Subramanian et al., 
2005).  In addition, MEF2 (myocyte enhancer factor 2) interacts with HDAC4 and indirectly with 
HDAC3.  Accordingly, HDAC4 is expressed highly in muscle tissue and may be involved in 
myogenesis through its interaction with MEF2.  The deacetylation of MEF2 by HDAC3/HDAC4 
represses the myoD gene promoter (Grozinger et al., 1999; Gregoire et al., 2007). 
HDAC6 plays a role in the regulation of autophagy through promoting autophagosome 
and lysosome fusion by assembling F-actin fibres (Lee et al., 2010).  In addition, HDAC6 can 
regulate cell adhesion, motility and protein chaperone functions (Hubbert et al., 2002; Wang et 
al., 2010) through targeting α-tubulin (Yang et al., 2008; Barneda-Zahonero and Parra, 2012), 
heat shock protein 90 (Hsp90) and cortactin for deacetylation (Valenzuela-Fernandez et al., 2008; 
Yang et al., 2013).  For example, deacetylation of the chaperone protein Hsp90 at lysine 294 can 
decrease its function and interaction with client proteins such as the glucocorticoid receptor 
(Kovacs et al., 2005; Scroggins et al., 2007).   
 Many additional non-histone targets of HDACs have also been identified.  Briefly, 
GATA2 interacts with HDAC3 to suppress transcription mediated by this transcription factor 
(Osawa et al., 2001), and HDAC3 can also deacetylate SRY, thus leading to the loss of its 
nuclear localisation (Thevenet et al., 2004).  HDACs 1 and 3 deacetylate the p65 subunit of NF-
κB, which enhances its DNA binding affinity (Kiernan et al., 2003; Singh et al., 2010). 
While the possible roles of these HDACs in carcinogenesis are detailed in the following 
section, it is interesting to note that oestrogen increases the protein and mRNA expression of 
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HDAC6 and results in enhanced cell motility, contributing to metastatic processes.  It has been 
shown that the anti-oestrogen tamoxifen decreases tubulin deacetylation mediated by HDAC6, 
thus reducing motility and metastatic potential (Saji et al., 2005).  It has also been illustrated that 
HDAC1 can reduce the activity of oestrogen receptor-alpha (ERα) signalling (Kawai et al., 
2003).   
 
1.3.6 Role of HDACs in Tumorigenesis 
 
The over-expression, dysregulation and/or mutation of HDACs, with subsequent aberrant 
genomic acetylation, has been implicated in many cancers (Sjoblom et al., 2006; Ma et al., 2009; 
Wanczyk et al., 2011; Barneda-Zahonero and Parra, 2012; Kelly and Cowley, 2013; Timp and 
Feinberg, 2013).  For example, the class IIa HDAC4 has been found mutated in breast cancers 
(Sjoblom et al., 2006; Timp and Feinberg, 2013), and truncating or inactivating mutations have 
been observed in 4% of these cancer types (Ropero et al., 2006).   
It has also been observed that HDACs can aberrantly interact with oncogenic fusion 
proteins that result from chromosomal translocations linked to some haematological cancers 
(Barneda-Zahonero and Parra, 2012; Ropero and Esteller, 2007).  In particular, the fusion 
proteins RARα-PML, RARα-PLZF and AML-ETO, have the ability to recruit HDACs through 
their association with retinoic acid-responsiveness elements (RAREs) in gene promoters.  This 
results in disruption of the cell cycle and abberant growth (Lin et al., 2001; Mehnert and Kelly, 
2007; Ropero and Esteller, 2007).  Therefore, there has been extensive research through siRNA 
knock-down and/or over-expression studies into the role of HDACs in tumorigenesis.   
The class I HDACs are frequently dysregulated in malignancies; the enhanced expression 
of HDAC1 is associated with poorer prognosis and has been observed in diverse cancers, 
including gastric, breast, renal, colorectal, pancreatic, prostate and lung carcinomas (Choi et al., 
2001; Zhang et al., 2005; Fritzsche et al., 2008; Weichert et al., 2008; Wilson et al., 2008; 
Adams et al., 2010; Minamiya et al., 2011).  Similarly, HDAC2 over-expression has been 
observed in cervical, gastic and colorectal cancers (Song et al., 2005; Zhu et al., 2005; Ropero 
and Esteller, 2007).  In breast cancer, HDAC1 and HDAC3 up-regulation correlate with 
expression and signalling of PgR and ERα hormone receptors (Krusche et al., 2005; Zhang et al., 
2005; Barneda-Zahonero and Parra, 2012).  Additional studies have illustrated that expression of 
 28 
 
HDAC8 is increased in many childhood neuroblastomas (Oehme et al., 2009).  
As previously mentioned, the class I HDACs are associated mainly with cell proliferation 
(Glaser et al., 2003; Weichert et al., 2008; Barneda-Zahonero and Parra, 2012).  For example, in 
breast cancer cell lines, knocking down HDAC1 suppressed proliferation and increased apoptosis 
(Senese et al., 2007), whereas silencing HDAC2 lead to increased DNA-binding activity of the 
tumour suppressor p53, as well as cellular senescence and cell cycle arrest (Harms and Chen, 
2007).  The knock-down of HDAC2 and HDAC8 increased apoptosis and differentiation, and 
decreased proliferation in cervical cancer cells (Barneda-Zahonero and Parra, 2012; Hua et al., 
2014), as well as inhibited proliferation in lung, colon and cervical cancer cell lines, respectively 
(Vannini et al., 2004; Barneda-Zahonero and Parra, 2012).  Furthermore, it was illustrated that 
up-regulation of HDACs 1 and 8, as well as the class IIb HDAC6, increased invasion of breast 
cancer cells (Park et al., 2011).  In addition, the ubiquitination of HDAC6 has been shown to be 
involved in tumorigenesis, wherein it interferes with normal gene expression during chromatin 
condensation (Hideshima et al., 2005; Yang et al., 2013). 
While extensive data have implicated class I HDAC involvement in tumorigenesis, the 
class II HDACs are likewise frequently up-regulated in cancer and associated with poor survival 
(Barneda-Zahonero and Parra, 2012; Timp and Feinberg, 2013).  For instance, Waldenstrom’s 
macroglobulinaemia can be associated with amplification of HDACs 4 and 9 (Sun et al., 2011), 
and expression of HDACs 5 and 9 are increased in certain medulloblastomas.  In these cases, the 
silencing of HDACs 5 and 9 has lead to apoptosis (Milde et al., 2010).  The over-expression of 
HDAC9 has also been observed in cervical cancer (Choi et al., 2007).  In advanced-stage oral 
squamous cell carcinoma, expression of HDAC6 was significantly higher than normal tissue or 
early-stage cancers (Sakuma et al., 2006); due to the role of HDAC6 in cell motility and 
adhesion, high levels can lead to decreased actin acetylation, which can thus increase migration 
of cancer cells and metastatic potential (Hubbard et al., 2002; Wang et al., 2010).  Furthermore, 
HDAC6-mediated deacetylation of cortactin can increase its association with F-actin, enhancing 
cell motility (Zhang et al., 2007).  In breast cancer, HDAC7 up-regulation leads to ERα-
dependent cellular growth (Malik et al., 2010). In addition to mutations in HDAC4 (Sjoblom et 
al., 2006; Timp and Feinberg, 2013), its protein expression can also be increased in breast cancer 
(Ozdag et al., 2006) and it is thought to have a role in the repression of the cell cycle inhibitor 
p21
WAF1
 through interaction with the Sp1 transcription factor (Mottet et al., 2009).  
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It has been established that the dysregulation of differentiation is a hallmark of cancer 
(Peng and Seto, 2011).  While extensive research has highlighted direct transcriptional-mediated 
impacts on differentiation, non-transcriptional-mediated processes can also affect differentiation.  
For instance, HDAC1 has been shown to act upon the myogenic activator (myoD), decreasing its 
transcriptional activity (Mal et al., 2001; Peng and Seto, 2011).  Additionally, the myocyte 
enhancer factor 2 (MEF2) transcription factor can be acted upon by HDACs 3 and 4, although the 
extent of HDAC4 involvement is currently unknown.  Together, these contribute to 
tumorigenesis through enhanced proliferation (Zhoa et al., 2005; Gregoire et al., 2007).  The 
acetylation status of RUNX1 is reversed by HDACs 4 and 5, and this abrogates its transformative 
ability (Jin et al., 2004; Yamaguchi et al., 2009).  Additionally, under hypoxic conditions, the 
protein stability and activity of the HIF-1α transcription factor can be positively influenced 
through binding to HDACs 1 and 3.  In this manner, HDACs can influence HIF-1α-mediated pro-
angiogenic processes (Kim et al., 2007).   
Despite the plethora of research implicating HDAC over-expression in carcinogenesis, 
contradictory observations have also been recorded.  While high levels of HDAC1 have been 
established in many cancers (Minamiya et al., 2011), it had also been observed that over-
expression correlated with improved survival in ERα- and PgR-positive breast cancers (Krusche 
et al., 2005; Sudo et al., 2011; Theocharis et al., 2011).  Genetic mutations and loss-of-function 
in HDAC1 enzymatic activity enhanced expression of genes controlled by the retinoblastoma 
(Rb) protein, a negative regulator of the cell cycle, potentially leading to tumorigenesis (Frolov 
and Dyson, 2004; Ropero and Esteller, 2007).  In addition, knocking down HDAC1 and HDAC2 
leads to leucaemia, while silenced HDAC3 is associated with hepatocellular carcinoma (Bhaskara 
et al., 2010; Santoro et al., 2013; Sun et al., 2013).  Furthermore, NCoR/SMRT up-regulation 
suppressed breast cancer progression through reduced signalling via the androgen receptor (Qi et 
al., 2013).   
A dual role for HDAC2 in neoplasia has also been reported; loss-of-function mutations 
have been observed in sporadic and hereditary non-polyposis colorectal cancer.  The mechanism 
of tumorigenesis has yet to be elucidated, but the mutation reduces HDAC2 protein expression 
and activity (Ropero et al., 2006; Ropero and Esteller, 2007).  In addition, HDAC6 is up-
regulated in breast cancer (Zhang et al., 2004; Ropero and Esteller, 2007; Timp and Feinberg, 
2013) and can be associated with improved prognosis (Zhang et al., 2004); however a second 
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study of breast cancer tissue illustrated no prognostic benefit regarding HDAC6 expression (Saji 
et al., 2005; Barneda-Zahonero and Parra, 2012).  Interestingly, HDAC4 can negatively or 
positively regulate p21
WAF1
; upon DNA damaging agents, p53 recruits HDAC4 to increase 
p21
WAF1




The dysregulation of HDACs has been implicated in cancer, contributing to aberrant 
cellular homeostasis contributing to tumorigenesis.  HDACs are involved in many cellular 
pathways and are quite complex in their functions, and it has become increasingly important to 
understand how HDACs work and are dysregulated in cancer (Peng and Seto, 2011).  While 
HDAC involvement in cancers has been controversial, with some exhibiting properties of tumour 
suppressor genes in rare cases, there has been extensive evidence that abnormal HDAC activity 
contributes to carcinogenesis (Choi et al., 2001; Zhang et al., 2005; Sjoblom et al., 2006; 
Fritzsche et al., 2008; Weichert et al., 2008; Ma et al., 2009; Minamiya et al., 2011; Wanczyk et 
al., 2011; Timp and Feinberg, 2013).  Thus, targeting HDACs have been considered a viable 
therapeutic option, and there are many synthetic and natural compounds in pre-clinical or clinical 
trials that inhibit these enzymes.  These HDAC inhibitors have been shown to be pro-apoptotic to 
cancer cells and several have shown promising results in clinical trials (Piccart-Gebhart et al., 
2005; Piekarz et al., 2007; Bicaku et al., 2008; Fan et al., 2008; Lee et al., 2008; Chavan and 
Somani, 2010; Martinet and Bertrand, 2011; Perez et al., 2011; Slamon et al., 2011; Lamond and 
Younis, 2014; Li and Zhu, 2014). 
 
1.4 Histone Deacetylase Inhibitors 
 
  The first natural compound identified to have inhibitory activity on HDAC enzymes was 
butyrate.  This is a short chain fatty acid produced in the colon by the anaerobic bacterial 
fermentation of dietary fibre.  It has been shown to prevent colon carcinogenesis in part through 
inhibiting DNA synthesis, proliferation and altering gene expression at the millimolar 
concentration (Canido et al., 1978; Hinnebusch et al., 2002; Davie et al., 2003).  It was later 
observed that this activity was in part due to the ability of butyrate to inhibit HDACs, thus 
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identifying it as the first ‘pan-specific’ histone deacetylase inhibitor (HDI).  Further supporting 
this, butyrate has been shown to increase acetylation of histones H3 and H4 in vitro and in vivo 
(Boffa et al., 1978; Canido et al., 1978; Hinnebusch et al., 2002; Davie et al., 2003). 
These HDIs are a novel class of chemotherapeutic and chemopreventative agents that act 
in part by inhibiting the activity of HDAC enzymes to induce global protein acetylation via the 
activity of histone acetyltransferases.  Partially through up-regulating tumour suppressor genes 
and/or down-regulating oncogenes, HDI treatment selectively induces apoptosis, differentiation 
and cell cycle arrest in tumour cells (Mehnert et al., 2007; Ma et al., 2009; Nebbioso et al., 2010; 
Wanczyk et al., 2011).  In addition to acetylation of histones and alterations in gene expression, 
HDIs also induce acetylation of non-histone proteins (Kim et al., 2006; Harms and Chen, 2007; 
Choudhary et al., 2009; Peng and Seto, 2011; Kaluza et al., 2013; Kelly and Cowley, 2013) and 
have been shown have genome-wide anti-neoplastic consequences.  Briefly, HDI treatment alters 
the acetylation of transcription factors (Ito et al., 2002), induce polyploidy (Xu et al., 2005), 
cause mitotic slippage during mitosis (Stevens et al., 2008) and premature chromatid separation 
(Magnaghi-Jaulin et al., 2007), and disrupt HDAC-protein phosphatase complexes (Chen et al., 
2008).  Certain aspects of these processes will be discussed in greater detail below. 
 
1.4.1 Cellular Actions of HDIs 
 
It has been demonstrated that HDAC inhibition increases the accumulation of H3K9/14 
acetylation, which in turn triggers the methylation of H3K4 at gene promoters, thus activating 
transcription (Felsenfeld, 1992; Wolffe, 1994; Yang et al., 2000; Keen et al., 2003; Jang et al., 
2004; Sharma et al., 2006; Ueda et al., 2006; Ropero and Esteller, 2007; Tsai and Baylin, 2011; 
Stark et al., 2013; Marmorstein and Zhou, 2014).  Despite the established role of HDACs in 
transcriptional activation, inhibiting HDACs through HDI treatment only results in the up-
regulation of a small subset of genes, approximately 2-10% depending on the study and methods 
utilised.  It has also been observed that a similar number of genes are repressed following HDI 
administration (Van Lint et al., 1996; Gray et al., 2004; Marks et al., 2004; Mitsiades et al., 
2004; Peart et al., 2005; Ropero and Esteller, 2007; LeBonte et al., 2009).  While HDI-mediated 
histone acetylation is partially responsible for gene up-regulation, the down-regulation of gene 
expression cannot be explained by enhanced histone acetylation (Ellis et al., 2008).  In addition, 
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while some HDIs can regulate highly similar genes in a cell line and result in apoptosis or cell 
cycle arrest, there are differences between other HDI treatments and altered gene expression 
profiles.  For instance, while HDIs collectively lead to apoptotic phenotypes, the gene expression 
profiles associated with each drug are different (Mitsiades et al., 2004; Peart et al., 2005).  
Therefore, the effects of HDIs on cellular processes are pleiotrophic and often cell-specific.  It 
has been established that HDIs can affect the acetylation of transcription factors and cytoplasmic 
proteins, playing a direct or indirect role in apoptosis, angiogenesis, cell cycle progression, 
mitotic cell death, and/or autophagy (Khan and La Thangue, 2012).  These effects are 
summarised in Figure 1.3. 
While the induction of genes, particularly the commonly-studied p21
WAF1
, by HDIs has 
been extensively studied, the effects of these drugs upon transcription will be the focus of a 
forthcoming section and will not be discussed below in great detail.   
 
1.4.1.1 Acetylation of Non-Histone Proteins 
 
As previously discussed, a vast majority of non-histone targets have been identified for 
HDACs (Gu and Roeder, 1997; Kim et al., 2006; Choudhary et al., 2009; Singh et al., 2010; 
Peng and Seto, 2011; Kelly and Cowley, 2013), and HDIs affect the acetylation pattern of many 
cytosolic and nuclear proteins (Ito et al., 2002).  These can influence numerous cellular 
processes, such as the ubiquitin-proteosome system, the cell cycle and apoptosis (Hubbard et al., 
2002; Wang et al., 2010).  In addition, HDIs can decrease or increase the stability and/or alter the 
activity of transcription factors; in this manner, HDIs can indirectly influence gene expression 
(Luo et al., 2000; Vigushin et al., 2001; Bicaku et al., 2008; Ma et al., 2009; Chatterjee et al., 
2013).  For example, the transcription factor p53 is acetylated and stabilised following HDI 
treatment (Luo et al., 2000; Ma et al., 2009).  The acetylation of Hsp90 (Kovacs et al., 2005) and 
ERα (Vigushin et al., 2001; Bicaku et al., 2008) are also enhanced after treatment with HDIs and 
effect downstream cellular processes. 
Particularly, HDAC6 has been shown to have a major role in the ubiquitin-proteasome 
system and the misfolded protein response (Kawaguchi et al., 2003; Boyault et al., 2006).  The 
chaperone protein Hsp90 is targeted by HDAC6 for deacetylation, and class II-specific or ‘pan-










Figure 1.3.  Pleiotrophic effects of histone deacetylase inhibitors.  Included are the non-
transcriptional and transcriptional effects of the class of inhibitors.  Cellular pathways activated 
upon treatment include apoptosis, cell cycle arrest, autophagy, mitotic abnormalities, and histone 




chaperone function.  This ultimately leads to the degradation of its oncogenic substrates, such as 
Akt (Rao et al., 2008; Khan and La Thangue, 2012).  The inhibition of HDAC6 also results in the 
accumulation of acetylated tubulin, stabilising the molecule and potentially inhibiting tumour cell 
growth (Glaser et al., 2003; Khan et al., 2008; Yasumichi et al., 2010). 
 
1.4.1.2 Inhibition of the Cell Cycle 
 
It is generally recognised that a global effect of HDI treatments are their shared ability to 
inhibit progression through the cell cycle (Sakajiri et al., 2005; Komatsu et al., 2006; Ma et al., 
2009).  While the inhibition of the cell cycle at G2/M affects both non-transformed and 
transformed cells, the latter generally lack a functioning G2 checkpoint and thus undergo 
apoptosis (Zhao et al., 2005; Zupkovitz et al., 2010).  The arrest of cellular growth at the G1/S or 
G2/M phase is partly due to the induction of the cyclin-dependent kinase inhibitor p21
WAF1
 
(Yoshida et al., 1995; Ogryzko et al., 2996; Noh et al., 2003; Gui et al., 2004).  Vorinostat 
mediates cell cycle arrest through two potential mechanisms; by disrupting the function of the 
Sin3 repressor complex mediated via Ing2 dissociation and by direct inhibition of the HDAC 
enzymes (Sardui et al., 2014).  It has been further demonstrated that Vorinostat interferes with 
Sin3 binding to the p21
WAF1
 promoter through this mechanism (Smith et al., 2010). 
In addition, the retinoblastoma protein (pRb), a negative regulator of the cell cycle, down-
regulates E2F-dependent gene expression through the recruitment of chromatin modifying 
enzymes to gene promoters.  pRb binds to class I HDACs and Sin3 complex, thus altering the 
balance of histone acetylation and repressing gene expression.  In addition, HDACs negatively 
affect transcription of E2F-dependent genes in G1 phase (Sellers et al., 1995; Brehm et al., 1998; 
Luo et al., 1998; Magnaghi-Jaulin et al., 1998; Meloni et al., 1999; Ross et al., 2001; Rayman et 
al., 2002; Frolov and Dyson, 2004).  It has been demonstrated that TSA impedes pRb-mediated 
inhibition of E2F-dependent genes (Zhang et al., 2000).  In addition to the induction of cyclin-
dependent kinase inhibitors, the cyclin family of proteins are repressed following HDI treatment 
(Mateo et al., 2009; Jin et al., 2012; Zhang et al., 2012; Vidal-Laliena et al., 2013), leading to a 
reduction in active, phosphorylated pRb, subsequent downstream signalling and cell cycle 
progression (Zhao et al., 2005; Wu and Yu, 2009).  Furthermore, HDIs stimulate degradation of 




1.4.1.3 Pro-Apoptotic Effects 
 
  HDI-mediated acetylation of non-histone proteins favours apoptosis (Insinga et al., 2005; 
Bolden et al., 2006).  The mechanisms of cell death are myriad and include the extrinsic (death 
receptor) and the intrinsic (mitochondrial) pathways, and reactive oxygen species (ROS)-
mediated cell death.  In addition, apoptosis is the end-point of various HDI-mediated defects in 
DNA repair mechanisms and mitotic abnormalities (Insinga et al., 2005; Bolden et al., 2006; 
Mehnert and Kelly, 2007; Khan and La Thangue, 2012).  For example, it has been observed that 
HDI-treated cells possess damaged pericentric heterochromatin and impaired segregation of 
chromosomes during mitosis.  Disrupting mitotic division initiates apoptosis and mitotic 
slippage, a phenomenon wherein mitotic cells re-enter G1 phase without completing mitosis 
(Gabrielli and Brown, 2012).  In addition, HDIs can also inhibit expression of proteins 
responsible for the spindle assembly checkpoint, leading to cell death (Taddei et al., 2001; Inche 
et al., 2006; Li et al., 2006; Stevens et al., 2008). 
HDI treatment results in a gene induction signature generally associated with pro-
apoptotic events.  The up-regulation of death receptors and ligands leads to apoptosis in 
transformed cells, as well as in murine models (Nebbioso et al., 2005; Borbone et al., 2010; Khan 
and La Thangue, 2012).  In addition, induction of the tumour necrosis factor-related apoptosis-
inducing ligand (TRAIL) ultimately leads to activation of caspase 3 via the extrinsic pathway 
(Nebbioso et al., 2005; Borbone et al., 2010; Srivastava et al., 2010).  HDIs also down-regulate 
pro-survival proteins and up-regulate pro-apoptotic proteins, such as Bcl-2 and BAX, leading to 
cellular death through the intrinsic pathway (Rikiishi et al., 2011).  In fact, HDI-mediated 
apoptosis had been abrogated in cell lines with reduced levels of the BAX protein (Ierano et al., 
2013).  Additionally, the acetylation of the chaperone protein Hsp90 leads to its destabilisation 
and subsequent degradation of its oncogenic substrates (Yu et al., 2002; Mehnert and Kelly, 
2007; Kramer et al., 2014).  Furthermore, ROS are a by-product of caspase-independent 
apoptosis, and HDI treatment increases ROS concentration within the cell, further exacerbating 
HDI-mediated cell death (Ungerstedt et al., 2005; Mehnert and Kelly, 2007; Bhalla et al., 2009). 
It has also been established that HDIs lead to apoptosis through activating the oncogenic 
pRb-E2F pathway (Zhao et al., 2005).  Interestingly, defects in the pRb-E2F pathway are able to 
increase proliferative genes, as well as pro-apoptotic genes (Sherr et al., 2002).  Drug treatment 
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increases the association of the transcription factor E2F1 with the promoter of the pro-apoptotic 
BH3-only protein BIM.  Due to this, cells with elevated E2F1 expression are more susceptible to 
HDI-mediated apoptosis (Zhao et al., 2005). 
 
1.4.1.4 Additional HDI-Mediated Anti-Neoplastic Effects 
 
  As previously indicated, HDI administration activates numerous anti-tumorigenic 
pathways.  For instance, HDIs mediate gene signatures associated with DNA repair, ultimately 
leading to cell death (Bakkenist et al., 2003; Adimoolam et al., 2007; Zhang et al., 2007).  In 
addition, the autophagic-lysosomal fusion degradation process is induced in cancer cells treated 
with these drugs (Rikiishi et al., 2011).  HDI treatment also inhibits metastasis through up-
regulation of certain metastatic suppressors (Ma et al., 2009).  The inhibition of class II HDACs 
can lead to cell-specific and retinoic acid-dependent differentiation in mouse embryonic 
carcinoma cells (Slingerland et al., 2013).    Furthermore, HDIs have the ability to decrease the 
action of HDACs 1, 2 and 3 on HIF-1α, inhibiting angiogenesis (Kim et al., 2007).  Therefore, it 
has been well established that HDIs have numerous anti-cancerous roles in the cell, in addition to 
their epigenetic modulation of oncogenetic and tumour suppressive genes (Stearns et al., 2007).  
Understanding the complex neoplastic effects of these drugs could be beneficial to the 
development of improved chemotherapeutics targeted to specific cellular pathways, improving 
patient survival. 
 
1.4.2 Chemical Classes of HDIs 
 
  The common mechanism by which the hydroxamic acids inhibt HDACs is through 
chelation of the Zn
2+
 ion at the active site; therefore, they can only affect isoforms of the class I, 
II and IV HDACs.  It has also been demonstrated that the benzamide class access the ‘foot 
pocket’ region which is adjacent to the active site.  Histone deacetylase inhibitors mimic 
acetylated lysine substrates and share common structural properties, including a surface 
recognition site necessary for contact with the active site, a linker domain that mimics acetylated 
substrate, and the metal binding domain, which mediates interaction with the Zn
2+
 site 
(Bieliauskas and Pflum, 2008; Ma et al., 2009; Bressi et al., 2010; Wanczyk et al., 2011; Parbin 
et al., 2013).  It is the linker domain which properly positions the metal binding domain and the 
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capping group for required interactions with the active site of the HDAC enzyme (Bieliauskas 
and Pflum, 2008).  It has also been shown that HDIs can block HDAC4 from entering the nucleus 
and thus prevent its catalytic activity within that subcellular compartment (Kong et al., 2011). 
  Based on their bidentate chelator, HDIs are grouped into four chemical classes, and 
include the hydroxamates, cyclic tetrapeptides, aliphatic acids and benzamides.  These are either 
considered to be ‘pan-inhibitory’, isoform- and/or class-specific for HDACs (Ma et al., 2009; 
Wanczyk et al., 2011; Bressi et al., 2010; Parbin et al., 2013).  It has been shown that cyclic 
tetrapeptide capping moieties and benzamide metal binding domains confer specificity to class I 
HDACs (Bieliauskas and Pflum, 2008), as removal of the amino group of benzamides reduced 
class I-specificity (Fournel et al., 2008).  The hydroxamates are generally ‘pan-specific’ to class 
I, II and IV (Bieliauskas and Pflum, 2008). 
  In part due to their chemotherapeutic and chemopreventative nature, many HDIs are 
currently in phase I and/or phase II clinical trials (Piekarz et al., 2007; Lee et al., 2008), and two 
have been approved for use in the clinic.  In 2006, the FDA approved Vorinostat (suberoylanilide 
hydroxamic acid; SAHA) for the treatment of cutaneous T-cell lymphoma, and later in 2009 the 
cyclic peptide Romidepsin (FK-228) had also been approved for treatment (Mann et al., 2007; 
Slingerland et al., 2013).  In addition, Vorinostat has shown promising results for non-Hodgkin’s 
lymphoma (Kirschbaum et al., 2011), and had modest effect when administered in conjunction 
with tamoxifen in tamoxifen-resistant breast cancers.  In this phase II trial, Vorinostat treatment 
was able to partially reverse tamoxifen resistance (Jagannath et al., 2010; Munster et al., 2011) 
and re-sensitise the cells to the anti-hormonal (Sharma et al., 2006; Zhou et al., 2006; Stearns et 
al., 2007).  In fact, there have been many pre-clinical phase I and/or II trials of Vorinostat in 
conjunction with aromatase inhibitors, anti-oestrogens or small molecule inhibitors (Fuino et al., 
2003; Stearns et al., 2007; Munster et al., 2011; Slingerland et al., 2013).   
  It has also been suggested that dual treatment of mesenchymal cells with Vorinostat and 
the aminoflavone pro-drug APF464 can be clinically beneficial in breast cancer.  The HDI 
sensitises triple-negative breast cancer cells to APF464 treatment, likely through a process 
involving HDI-mediated ERα re-expression.  It was illustrated that Vorinostat induced ERα 
mRNA levels after 24 hr treatment, restoring aminoflavone responsiveness.  Mouse xenograft 
experiments also supported these in vitro observations.  Therefore, HDIs have the ability to alter 
gene expression of the triple-negative MDA-MB-231 and Hs578T cell lines, producing a less 
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aggressive phenotype (Stark et al., 2013).  In addition, a pre-clinical study illustrated that co-
treatment of breast cancer cells with an HDI and tamoxifen triggers apoptosis (Thomas et al., 
2011).  Furthermore, in a phase II study, the benzamide Entinostat has shown promise when 
administered in conjunction with the aromatase inhibitor exemestane in ERα-positive metastatic 
breast cancer.  In September 2013, it had been labelled as a ‘breakthrough therapy’ by the FDA 
(Yardley et al., 2013).   
As previously indicated, butyrate was the first identified HDI, followed by Trichostatin A 
(TSA) in the 1990s (Tsuji et al., 1975; Yang et al., 2007; Waldecker et al., 2008; Ma et al., 
2009).  Presently, there are many newly-developed synthetic compounds with diverse structures 
being tested in the laboratory that harbour HDI-activity (Yang et al., 2007; Ma et al., 2009).  
There has also been a focus on synthesising isoform- or class-specific HDIs, but due to the high 
sequence homology observed between isoforms, it has been a challenging process (Bieliauskas 
and Pflum, 2008).  As such, while there are many different classes and types of inhibitors, only 
those of interest will be discussed below. 
  Trichostatin A (Figure 1.4 A) is an anti-fungal antibiotic isolated from Streptomyces 
hygroscopious and interacts at nanomolar concentrations directly with the Zn
2+ 
ion at the active 
site of HDACs (Tsuji et al., 1975; Butler and Kozikowski, 2008).  It belongs to the hydroxamates 
chemical class, shares structural similarity to Vorinostat and is able to inhibit class I, II and IV 
HDACs.  Therefore, TSA is considered a ‘pan-inhibitory’ HDI (Haggarty et al., 2003; Duvic et 
al., 2007; Khan et al., 2008; Slingerland et al., 2013).  In many cancer cell lines, TSA has been 
shown to increase histone acetylation, apoptosis and induce p21
WAF1 
expression, and exhibit anti-
proliferative properties (Vigushin et al., 2001; Glaser et al., 2003).  Interestingly, ERα-positive 
breast cancer cell lines were more sensitive to the drug, indicating that TSA could target different 
mechanisms of growth between the ERα-positive and -negative cell lines (Vigushin et al., 2001).  
In addition, the loss of ERα expression in ERα-negative cancers can be associated with loss of 
methylation of the promoter (Lapidus et al., 1998; Stearns et al., 2007).  TSA reactivated ERα 
expression and functions synergistically with the DNMT inhibitor AZA to re-express ERα 
mRNA.  HDI treatment results in acetylated histones at the ERα promoter in MDA-MB-231 
breast-derived cells.  In addition, the progesterone receptor, an ERα responsive gene, was 






Figure 1.4.  The chemical structures of histone deacetylase inhibitors.  Depicted are the 
structures of (A) TSA, a hydroxamic acid, (B) Apicidin, a cyclic tetrapeptide, and (C) Entinostat 
and (D) Mocetinostat, the benzamides. 
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  Apicidin (Figure 1.4 B) is a fungal metabolite with anti-protozoan activities isolated from 
Fusarium species (Darkin-Rattray et al., 1996). It is a cyclic tetrapeptide with specificity for class 
I HDACs, particularly HDACs 1, 2 and 3, in the nanomolar range (Furumai et al., 2002; Khan et 
al., 2008).  However, despite its classification as a class I-specific HDI, Apicidin treatment 
decreased protein expression of HDAC4 in the SK-OV-3 ovarian cancer cell line.  This correlated 
with diminished invasive properties and altered gene expression profiles involving MMP-2 
(metalloproteinase-2) and RECK (reversion-inducing-cysteine-rich protein with kazal motifs) 
levels.  It was further observed that repression of HDAC4 abrogated its binding to the Sp1 
binding elements of the RECK gene promoter (Ahn et al., 2012).  Apicidin treatment of ERα-
positive breast, endometrial and ovarian cancer cell lines increases acetylation of H3 and H4, in 
addition to inducing cytotoxicity, apoptosis and cell cycle arrest at the G1 and/or G2/M phases.  
This growth inhibition was likely achieved through the down-regulation of cyclins and cyclin-







(Ueda et al., 2006; Jy et al., 2008; Khan et al., 2008; My et al., 2009).  It was 
additionally observed that these cells underwent intrinsic apoptosis through up-regulating BAX 
(Jy et al., 2008; My et al., 2009).  This Apicidin-mediated cell death and proliferative inhibition 
was selective to cancer cell lines, as a non-cancerous endometrial cell line was far more resistant 
to cytotoxic effects (Ueda et al., 2006).  
The two benzamides, Entinostat (MS-275) (Figure 1.4 C) and Mocetinostat (MGCD0103) 
(Figure 1.4 D) are specific for class I HDACs in the nanomolar to micromolar range (Fournel et 
al., 2008; Khan et al., 2008); however, it has been shown that they have more activity toward 
HDAC1 than HDAC3 (Hu et al., 2003; Beckers et al., 2007; Ropero and Esteller, 2007; 
Bieliauskas and Pflum, 2008), with HDAC8 only inhibited at high micromolar concentrations 
(Khan et al., 2008; Beckers et al., 2007). Interestingly, Mocetinostat also showed activity against 
the class IV HDAC11 in the high nanomolar to low micromolar range (Kalita et al., 2005; 
Fournel et al., 2008), while Entinostat harbours specificity toward HDAC9 (Binder and Lee, 
2008).  Mocetinostat and Entinostat have entered clinical trials, and as previously mentioned, the 
FDA has labelled Entinostat as ‘breakthrough therapy’ (Yardley et al., 2013).  Furthermore, in a 
phase II clinical trial evaluating Mocetinostat’s efficacy against relapsed classical Hodgkin’s 
lymphoma, it was found that the chemotherapeutic was well tolerated with promising results 
(Younes et al., 2011).  It also exhibited anti-tumour effects, such as cell death and an autophagic 
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response (Boumber et al., 2011). 
Both Entinostat and Mocetinostat induce histone acetylation, cell cycle arrest, p21
WAF1 
expression, cellular differentiation and apoptosis in a range of cancer cell lines, such as breast, 
colorectal, lung and leucaemia (Beckers et al., 2007; Fournel et al., 2008; Kelly and Cowley, 
2013).  It has also been shown that cell lines derived from normal breast tissue are resistant to 
cytotoxic and anti-proliferative effects of these benzamides (Fournel et al., 2008).  In xenographs 
of immune-compromised mice, Mocetinostat inhibited tumour growth and reduced tumour 
volume (Fournel et al., 2008), and Entinostat has shown in vitro activity against trastuzumab-
resistant HER2-amplified cell lines.  In fact, co-treatments of Entinostat with the HER2-antibody 
have synergistic effects wherein Entinostat re-sensitises the cells to trastuzumab-mediated cell 
cycle arrest and apoptosis (Huang et al., 2011).  In addition, Entinostat combined with the 
HER2/neu kinase inhibitor lapatinib resulted in synergistic inhibition of proliferation, colony 
formation and tumour size in vivo.  In a similar manner, Entinostat re-sensitised trastuzumab- or 
laptinib-resistant cells to the aforementioned treatment, and enhanced growth arrest and apoptosis 
by FOXO3-mediated BIM1 expression (Lee et al., 2014).  It has also been established that 
Entinostat can reverse the epithelial-to-mesenchymal transition in triple-negative breast cancer 
cell lines via up-regulation of E-cadherin.  Potentially, Entinostat can reduce invasive and 
metastatic potential of tumours (Shah et al., 2014). 
  Particularly relevant to ERα-positive breast cancers, it has been shown that these 
inhibitors are able to repress ERα and PgR expression in breast cancer cell lines.  Inhibition of 
HDAC2 leads to the down-regulation of PgR.  Enhanced apoptosis in ERα-positive cell lines was 
observed when HDIs were combined with tamoxifen.  Thus, HDIs act synergistically with anti-
hormonal therapies to induce apoptosis in certan subtypes of breast cancer cell lines (Bicaku et 
al., 2008).  As highlighted earlier, HDI treatment differentially affects ERα expression in 
hormone-receptor positive and negative cell lines; it up-regulates ERα in ERα-negative cell lines, 
but represses expression in ERα-positive cell lines.  Furthermore, ‘pan-specific’ or class I-
specific drugs also reduced PgR mRNA and protein expression, whereas both class I and II 
inhibition affected ERα expression (Duong et al., 2006; Hodges-Gallagher et al., 2006; Sharma et 





1.4.3 Differential Effects of HDI Treatment 
 
It has been well-established in the literature that global histone acetylation is observed 
upon HDI treatment (Glaser et al., 2003; Beckers et al., 2007; Ueda et al., 2007; Im et al., 2008; 
Fournel et al., 2008; Khan et al., 2008; Ahn et al., 2009; Wang et al., 2009; Kelly and Cowley, 
2013).  However, it has recently been found that activated genes do not necessarily harbour 
enhanced acetylation at their promoters or within coding regions.  Therefore, despite HDI-
mediated up-regulation of gene expression, the associated ‘active’ histone acetylation marks were 
non-significant (Halsall et al., 2012).  There is also evidence that HDI treatment only results in 
transient acetylation (Rada-Iglesias et al., 2007) and that this affects genes which are already in 
the transcriptionally active state (Wang et al., 2009).   
  It is likely that HDIs exert the aforementioned effects via binding to the multi-protein 
complexes that HDACs function in, and it has been observed that HDIs have varied affinities for 
the subunits and HDAC enzymes.  These included HDIs with higher affinities for certain 
isoforms or complex subunits, as well as isoforms which did not respond to some HDIs.  For 
example, the hydroxamates and cyclic tetrapeptides exhibited higher specificity for the Sin3 
complex, while the benzamides had preference to the NCoR/SMRT and HDAC3 complex.  It 
was also observed that HDIs interact with different co-repressors, although these multi-protein 
complexes share the same catalytic HDAC subunit (Bantscheff et al., 2011).  
Furthermore, despite their shared ability to inhibit HDAC enzymes, there are only a small 
percentage of similarities between altered gene expression profiles following drug treatment.  As 
previously highlighted, these inhibitors belong to several chemical classes based on their 
structures.  Thus, the differential effects of HDAC inhibitors question the non-histone and non-
transcriptional targets of these compounds.  For instance, the transcriptional responses mediated 
by HDIs could be due to the acetylation of transcription factors that then act upon gene 
promoters.  It has also been observed in vitro that only certain HDIs, such as TSA and Vorinostat, 
are pro-apoptotic, while other inhibitors had no effect.  However, these HDIs could inhibit cell 
cycle progression at the G2/M phase (Halsall et al., 2012).  Distinct biological effects of ‘pan-
inhibitory’ hydroxamate HDIs have also been observed between two inflammatory breast cancer 
cells.  In addition to differential sensitivities between the cell lines, there were altered gene 
signatures that resulted in apoptosis and cell cycle arrest (Halsall et al., 2012; Chatterjee et al., 
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2013).   
In breast and bladder cell lines, hydroxamates such as TSA and Vorinostat, were 
associated with different gene expression signatures than the benzamide Entinostat, and only a 
small subset of genes were modulated similarly by all three HDIs in multiple cell lines.  These 
genes were most often associated with apoptosis and cell cycle inhibition (Glaser et al., 2003).  
Numerous studies have also highlighted differential HDI-mediated gene signatures between the 
same chemical classes, wherein less than 10% of genes were similarly altered.  The treatment of 
two inflammatory breast cancer cell lines with hydroxamic acids, TSA and CG-1521, inhibited 
the cell cycle, albeit at different cellular checkpoints (G1 versus G2/M), and initiated apoptosis, 
but exhibited variations between gene expression.  There were also diverging effects on 
cytoskeleton and actin acetylation, leading to cytoskeletal abnormalies.  It was postulated that 
these differences were due to the heterogeneity of the breast cancer cell lines and complement of 
expressed HDACs (Chatterjee et al., 2013).   
Studies involving selective knock-down of individual HDAC enzymes and class-specific 
treatment with HDIs have illustrated additional differential effects of HDIs.  For example, while 
the short-chain fatty acid valproate and the hydroxamic acid Belinostat are both class I-specific 
compounds, they affected the regulation of different sets of genes in the HeLa cell line.  Knock-
down of HDACs 1 through 3 didn’t mimic HDI-mediated gene effects within the cells, and 
resulted only in reduce viability with no effect on cell cycle progression (Dejligbjerg et al., 
2008).  Furthermore, in colorectal cell lines, ‘pan-inhibitory’ hydroxamates Vorinostat and 
LBH589, shared similar cellular effects such as apoptosis, histone acetylation and cell cycle 
arrest, but differentially responded with respect to gene expression.  A small percentage of genes 
associated with mitosis, anti-angiogenesis and anti-apoptosis were similarly regulated between 
two cell lines (LeBonte et al., 2009).  
  In addition to HDIs inhibiting HDACs, it is likely that they inhibit other Zn
2+
-dependent 
enzymes, and could likely exert their effects through additional pathways.  It has recently been 
demonstrated that Vorinostat disrupts the Sin3 co-repressor complex through dissociation of the 
Ing2 subunit.  Thus, in addition to the effects of these compounds on the inhibition of HDAC 
enzymes, they also possess off-target effects and disrupt the integrity of the co-repressor 
complexes (Sardiu et al., 2014).  Furthermore, HDACs are able to act within the cell in the 
absence of their deacetylase ability.  It is also interesting to note that HDAC knock-out does not 
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phenocopy HDI treatment (Dejligbjerg et al., 2008; Sun et al., 2013).  For example, it has been 
shown that simultaneous knock-down of HDAC1 and Belinostat treatment negated the apoptotic 
effects of HDI treatment, which was not observed with knock-down of other class I HDACs 
(Dejligbjerg et al., 2008).   
 






  In 1993, three independent research groups identified a gene whose protein induction was 
involved in growth suppression and associated both with wild-type p53 and cyclin-dependent 
kinase (CDK)/cyclin complexes.  This gene encoded a 21 kDa protein and was named p21 WAF1 
(wild-type associated factor-1) and p21 CIP1 (CDK-interacting protein) (el-Deiry et al., 1993; 
Harper et al., 1993; Lagger et al., 2003).  It will be referred to as p21
WAF1
 in this thesis.  It was 
illustrated that this gene contained a p53 binding site located 2.4 kilobase-pairs upstream of the 
coding region (el-Deiry et al., 1993), and interacted with cyclins A, D1 and E with CDK2 in co-
immuno-precipitation experiments (Harper et al., 1993).  In addition to p53-dependent 
transcription, p21
WAF1
 is transcribed in a non p53-dependent manner.   
The cell cycle is tightly regulated through the activity of cyclin/CDK complexes and the 
cyclin-dependent kinase inhibitors (CKIs) (Jung et al., 2010; Warfel and el-Deiry, 2013).  These 
cyclin and CDK complexes function to phosphorylate pRb and thus induce expression of E2F 
regulatory genes involved in cell proliferation.  The CKIs are a family which includes the 






, and share conserved 
domains at their amino-terminal region, with variable regions at the carboxy-terminal region 
(Gartel and Tyner, 2002; Warfel and el-Deiry, 2013).  The cyclin-dependent kinase inhibitor 
p21
WAF1
 negatively regulates the progression of the cell cycle through inhibition of cyclin/CDK2 
complex activity (Sherr and Roberts, 1999).  The over-expression of p21
WAF1 
is associated with 
cell cycle arrest at the G1, G2 or S phases (Gartel and Tyner, 2002), and dysregulation of 
p21
WAF1
 is frequently observed in various tumours, leading to cellular growth advantages (Figure 
1.5) (Warfel and el-Deiry, 2013).  It has been extensively documented in the literature that HDI 
treatment induces p21
WAF1














Figure 1.5.  Functions of the p21
WAF1 
tumour suppressor gene.  When activated, p21
WAF1 
leads to cell cycle arrest through inhibiting the action of cyclin/CDK complexes and 
repressing pro-mitotic genes.  Alternatively, when de-regulated, the repressive qualities of 
p21
WAF1




and Tyner, 2002). 
 




  The promoter of p21
WAF1
 has six conserved GC boxes that bind the Sp1 family of 
transcription factors.  It has further been demonstrated that a critical region -78 and -72 upstream 
is required for HDI-mediated activation (Sowa et al., 1997; Huang et al., 2000; Lagger et al., 
2003).  It is thought that the growth inhibition mediated by p21
WAF1
 induction contributes to the 
anti-cancerous effects of these chemotherapeutics.  While p21
WAF1
 expression is activated both in 
a p53-independent and -dependent manner, the activation of p21
WAF1
 following HDI treatment is 
independent of the tumour suppressor protein p53 and new protein synthesis (Lagger et al., 2003; 
Simboeck et al., 2010).  In addition, the up-regulatory effects that these compounds have on 
p21
WAF1
 expression are likely due to the accumulative effect of several mechanisms.   
  It has previously been illustrated that Vorinostat-mediated induction of p21
WAF1
 is likely 
through the two Sp1 binding sites at the promoter, and that Vorinostat failed to alter the binding 
affinity of the Sp1 and Sp3 transcription factors to these sites (Huang et al., 2000).  Furthermore, 
Vorinostat treatment modified the acetylation and methylation of histones at the p21
WAF1
 
promoter, an effect absent in genes unaffected by HDI treatment.  This was accompanied by a 
decrease in HDAC1 and increase in RNA pol II at the promoter region (Gui et al., 2003).  In 
addition, enhanced p21
WAF1 
expression due to TSA administration is mediated through MAP 
kinase (MAPK) signalling, resulting in histone H3 serine 10 (H3S10) phosphorylation at the 
promoter region of p21
WAF1
.  This preceeded the acetylation of H3K14 and RNA pol II binding.  
However, acetylation mediated by TSA is not sufficient for activation; MAPK signalling and 
phosphorylation of H3S10 is additionally required (Simboeck et al., 2010).  Furthermore, 
disruption of the Ing2 and Sin3 complex mediated by Vorinostat abrogates the co-repressor 
binding to the p21
WAF1
 promoter, contributing to the anti-proliferative effects of these compounds 
(Smith et al., 2010). 
 It has also been shown that p21
WAF1
 is silenced when HDAC1 and PP2A associate with 
co-repressor complexes and the Sp1 and Sp3 transcription factors at the promoter (Sun et al 
2002; Simboeck et al., 2010).  In addition, the protein kinase CK2 associates with Sp3-recruited 
HDAC2 to phosphorylate it and increase oestrogen-dependent proliferation in breast cancer cells 
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(Sun et al., 2002).  Furthermore, HDAC1 regulates cellular proliferation and represses p21
WAF1
 in 
embryonic mouse cells; hdac-null mouse embryos exhibited increased p21
WAF1
 expression and 
hindered proliferation.  In this way, HDAC1 is involved in cellular proliferation mediated 
through p21
WAF1
, as previously highlighted (Lagger et al., 2003; Gui et al., 2004; Senese et al., 
2007; Zupkovitz et al., 2010).   
  While p21
WAF1
 is universally up-regulated with HDI treatment (Gartel and Tyner, 2002; 
Ocker and Scheider-Stock, 2007; Simboeck et al., 2010), gene repression mediated by these 
compounds are more diverse and dependent upon the inhibitor utilised.  The Bonham Lab has 
demonstrated that SRC, and more recently MYC, are transcriptionally repressed in cancer-
derived cell lines following treatment with ‘pan-specific’ HDIs, such as TSA and sodium 
butyrate (NaB) (Kostyniuk et al., 2002; Dehm and Bonham, 2004; Bonham and Beaton-Brown, 
unpublished data).  This repression is independent to imbalances in the HAT/HDAC ratio and 
inhibition of HDAC enzymes, and is likely due to non-target effects that these compounds have 
within the cell.  Both SRC and MYC are proto-oncogenes and will be discussed in more detail 
below.   
 
1.5.2 SRC        
 
The proto-oncogene SRC encodes the non-receptor tyrosine kinase pp60
Src
 (Src) and is 
the founding member of the Src-family kinases (SFKs).  It is the cellular homologue of the 
oncogenic viral protein v-Src, the avian Rous Sarcoma virus isolated from poultry (Rous, 1911; 
Brown et al., 1996; Wheeler et al., 2009), and since its discovery in 1976, several homologues 
have been identified in the human genome.  These SFKs include the ubiquitously expressed Fyn 
and c-Yes, as well as the haematopoietic-specific kinases Hck, Lck, Yrk, Blk, c-Fgr and Lyn 
(Cance et al., 1994; Lee et al., 1994; Oberg-Welsh and Welsh, 1995; Thuveson et al., 1995; 
Parsons et al., 2004; Roskoski, 2004; Wheeler et al., 2009).  Through downstream mediators, Src 
is involved in myriad oncogenic cellular processes, such as proliferation, cell motility, 
angiogenesis, cell-cell adhesion, survival and differentiation (Thomas and Brugge, 1997; Biscardi 
et al., 1999; Frame, 2004).  Thus, over-expression and/or enhanced activity of Src signalling is 
commonly observed in many cancers.  In fact, it has been illustrated both in our laboratory and 
other research groups that Src is up-regulated and activated in many cancer-derived cell lines and 
 48 
 
contributes to tumorigenic processes (Cartwright et al., 1989, 1990; Iravani et al., 1998, Brunton 
et al., 1997, Dehm and Bonham, 2004; Alvarez et al., 2006; Wheeler et al., 2009).  While these 
processes will be discussed in greater detail in a forthcoming section, it was further determined 
that this over-activation is resultant from enhanced transcription of the SRC gene (Dehm et al., 
2001).  This transcriptional activation of SRC and its repression by certain HDIs has become a 
focus in our laboratory. 
 
1.5.2.1 The Regulation of SRC and Src 
 
1.5.2.1.1 SRC Transcriptional Regulation  
 
SRC contains 14 exons and is transcribed from two alternative promoters associated with 
a unique 5’ UTR (Figure 1.6).  These promoters, which were labelled 1A and 1α, are 1 kilo-
basepairs away from one another.  SRC 1α is tissue-specific to the stomach, liver, kidney, 
prostate and pancreas, while the 1A promoter is ubiquitously expressed.  While both the SRC 
promoters have an initiator element and lack a TATA box, they are controlled by different 
mechanisms critical for function.  The 1α promoter is regulated by the transcription factor HNF-1 
(hepatocyte nuclear factor-1), whereas the housekeeping 1A promoter has a high GC content and 
is controlled by the Sp1 family of transcription factors through the GC1 and GA2 sites.  SRC 1A 
also associates with the hnRNP K through three polypurine:polypyrimidine tracts (Bonham et al., 
1993, 2000).   
It has been illustrated that both promoters are active and able to control transcription in 
cancer-derived cell lines, although certain preferences exist.  For instance, the T47D breast 
cancer cell line transcribes SRC predominantly from the 1A promoter while the Colo201 
colorectal cells utilise both 1A and 1α (Bonham et al., 2000).  Despite the different regulatory 
mechanisms of the 1A and 1α promoters, both are repressed equally by certain HDIs, such as 
NaB and TSA.  This down-regulation did not depend on neo-protein synthesis and was observed 
at both the RNA and protein levels (Kostyniuk et al., 2002).  As mentioned, this HDI-mediated 
repression has been extensively investigated in our laboratory. 
It has also been found that SRC expression is down-regulated following HDI treatment 








Figure 1.6.  The organisation of the SRC gene.  Indicated are the 1α and 1A promoters, 




additional SFK members.  HDI-mediated down-regulation of gene expression occurred upon 
TSA and NaB treatment in a dose- and time-dependent manner in colorectal and 
hepatocarcinoma cell lines (Kostyniuk et al., 2002; Dehm and Bonham, 2004; Hirsch et al., 
2006).  This down-regulation of mRNA expression occurred through transcriptional repression 
independent of new-protein synthesis (Hirsch et al., 2006).  Recent research in the Bonham Lab 
has illustrated that it is likely due to a post-initiation event stalling RNA pol II at the promoter.  
In fact, chromatin immuno-precipitation (ChIP) experiments performed by PhD candidate Erika 
Beaton-Brown have illustrated that H3 acetylation and H3K4 tri-methylation increases at the 
promoter of SRC, suggesting activation of the gene.  In addition, ChIP analyses have indicated 
that RNA pol II is present at the promoter, whereas H3K36 tri-methylation, a marker of 
elongation, is decreased across the coding region of the gene.  The presence of the negative 
elongation factor NELF is also increased at the promoter, indicating a promoter proximal paused 
gene.  These observations have also been demonstrated for two additional genes regulated in a 
similar manner to SRC, in particular the oncogenic transcription factor MYC (Bonham and 
Beaton-Brown, unpublished data).    
 
1.5.2.1.2 Src Regulation 
 
The structures of the SFKs are highly conserved and diverge only in their amino-terminal 
‘unique’ domain.  Src family kinases are targeted to the plasma membrane through 
myristoylation of the Src homology 4 (SH4) domain, amino-terminal to the unique domain.  The 
Src homology 3 (SH3) domain, which binds polyproline-rich sequences, and the Src homology 2 
(SH2) domain are adjacent to a polyproline-rich linker domain (Cooper and King, 1986; 
Roskoski et al., 2004; Okada, 2012).  The SH2 domain, highly conserved among species, 
recognises phospho-tyrosine proteins and contains an arginine molecule that contributes to the 
electrostatic interactions (Eck et al., 1993; Watts et al., 1993; Boggon and Eck, 2004), and the 
SH3 domain contains hydrophobic and aromatic amino acids that recognise ‘PxxP’ sequences 
(Feng et al., 1994; Lim et al., 1994; Boggon and Eck, 2004).  The catalytic tyrosine kinase 
domain contains a positive regulatory tyrosine residue in the activation loop, whereas the 
carboxy-terminal tail region contains a negative regulatory tyrosine (Cooper and King, 1986; 
Roskoski et al., 2004; Okada, 2012).  
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Src contains three domains which are essential for proper regulation and function, and is 
controlled through reciprocal phosphorylation and dephosphorylation of the key regulatory 
tyrosine residues (Copper and King, 1986; Courtneidge, 1985; Okada and Nakagawa, 1989; 
Okada, 2012).  In normal resting cells, Src is tightly locked into a closed conformation through 
interaction of phosphorylated tyrosine 530 in the carboxy-terminal tail with the SH2 domain, 
mediated by the negative regulator of Src function, the cellular Src kinase (Csk) (Copper and 
King, 1986; Courtneidge, 1985; Okada and Nakagawa, 1999).  The intra-molecular interaction of 
the phospho-tyrosine with the SH2 domain properly positions the additional interaction of the 
SH3 domain with the polyproline-rich linker domain, contributing to the auto-inhibitory ‘locked’ 
state by burying the positive regulatory tyrosine 417 (Williams et al., 1997; Xu et al., 1997; 
Boggon and Eck, 2004).  Src is activated through a series of dephosphorylation and 
phosphorylation events upon signalling effectors, which interact with the SH2 domain to 
destabilise the intra-molecular interactions and unlock the conformation of Src.  This leads to the 
dephosphorylation of tyrosine 530 and autophosphorylation of tyrosine 417, which is no longer 
buried within the protein structure.  Upon activation, Src can interact with and phosphorylate 
downsteam effectors and propagate cellular signalling, leading to neoplasticity (Courtneidge, 
1985; Cooper and King, 1986; Kmiecik et al., 1988; Okada and Nakagawa, 1989; Wheeler et al., 
1999; Okada, 2012).   
 
1.5.2.2 The Role of Src in Cancer 
 
 Due to the role of Src in tumorigenic processes such as increased proliferation, cell 
motility, angiogenesis, cell-cell adhesion, cell survival, it is unsurprising that it is up-regulated in 
cancer.  In fact, the over-expression and/or aberrant activity of Src
 
has been observed in many 
cancers and cell lines derived from cancerous tissue, including breast and colorectal, and 
mediates pathways that lead to cellular proliferation and angiogenesis (Cartwright et al., 1989, 
1990; Dehm and Bonham, 2004; Alvarez et al., 2006; Wheeler et al., 2009).  Interestingly, it was 
shown early in the literature that NIH-3T3 murine cells transfected with either chicken SRC, 
Rous Sarcoma v-Src or recombinant Src plasmids constructed from the 5’ of SRC and the 3’ of 
v-Src exhibited differential transformation properties, indicating that oncogenic potential of SRC 
is dependent upon additional signalling.  Although SRC transfected cells exhibited increased 
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tyrosine kinase activity and morphological characteristics differentiating them from normal 
untransformed cells, SRC was unable to transform the cells.  However, v-Src and recombinant-
Src exhibited transformative properties (Shalloway et al., 1984).  It was then speculated that the 
oncogenic potential for v-Src lies within the 3’ region, which differs from Src in that it lacks the 
carboxy terminal tail and therefore the negative regulatory tyrosine (Shalloway et al., 1984; 
Cooper et al., 1986; Courtneidge et al., 1987; Okada et al., 1999). 
It has been established for approximately two decades that the kinase activity of Src is 
significantly increased in carcinoma compared to normal tissue (Cartwright et al., 1990; 
Ottenhoff-Kalff et al., 1992; Talamonti et al., 1993).  Furthermore, Src activation is an early 
event in carcinogenesis (Cartwright et al., 1990) and can lead to metastasis (Talamonti et al., 
1993).  It has been observed that this enhanced activity is mediated by enhanced transcription of 
the gene and/or the autophosphorylation of the activating tyrosine 416 site (Kmieck et al., 1988; 
Dehm and Bonham, 2004).  Through phosphorylating downstream signal effectors, Src 
contributes to the progression of a variety of oncogenic signalling processes, such as cellular 
proliferation, angiogenesis, invasion and migration (Figure 1.7) (Frame, 2004; Li et al., 2009). 
While up-regulation of Src alone cannot transform cells or prolong tumour growth in 
mice (Shalloway et al., 1984; Luttrell et al., 1988; Biscardi et al., 2000), Src is thought to 
contribute to oncogenic processes by activating its downstream signalling pathways (Guy et al., 
1994; Biscardi et al., 2000).  Src can interact with various receptors and signalling molecules, 
and is frequently up-regulated with other oncogenic proteins (Maa et al., 1995; Tice et al., 1999).  
For instance, Src is required for the polyomavirus middle T oncogene to initiate mammary 
tumour development in transgenic mice (Guy et al., 1994). It has also been well-established that 
SRC can co-operatively act with receptor tyrosine kinases, such as the human epidermal growth 
factor receptor 1 (EGFR) to induce tumour formation in immune-compromised mice (Maa et al., 
1995).  Both Src and EGFR have been shown to be elevated in cancer and form heterocomplexes, 
synergistically acting to promote cellular growth.  Src potentiates EGFR-induced DNA synthesis, 
proliferation and tumour formation in immune-compromised mice (Maa et al., 1995; Tice et al., 
1999). 
In addition, there is a regulatory network between Src and ERα signalling, where 
oestrogen administration activates downstream pro-mitotic effectors in a manner dependent on 













Figure 1.7.  Tumourigenic and anti-neoplastic effects of Src signalling.  Src is over-expressed 
in many cancers and leads to tumourigenic processes such as proliferation, survival and 





proliferation, Src expression leads to the loss of intercellular adhesions (Avizienyte et al., 2002; 
Frame, 2004) as well as increased resistance to anoikis, likely through activation of the PI3K/Akt 
pathway.  For example, colorectal cancer cell lines transfected with antisense SRC exhibited 
detachment-induced cellular death (Windham et al., 2002; Frame, 2004).   
Src over-expression and increased activity can also propagate tumorigenic processes.  For 
instance, Src-mediated phosphorylation of the Crk-associated substrate (p130
Cas
 or Cas), a 
component of the focal adhesion complex, enhances migration and metastasis in transformed 
cells (Goldberg et al., 2003).  It has been shown that phosphorylation of Cas at the YxxP motifs 
within its substrate domain mediates binding to SH2-domain containing effectors (Shin et al., 
2004; Li et al., 2009).  This process has been shown to be augmented by microRNA (miRNA), 
wherein active Src leads to induction of miR-224, further enhancing cellular growth.  These 
miRNA are small, non-coding transcripts controlling gene expression and will be discussed in 
further detail in an upcoming section. 
Interestingly, Src signalling represses miR-126, which targets the 3’ UTR of Crk, another 
focal adhesion complex component, to inhibit Src-mediated migration of transformed cells.  
Furthermore, contact normalisation, a process where SRC-transformed cells regain their normal 
morphology upon contact with non-transformed cells, is mediated by miR-126.  Therefore, Src 
activates Cas/Crk signalling in a dual manner, by activating Cas through phosphorylation and by 
decreasing miR-126 production, leading to an increase of Crk (Li et al., 2009).   
It has been reported that enhanced Src signalling promotes latent bone metastases in 
primary breast cancer, and is an indicator of poor prognosis in patients with bone metastasis 
(Zhang et al., 2009, 2012).  A gene expression profile associated with Src signalling correlated 
with increased bone metastases, independent of ERα expression, molecular subtype, 
differentiation and tumour grade of the primary tumour.  Furthermore, as illustrated in lung- and 
brain-derived cell lines, the increased levels of activated Src were insignificant compared to those 
observed in bone metastatic-derived cell lines.  Therefore, signalling from the SRC kinase, but 
not SFK members c-Yes and Fyn, promotes disseminated cancer cells to proliferate in the bone 
marrow tumour microenvironment.  It is thought that Src functions through the chemokine 
CXCL12 to advance cell growth and lessen pro-apoptotic signalling (Zhang et al., 2009).  
Src signalling has also been implicated in invasive properties in hormone- and growth 
factor-resistant ERα-positive tumours.  As previously highlighted, hormone receptor-positive 
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breast cancers treated with endocrine therapies can develop resistance to treatment, ultimately 
leading to relapse and increased mortality among survivors.  It has been shown that increased Src 
signalling is associated with endocrine therapy resistance, due to the role Src plays in cell-cell 
and cell-matrix functions, promoting an aggressive, invasive phenotype (Hiscox et al., 2006).  
Furthermore, Src kinase activity is amplified in metastatic, invasive cell lines (Mao et al., 1997; 
Jackson et al., 200l; Slack et al., 2001; Irby and Yeatman, 2002; Hiscox et al., 2006) and Src 
inhibition mediated by AZD0530, a Src/Abl small molecule inhibitor, negates invasion and 
migration in resistant cell lines.  In addition, acquired resistance to tamoxifen involves Src kinase 
activity (Hiscox et al., 2006).    
Due to its role and enhanced activation in cancers, Src is an attractive target in 
chemotherapy treatments (Dehm and Bonham, 2004; Alvarez et al., 2006; Wheeler et al., 2009).  
There are various small molecule tyrosine kinase inhibitors in clinical trials that have shown 
efficacy against treating numerous malignancies, including breast, colorectal and prostate 
cancers.  For instance, dasatinib targets the SFKs, as well as c-Kit and platelet-derived growth 
factor receptor (PDGFR), to inhibit proliferation and migration in vitro and decrease metastatic 
potential and tumour growth in vivo (Montero et al., 2011).  It can also lead to apoptosis, a 
process mediated through inactivation of Src (Vandyke et al., 2009).  In fact, the inactivation of 
Src activity, mediated by inhibitors such as dasatinib, is thought to be partially responsible for the 
anti-cancerous effects of the small molecule tyrosine inhibitors (Ishizawar et al., 2004; Park et 
al., 2008). 
 
1.5.3 MYC       
 
The MYC proto-oncogene, discovered over three decades ago, is the mammalian 
homologue of the avian myelocytomayosis viral v-MYC oncogene (Bishop, 1982; Escot et al., 
1986; Lao and Dickson, 2000; Singhi et al., 2012).  It is located at chromosomal location 8q24.1 
and transcribes three separate proteins from separate initiation sites; the major product is a 62 
kDa protein (termed ‘MYC2’) and is the form frequently referred to as ‘MYC’ in the literature.  
MYC1 and MYC2, respectively transcribed from a non-AUG and an AUG start codon, encode 
proteins approximately 62-64 kDa (Henriksson and Luscher, 1996; Facchini and Penn, 1998; 
Xiao et al., 1998; Lao and Dickson, 2000).  The promoter(s) of MYC shares similarity to SRC 
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and contains several upstream positive and negative cis- and trans-elements, such as 
CCCTCCCCA (CT)-elements that can bind a myriad of regulatory factors, including Sp1 and 
hnRNPK.  Furthermore, the promoter can be acted upon by various transcription factors (Levens, 
2008). 
Myc is a nuclear phospho-protein transcription factor thought to co-operate with other 
transcription factors to control approximately 10-15% of the human genome, including those 
genes implicated in cell growth and transformation.  While Myc regulation is tightly controlled 
by characteristically short protein and mRNA half-lives in non-mitotic or differentiated cells, it is 
up-regulated following mitogenic signals.  Hence, it is often associated with increased 
proliferation (Spencer and Groudine, 1991; Nass and Dickson, 1997; Levens, 2008).  The cellular 
processes controlled by Myc are diverse and include pathways such as apoptosis, differentiation, 
growth, adhesion, metastasis and metabolism (Figure 1.8).  Although, it has been shown that 
those genes activated or repressed by Myc can be cell- or context-specific, and therefore Myc can 
therefore regulate both oncogenic and tumour suppressive functions (Nass and Dickson, 1997; 
Jamerson et al., 2004; Chen and Olopade, 2008).   
Myc contains an amino-terminal transactivation domain (TAD) with two Myc homology 
boxes (MI and MBII) conserved across Myc family members.  The MBI domain is necessary for 
the transactivational functions of Myc, while the MBII domain is required for transcriptional 
repression (Cole and McMahon, 1999; Sakamuro and Prendergast, 1999; Lao and Dickson, 
2000).  Additionally, it has been shown that the TAD modulates apoptosis (Chang et al., 2000; 
Lao and Dickson, 2000).  The carboxy-terminus harbours a basic region (BR) and a helix-loop- 
helix/leucine zipper (HLH/LZ) domain, which are necessary DNA binding and hetero-
dimerisation with the Max and/or TFII-I transcription factors.  The transcriptional activation of 
Myc is mediated through the Max/Myc complexes upon binding to E-box elements in DNA 
sequences, whereas transcriptional repression is mediated through TFII-I/Myc complexes.  These 
E-box elements contain central CAC(G/A)TG sequences (Roy et al., 1993; Nass and Dickson, 
1997; Facchini and Penn; 1998; Dang 1999; Lao and Dickson, 2000).  
 
1.5.3.1 The Role of Myc in Breast Cancer 
 
Since its discovery, the MYC proto-oncogene has been shown to be amplified, rearranged 















Figure 1.8.  The tumourigenic functions of Myc.  Myc, a transcription factor activated in 
numerous cancers, leads to cellular processes associated with aberrant growth mainly through 
gene activation and/or repression.  Inhibiting Myc has been considered a viable therapeutic 




aggressiveness, poor prognosis and clinical outcome (Escot et al., 1986; Wong et al., 1986; 
Dubik et al., 1987; Blanchard et al., 1988; Bonilla et al., 1988; Garcia et al., 1989; Chen and 
Olopade, 2008; Horiuchi et al., 2012).  MYC amplification is also observed in non-mammary 
tumours, such as colon and small-cell lung carcinoma cell lines (Little et al., 1983; Escot et al., 
1986; Jenkins et al., 1997; Visscher et al., 1997).  Through chromosomal analysis, it has been 
demonstrated that the MYC locus can be copied between 2-20 times, and is often correlated with 
hormone receptor-negative and basal breast cancers (Garcia et al., 1989; Aulmann et al., 2006).  
In addition, MYC-amplified tumours relapse earlier than non- amplified, and those tumours 
which did not exhibit MYC copy number variations showed increased copies upon relapse and 
metastasis (Aulmann et al., 2006; Singhi et al., 2012).  This potentially indicates that MYC 
amplification is an acquired event in metastasis and that up-regulation is important for cancer 
progression (Singhi et al., 2012). 
  Triple-negative breast cancers have both elevated Myc expression (Lao and Dickson, 
2000) and high expression of Myc target genes over those cancers which are hormone-positive, 
and this correlates with a higher rate of proliferation in vitro and in vivo (Horiuchi et al., 2012).  
Repressing Myc and its target genes in triple-negative breast cancers could be therapeutically 
beneficial and offers a new treatment strategies for those cancers (Chen and Olopade, 2008; 
Horiuchi et al., 2012).   
  Furthermore, MYC amplification is positively associated with HER2-enrichment in breast 
tumour biopsies (Gaffey et al., 1993; Bolufer et al., 1994; Lao and Dickson, 2000), and could be 
implicated in tumorigenesis of ERα-positive breast cancers.  The MYC promoter contains a 
partial ERE site and CG-rich Sp1 binding site, and upon ERα binding, induces transcription 
(Dubik and Shiu 1992; Nass and Dickson, 1997).  In addition, oestradiol increases MYC mRNA 
levels in ERα-positive cell lines, a phenomenon inhibited by tamoxifen treatment (Dubik et al., 
1987; Wong et al., 1991; Shui et al., 1993; Tsai et al., 1997; Lao and Dickson, 2000).  
Interestingly, it has also been illustrated that MYC amplification confers resistance to anti-
oestrogen treatments (Venditti et al., 2002) and that ERα-negative breast cancers exhibit Myc 
induction, which is often associated with enhanced growth (Sorlie et al., 2001; Naidu et al., 2002; 
Alles et al., 2009).   
Myc is moderately and spontaneously tumorigenic in mouse models; furthermore, this 
tumorigenicity is enhanced when another proto-oncogene is simultaneously over-expressed (Nass 
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and Dickson, 1997; Lao and Dickson, 2000; Rose-Hellekant and Sandgren, 2000).  Transgenic 
mice expressing MYC under the control of the mouse mammary tumour virus (MMTV) promoter 
exhibit low latency mammary carcinoma development within one year of age, regardless of 
pregnancy or virgin status of the female mouse (Nass and Dickson, 1997; Lao and Dickson, 
2000; Rose-Hellekant and Sandgren, 2000).  However, co-transfection with a plasmid expressing 
a secondary oncogene, such as HER2/neu, increased both breast tumour development and the 
frequency of tumour formation (Stewart et al., 1984; Nass and Dickson, 1997; Lao and Dickson, 
2000; Jamerson et al., 2004).  In fact, tumours developed in all test sample mice, and the 
observed latency period reduced from one-plus year to approximately three months (Muller et al., 
1988; Jamerson et al., 2004).  It is interesting to note that the HER2/neu and MYC transgenic 
mice also exhibited elevated Src activity, likely due to HER2-mediated SRC activation (Cardiff 
et al., 1991; Muthuswamy et al., 1994; Nass and Dickson, 1997; Singhi et al., 2012).  In addition, 
the tumour suppressive gene BRCA1 is able to block the transactivation properties of Myc, and 
BRCA1-null mice models exhibit dysregulated MYC expression, further contributing to 
neoplasia (Jamerson et al., 2004). 
Additionally, MYC transgenic mouse models with homozygous deletions of the p53 
tumour suppressive gene exhibit chromosomal instability and aggressive lymphoma 
(McCormack et al., 1998).  Contrary, p21
WAF1-/-
 null mice expressing MYC under the MMTV 
promoter had increased breast tumour latency and decreased incidence of tumour formation.  It 
was postulated that p21
WAF1
 acts as a modifier for Myc-mediated tumorigenesis by enhancing 
cyclin D expression and progression through the cell cycle.  This potentially highlights the 
complicated role Myc plays in cancer progression (Bearss et al., 2002; Jamerson et al., 2004). 
  While MYC has been demonstrated to regulate numerous processes, extensive research 
has also indicated a role for Myc in cell cycle control and apoptosis, particularly in carcinoma 
cells (Nass and Dickson, 1997; Lao and Dickson, 2000; Jamerson et al., 2004).  The over-
expression of Myc is also correlated with these cellular functions (Evan et al., 1993; Singhu et 
al., 2012).  Myc is induced in breast cancer cell lines following activation of growth factor and 
hormone pathways, such as through the EGF-, oestrogen- and TGFα-induced pathways; this is 
associated with increased proliferation (Dubik et al., 1987; Leygue et al., 1995; Nass and 
Dickson, 1997).  While Myc is not thought to control cell cycle regulatory genes directly, as they 
lack the E-box motif, it is able to modulate regulation of cyclins and CDK kinase activities.  
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Myc-mediated cyclin E induction and p27
KIP1
 repression leads to increased activity of CDK2 and 
reduction of phosphorylated pRb (Nass and Dickson, 1997).  The inactivation of Myc reduces 
invasion in vitro and impairs metastasis in vivo (Wolfer et al., 2010). 
  An additional role for Myc in oncogenic processes has been shown through its 
involvement in apoptotic control.  Myc over-expression induces apoptosis in the absence of 
growth-factor signalling.  In the presence of growth factor signalling and Myc over-expression, 
apoptosis is inhibited.  Myc can also activate p53 and BAX, thus preventing the survival of cells 
with oncogenic backgrounds (Reisman et al., 1993; Miyashita et al., 1995; Nass and Dickson, 
1997).  This anti-apoptotic event can be bypassed by Bcl-2-mediated pro-apoptotic signals in the 
presence of MYC amplification (Strasser et al., 1990; Bissonnette et al., 1992; Fanidi et al., 
1992; Wagner et al., 1993; Nass and Dickson, 1997). 
 
1.5.4 microRNA       
 
  In 1993, researchers discovered a gene encoding a pair of short RNAs in Caenorhabditis 
elegans with anti-sense complementary to the 3’ untranslated region (UTR) of the developmental 
mRNA lin-14.  It negatively regulated lin-14 through binding to the 3’ UTR and inhibiting 
translation (Lee et al., 1993; Wightman et al. 1993; Bartel et al., 2004).  Due to its role in C. 
elegans developmental timing, this RNA strand was termed ‘short temporal RNA’ (stRNA).  For 
seven years, it appeared that lin-4 and its regulatory mechanism were particular to C. elegans, but 
the subsequent discovery of let-7 led to the identification of homologues in other species’ 
genomes through cloning efforts.  These also exhibited evolutionary conservation between the 
plant and animal kingdoms (Pasquininell et al., 2000; Brennecke et al., 2005; Schanen and Li, 
2011).   
 These short RNA molecules were found to be involved in processes other than developmental 
timing, and therefore were then termed as ‘microRNAs’ (miRNAs).  miRNA are small non-
coding transcripts that mediate post-transcriptional regulation of target messenger RNAs 
(mRNAs) through semi-perfect- or perfect-complementary binding to the 3’ UTR, leading to 
translational inhibition or mRNA decay (Bartel et al., 2004; Bagga et al., 2005).  It has been 
found that miRNA genes constitute approximately 1% of the genome (Brennecke et al., 2005) 
and regulate one-third of protein-coding genes in biological processes, including developmental 
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timing, haematopoiesis, cell differentiation, apoptosis and proliferation.   In addition, due to 
their promiscuous nature, multiple miRNA potentially target the 3’ UTR of one mRNA molecule 
(Bartel 2004; Schanen and Li, 2011).   
 
1.5.4.1 Transcriptional Regulation of microRNA   
                
The genomic location of miRNA can be categorised into ‘intragenic’ or ‘intergenic’.  
Simply, intergenic miRNA are located between genes, whereas intragenic miRNA are within 
genes.  Intragenic miRNA can be found within any genomic region of the chromosome, such as 
within introns of protein-coding genes (‘intronic’), or within introns and/or exons (‘exonic’) of 
non-coding genes (Corcoran et al., 2009; Ozsolak et al., 2009; Schanen and Li, 2011).  
Interestingly, due to variations in splicing, some intragenic miRNA span an exonic and intronic 
region (Rodriguez et al., 2004), and generally have different mechanisms of biogenesis than 
intergenic miRNA.   
Intragenic miRNA commonly share their transcriptional start sites (TSS) with their host 
gene (Rodriguez et al., 2004; Ozsolak et al., 2009); however, it has also been shown that some 
intronic miRNAs are controlled by their own promoters, which are embedded within an exon of 
their respective host genes.  Traditional mapping of potential TSS relying on RNA analyses are 
challenging due to the transient nature of primary miRNAs (pri-miRNAs) and their low 
concentration within cells.  Elucidations of  promoter regions of pri-miRNAs include 
computational approaches involving genome-wide RNA pol II binding patterns (Wang et al., 
2010) and ChIP-chip methods targeted for RNA pol II (Corcoran et al., 2009), or active 
chromatin markers H3K4me and/or H3K9/14Ac (Ozsolak et al., 2009).   
Potential promoter regions located upstream of the primary miRNA sequences for both 
intragenic and intergenic miRNAs were established through these assorted methods.  Similarities 
between miRNA and RNA pol II-controlled protein-coding gene promoters were identified, such 
as the presence of a TATA box, GC-rich regions, TFIIB recognition elements, chromatin 
modifications (H3K4me and/or H3K9/14Ac) or evolutionary conservation (Ozsolak et al., 2007, 
2009; Corcoran et al., 2009; Wang et al., 2010).  In addition, miRNA expression can be 
controlled by transcription factors; the oncogenic miR-17~92 polycistronic cluster, which is over-
expressed in B-cell lymphoma, can be transcribed upon MYC binding (Mu et al., 2009).  
However, there are some miRNA promoters that have no similar sequences to the protein-coding 
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genes, and lack a TATA box, TFIIB recognition element or other promoter-specific chromatin 
markers, such as the promoter identified for the multi-cistronic cluster of miR-23a~27a~24-2 
(Lee et al., 2004).   
Intragenic miRNA can be transcribed dependently or independently of their host gene, 
and regulatory sites possessing RNA pol II elements, such as CpG islands and transcription factor 
binding sites, have been identified upstream.  A small percentage have RNA pol III regulatory 
sequences as well as their host TSS, and can be transcribed both by RNA pol II and III (Monteys 
et al., 2010; Corcoran et al., 2009).  However, the majority of miRNA are intergenic and possess 
their own TSS (Rodriguez et al., 2004; Corcoran et al., 2009; Ozsolak et al., 2009; Schanen and 
Li, 2011).   
microRNA biogenesis is a three-step process occurring co-transcriptionally and within 
both the nucleus and cytoplasm (Figure 1.9).  Furthermore, the processes can be regulated at any 
stage.  microRNAs are transcribed in the nucleus as long nucleotide transcripts referred to as pri-
miRNA, most frequently by RNA pol II (Lee et al., 2004), although some miRNA undergo self-
directed transcription (Song et al., 2010) or as previously mentioned, transcription by the short 
non-coding RNA pol III (Borchert et al., 2006).  Generally, RNA pol II transcribes intragenic 
miRNA, whereas intergenic genes can be transcribed by both RNA pol II and III, or non-
canonical transcription (Schanen and Li, 2011).  Alu-elements can act as a promoter for miRNA 
and initiate transcription by RNA pol III (Gu et al., 2009), and clustered or ‘polycistronic’ 
miRNA are most often transcribed by the same TSS into one pri-miRNA molecule (Lee et al., 
2004).  Additionally, a small fraction of miRNA can self-transcribe in the absence of a promoter 
or control their own expression in a negative feedback loop.  For instance, mature miR-145 can 
activate p53, which in turn stimulates transcription of pri-miR-145 (Schanen and Li, 2011).  
Biogenic processing of miRNA, described in more detail below, depends on the method of 
transcription as well as the position of the miRNA within the genome.  Additionally, miRNA 
expression can be regulated at both the transcription and processing levels (Lee et al., 2003; Yi et 
al., 2003; Zeng et al., 2003; Rodriguez et al., 2004; Lund et al., 2004; Schanen and Li, 2011).  
Biogenesis includes cleavage of the pri-miRNA structure by the nuclear RNase 
endonuclease III Drosha, resulting in an approximately 65 to 70 nucleotide (nt) hairpin precursor 
miRNA (pre-miRNA) stem loop.  At this biogenic stage, those clustered pri-miRNAs transcribed 





Figure 1.9.  miRNA transcription and biogenesis.  Schematic representation of intragenic or 
intergenic miRNA transcription mediated by RNA pol II and/or III and subsequent processing by 
Drosha and Dicer.  The mature miRNA sequence is associated into the RISC complex with 




2003; Zeng et al., 2002, 2003; Yi et al., 2003; Lund et al., 2004; Rodriguez et al., 2004; Schanen 
et al., 2011).  Processing by Drosha on intronic miRNA occurs co-transcriptionally prior to 
splicing; both RNA pol II and Drosha have been demonstated to associate with the miRNA 
sequence of the gene (Morlando et al., 2008).  In addition, RNA pol II-transcribed pri-miRNAs 
have a 5’ cap structure and a 3’ poly(A) tail, similar to protein-coding genes, which are cleaved 
during subsequent processing (Cai et al., 2004).     
The pre-miRNAs are then transported to the cytoplasm through a RanGTP-dependent 
process utilising Exportin-5, where they are further processed into double stranded 20-25 nt 
duplex RNA by the cytoplasmic RNase III endonuclease, Dicer.  The mature miRNA specificity 
comes from Dicer rather than Drosha (Lee et al, 2003; Yi et al., 2003; Zeng et al., 2003; Lund et 
al., 2004; Rodriguez et al., 2004; Schanen and Li, 2011), and further studies have illustrated that 
Dicer cleavage is rate-limiting and could occur several hours following pri-miRNA transcription.  
It is also interesting to note that in studies examining pri-miRNA transcription and mature 
miRNA expression, fold-changes of pri-miRNA were generally higher, thus indicating a potential 
post-transcriptional regulation (Castellano et al., 2009).  Dicer recognises a double-stranded RNA 
molecule and cleaves two helical turns away from the terminal stem loop, leaving a double-
stranded RNA with a 5’ phosphate and a two nt 3’ overhang.  Multi-protein complexes composed 
of argonaute (Ago) proteins associate with the strand possessing the more stable 5’ end, and this 
RNA-induced silencing complex (RISC) then binds to the 3’ UTR of protein-coding mRNA.  
The seed sequence at the 5’ region of the miRNA is responsible for recruiting Ago proteins (Lee 
et al, 2003; Yi et al., 2003; Zeng et al., 2003; Lund et al., 2004; Rodriguez et al., 2004; Schanen 
and Li, 2011).  Furthermore, co-immuno-precipitation (co-IP) experiments have illustrated that 
Ago proteins associate with the RISC machinery and co-IP with mRNA targets; this has 
additionally been utilised to identify potential miRNA target genes (Karginov et al., 2007).  The 
less-common strand is typically degraded, although in certain circumstances, both strands serve 
as functional and mature miRNA sequences; while the less-common strand had been historically 
annotated by an asterisk (*) after the miRNA name, it is now commonly denoted by the ‘-3p’ 
strand, and the common miRNA by the ‘-5p’ strand (Lee et al, 2003; Yi et al., 2003; Zeng et al., 
2003; Lund et al., 2004; Schanen and Li, 2011).  Interestingly, miRNA possessing Alu-elements 
frequently bypass the processing machinery, and are less-responsive to exert transcriptional 
regulation on their target mRNA genes.  This is likely due to altered secondary structure or 
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adenosine to inosine editing (Hoffman et al., 2013). 
There are several differences that occur between intronic and exonic miRNA processing.  
It has been shown that unspliced transcripts with exonic miRNA sequences are located in the 
nucleus and available for Drosha cleavage, whereas spliced transcripts are found in the nucleus 
and cytoplasm.  Therefore, both spliced and unspliced transcripts result in pre-miRNA hairpins 
(Slezak-Prochazka et al., 2013).  It is also interesting to note that pri-miRNA embedded within 
their host transcript can function both as a pri-miRNA and mRNA.  This offers an additional 
level of regulation, as those pre-miRNA in the cytoplasm cannot be processed by Dicer.  The 
miRNA stem-loop located in a 3’ UTR of its host gene has the ability to moderately repress 
expression of the protein by sequestering it inside the nucleus, and following excision of the pre-
miRNA, splicing of the introns and subsequent translation can occur.  Contrary to intronic 
miRNA, exonic miRNA transcripts can only function as an mRNA or as a pre-miRNA, as 
excision of the pre-miRNA would disrupt the coding sequence (Cai et al., 2004).  Intronic 
processing often occurs co-transcriptionally and in co-operation with the splicing complex 
producing an mRNA transcript (Cai et al., 2004; Kim and Kim 2007), although pri-mRNA 
cleavage by Drosha can also occur post-splicing in the absence of splicing machinery, and does 
not affect mature miRNA or mRNA production (Kim and Kim 2007).  Furthermore, non-coding 
transcripts in the cytoplasm can serve as competing endogenous targets and sequester miRNA 
from their protein-coding gene targets (Cai et al., 2004). 
Interestingly, it has recently been shown that Ago1, which is usually cytoplasmic, 
associates with RNA pol II and active chromatin marker H3K4me
3
 at miRNA-putative genomic 
regions.  While Ago1 presence could be found at various genetic regions, such as promoters, 5’ 
and/or 3’ UTRs, introns or exons, it was enriched at the TSS of transcriptionally active genes, 
particularly those involved with oncogenic processes.  Due to Ago1 lacking a proper DNA-
binding motif, it is speculated that miRNA are required for the interactions to occur.  This is 
further supported by experimental knock-down of Dicer and Drosha, which reduced RNA pol II-
Ago 1 binding to the chromosome.  This potentially illustrates an additional regulatory role of 






1.5.4.2 microRNA-Mediated Regulation of Gene Expression 
 
Bioinformatics have been used to predict many mRNA targets with ‘miRNA response 
elements’ (MREs).  microRNA can perfectly or imperfectly bind to the 3’ UTR of target protein-
coding genes and lead either to mRNA cleavage and degradation, or translational inhibition, 
respectively (Bartel 2004; Bagga et al., 2005; Schanen and Li, 2011).  However, it has been 
shown that let-7 can bind imperfectly to lin-14 and result in transcript degradation (Bagga et al., 
2005).  It is thought that the specificity of miRNA binding to the 3’ UTR comes in part from the 
2-8 nt region at the 5’ end, referred to as the ‘seed region’, although other requirements and 
factors for target binding exist (Brennecke et al., 2005; Grimson et al., 2007).  It has been shown 
that many miRNA recognition sites can be hindered by several factors, including the presence of 
AU rich base-pairs near the seed region, the adjacent proximity of co-repressive miRNA sites 
and/or a close distance to the stop codon.    microRNA tend to act synergistically as well, and 
often two or more miRNA are required for optimal repression (Grimson et al., 2007). 
mRNA:miRNA recognition sites can be classified into three categories; canonical 5’ 
dominant sites, seed 5’ dominate sites and 3’ compensatory sites.  Canonical and seed 5’ 
dominant sites exhibit strong 5’ nucleotide base-pairing, with either strong or weak 3’ pairing, 
respectively, and 3’ compensatory sites possess weak 5’ pairing and strong 3’ pairing.  These 
classifications are evolutionary conserved, and miRNA families are typically different only in 
their 3’ regions (Brennecke et al., 2005). 
As mentioned previously, miRNA mediate their effects by destabilising the mRNA 
transcript or by inhibiting translation.  mRNA degradation is mediated by decapping and 
depolyadenylation followed by cleavage dependent upon 5’-3’ or 3’-5’ exonuclease activity, 
respectively (Bagga et al., 2005), whereas translational inhibition is thought to be mediated 
through cytoplasmic foci known as ‘p-bodies’.  These are sites which contain non-translated 
mRNA meant for degradation.  Upon RISC and miRNA binding to the 3’ UTR, the miRNA are 
targeted for translational repression through sequestration in p-bodies.  It has been shown that the 
Ago protein components of the RISC machinery as localised to p-bodies upon miRNA binding 
(Liu et al., 2005; Sen and Blau, 2005). 
Additionally, in vitro transfection experiments have shown that miRNA can influence 
gene expression in a way that is reminiscent of transcriptional activators.  For instance, following 
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transfection of duplex miR-373, it binds to the 5’ UTR of complementary sequences found in the 
E-cadherin and CSDC2 promoters.  This increases RNA pol II presence along the promoter 
region and enhances gene expression.  However, this phenomena was cell-line specific (Place et 
al., 2007).   
 
1.5.4.3 Role of Tumour Suppressive and Oncogenic microRNA in Tumorigenesis 
 
 In the last decade, there has been extensive research into the role of miRNAs in cancer, 
and many researchers have reported oncogenic and tumour suppressive miRNA can influence 
processes such as proliferation, invasion, metastasis and apoptosis (Iorio et al., 2005; Lu et al., 
2005; Scott et al., 2006; Iorio et al., 2007; Shenouda and Alahari, 2009; Pang et al., 2010; Shih et 
al., 2011).  It is suggested miRNAs could play a role in the pathogenesis of various cancers and 
therefore offer new targets for chemotherapeutic treatment (Iorio et al., 2005; Lu et al., 2005; 
Scott et al., 2006; Lowery et al., 2009; Shenouda and Alahari, 2009).    
The first evidence for the role of tumour suppressive miRNA in cancer came from studies 
involving the chromosomal deletion of 13q14 in B-cell chronic lymphocytic leucaemia (CLL).  It 
was shown that this genomic region harbours the miR-15a and -16 genes.  In addition, in those 
CLL patients without 13q14 deletion, miR-15a and -16 were frequently down-regulated (Calin et 
al., 2002).  13q14 chromosomal deletions also occurred in prostate cancer cell lines (Calin et al., 
2002).  It has been illustrated that many miRNA are located at genomic fragile sites or loss-of-
heterozygosity regions implicated in carcinogenesis (Calin et al., 2003; Scott et al., 2006; Lu et 
al., 2005).  The polycistronic miR-17~92 was one of the first oncogenic miRNA identified (He et 
al., 2005; Olive et al., 2009; Wong et al., 2010), and up-regulation can increase cell proliferation 
in vitro and lymphoma in mice, dependent upon the MYC transcription factor.  It is thought this 
is achieved through inhibiting p21
WAF1
 expression, as the miR-17~92 gene harbours MREs in its 
3’ UTR (He et al., 2005; Olive et al., 2009; Wong et al., 2010). 
It has also been reported that miRNA signatures between cancerous tissue and derived 
cell lines are altered from those of their normal counterparts.  For instance, in breast and ovarian 
cancer, the up- or down-regulation of certain miRNAs were reported to associate with disease 
states as well as histopathological features.  In ovarian cancer, these included the over-expression 
of miR-200a, -200c and -141, and the down-regulation of miR-145a, -140 and -125b (Iorio et al., 
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2007).  Moreover, nine miRNA, such as miR-10b, miR-125b and miR-21, were significantly 
induced or repressed in breast tumours.  This differential expression pattern correlated between 
subtypes of breast cancer, such as hormone receptor-positive or -negative, vascular intrusive, 
proliferative index and lymph node metastatic (Iorio et al., 2005).  Furthermore, miR-645 and -
410 were indicative of poor survival in advanced serous ovarian cancer (Shih et al., 2011). 
 In addition, it has been illustrated that altered epigenetic regulation can contribute to the 
down- or up-regulation of miRNA in cancer.  As mentioned, sequencing has indicated that many 
miRNA promoters contain CpG islands, and those associated with hyper-methylation are 
frequently silenced (Lujambio et al., 2007; Tsai et al., 2011).  In pancreatic cancer, promoter 
hyper-methylation of miR-132 interfered with Sp1 binding, and led to down-regulation of this 
tumour suppressive miRNA in cell lines.  It was further shown that miR-132 induction could 
reduce proliferation and colony formation (Zhang et al., 2011), and methylation of miR-34b and 
miR-129-3p in cancerous cell lines exhibited reduced transcriptional activation, and were 
associated with poor prognosis in gastric cancers (Tsai et al., 2011).  Studies have also identified 
Let-7 down-regulation in lung cancers (Saito et al., 2006), and increased levels of miR-27a in 
breast cancer cell lines, the latter which led to induced expression of the Sp transcription factors, 
potentially driving oncogenic processes (Li et al., 2010).      
 Among the oncogenic miRNA, miR-21 has been shown to be over-expressed in many 
cancers and able to induce tumorigenesis.  Many studies have shown that suppressing miR-21 
expression inhibits tumour growth and volume, as well as reduces cell proliferation and increases 
apoptosis in vitro (Si et al., 2007; Zhu et al., 2007; Lu et al., 2008).  For instance, in the MCF-7 
breast cancer cell line, exogenous induction of miR-21 increases cell proliferation, inhibits 
apoptosis and leads to transformation (Lu et al., 2008).  While myriad mechanisms of miR-21-
mediated tumorigenesis exist, it is likely that it is partially established through inhibiting 
translation of tumour suppressive genes, such as TMP1, Bcl-2 (Zhu et al., 2007), PTEN and 
PDCD4 (Lu et al., 2008).   
In addition, expression of miRNAs from ER-positive or -negative, and HER2/neu 
amplified cancer can predict prognosis.  miRNAs such as miR-7, miR-128a, miR-210 and miR-
516-3p have been shown to be associated with the aggressiveness of lymph node negative and 
ER-positive breast cancer (Lowery et al., 2009).  Furthermore, miR-221/-222 is elevated in 
ER-negative breast cancers and down-regulates expression of ER mRNA through interaction 
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with the 3’ UTR.  Increased expression of miR-221/-222 in ER-positive T47D and MCF-7 cell 
lines decreases the protein levels of ER, but had no effect upon mRNA levels.  It is thought that 
these miRNAs contribute to the progression of ER-positive to ER-negative breast cancers, and 
confer tamoxifen resistance in cell lines.  Additionally, it was demonstrated that knockdown of 
miR-221/-222 in the ER-negative cell line MDA-MB-468 restored ER expression and 
tamoxifen sensitivity (Zhao et al., 2008; Di Leva et al., 2010; Li et al., 2010).  It was further 
shown that ER is able to bind to EREs in the 3’ UTR of miR-221/-222 and these genes 
participate in a regulatory feedback loop (Di Leva et al., 2010).   
In ER-positive and -negative cell lines, miR-221/-222 and miR-206 have different 
cellular roles.  In ER-positive, miR-221/-222 cluster can increase proliferation, while in ER-
negative, it has the opposite effects and decreases cell growth.  Moreover, miR-221/-222 induces 
apoptosis in ER-negative cells.  This potentially demonstrates the importance of determining 
the characteristics of breast cancer for targeted treatment (Di Leva et al., 2010).  ChIP studies 
have also indicated that ER, in conjunction with retinoic acid receptors, binds to promoter 
regions in miR-23a and -210 (Saumet et al., 2012).  Furthermore, miR-424 can be regulated by 
oestrogen in the ER-positive MCF-7 cell line (Bhat-Nakshatri et al., 2009; Castellano et al., 
2009; Saumet et al., 2012). 
As previously mentioned, MYC induces transcription of the polycistronic miR-17~92, 
miRNAs which are frequently over-expressed in cancer (He et al., 2005; O’Donnel et al., 2005; 
Mu et al., 2009; Olive et al., 2009; Wong et al., 2010).  It was further elucidated that miR-19b 
and -19a within this cluster are responsible for tumour formation in MYC-driven B-cell 
lymphoma mouse models, in part by suppressing apoptosis.  Antago-miRs targeting the miR-
17~92 cluster decreased tumour growth in the MYC-driven B-cell lymphoma mouse model, in 
part by targeting PTEN (Mu et al., 2009).  The importance of MYC-driven miR-17~92 cluster 
has also been illustrated in ERα-positive breast cancer cell lines upon oestrogen treatment.  
Oestrogen-mediated miR-17~92 transcription, as well as transcription of the paralogous and 
polycistronic miR-106a~363, increased expression of the mature miR-18a, -19b and -20a within 
the clusters, leading to translational inhibition of ERα in a negative feedback loop.  This occurred 
in a MYC-dependent manner, and interestingly, it was also shown that miR-17~92 could induce 
MYC expression by a feedback mechanism (Castellano et al., 2009).   
There has also been extensive research into the therapeutic benefits of miRNA (Dyrskjot 
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et al., 2009; Yang et al., 2012).  For example, in metastatic breast cancer, the expression of miR-
34a and -34c are reduced compared to primary tumours, and over-expressing these tumour 
suppressive miRNA inhibited migration in vitro and distal pulmonary metastasis in vivo.  It is 
thought inhibition of the oncogenic Fra-1 is responsible for miR-34a- and -34c-mediated anti-
carcinogenesis (Yang et al., 2012).   
Additional roles of miR-34 homologues (miR-34a, -34b and -34c) have been 
demonstrated in pancreatic cancer cells, where miR-34a expression is silenced through gene 
deletion and p53 suppression.  p53-mediated transcription of the miR-34 family promotes 
apoptosis and p53-dependent changes in gene expression, such as those involved in DNA repair, 
anti-angiogenesis and apoptosis.  Inducing miR-34a enhances p53-independent and -dependent 
apoptosis (Chang et al., 2007).  Furthermore, over-expression of miR-129 arrested the cell cycle 
and induced cell death in bladder carcinoma cells, likely through down-regulation of the pro-
apoptotic MCL1 protein (Mott et al., 2007; Dyrskjot et al., 2009), and miR-126 and -335 have 
been shown to suppress breast cancer metastasis (Tavazoie et al., 2008; Dyrskjot et al., 2009). 
 
1.5.4.4 HDI-Mediated Regulation of miRNA Expression       
 
 Through the use of microarray techniques, it has been illustrated that miRNA expression 
is both tissue- and disease-specific, and that HDAC inhibitors can influence the expression 
profiles of miRNAs.  It is suggested that targeting these tumour suppressive or oncogenic 
miRNA offers a new strategy for anti-cancer therapies (Scott et al., 2006; Lu et al., 2005). 
Evidence for the role of aberrant epigenetic modifications in tumorigenesis comes from 
studies which disrupt DNA methylation patterns, leading to altered miRNA expression; for 
instance, hyper-methylation of CpG islands inactivates the expression of miR-124a (Lujambio et 
al., 2007).  Additional studies have shown that the previously mentioned miR-15a and -16, as 
well as miR-29b, can be silenced by HDACs 1 through 3.  Interestingly, those HDACs are over-
expressed in approximately one-third of CLL patients with miR-15a and -16 silencing and 
deletion of chromosomal location 13q14 (Calin et al., 2002; Sampath et al., 2011).  Furthermore, 
Entinostat and Vorinostat treatment increases expression of these miRNA, most likely through 
increased H3K4 methylation following increased histone acetylation (Sampath et al., 2011).  
Histone deacetylase inhibitor treatment also induced expression of miR-409 (Tsai et al., 2011), as 
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well as miR-127 (Saito et al., 2006; Tsai et al., 2011), which targets the 3’ UTR of BCL6 (Saito 
et al., 2006).  In addition, Entinostat has been shown to increase miR-125a, -125b and -205 
expression in HER2-enriched cell lines, functioning synergistically to impair translation of 
HER2/neu and lead to apoptosis.  The hydroxamates were unable to alter expression of these 
miRNA, and instead drug treatment led to reduced HER2/neu by different mechanisms, 
potentially dependent on reduced mRNA stability (Wang et al., 2013). 
Studies have indicated that HDAC9 represses transcription of several pri-miRNA.  While 
previous reports have implicated miR-18a, -19a and -19b in cancer proliferation, experimental 
evidence in mice models suggest that HDAC9 negatively regulates miR-17 and is involved in 
angiogenic processes.  Inhibiting HDAC9 through ‘pan-inhibitory’ HDIs increased expression of 
the polycistron, and led to decreased vascular density and retinal vascularisation.  It is interesting 
to note that polycistronic miRNA potentially play reciprocal roles in carcinogenesis, and HDI 





2. HYPOTHESIS AND SPECIFIC AIMS 
 
Recent research completed in the Bonham Lab has demonstrated that the SRC and MYC 
proto-oncogenes are repressed in a variety of cancer-derived cell lines following HDI treatment.  
However, this observation was specific to ‘pan-specific’ inhibitors, such as TSA and NaB, as 
well as the class I-specific cyclic tetrapeptide Apicidin; the benzamides Entinostat and 
Mocetinostat had no effect on SRC and MYC expression levels.  It is currently unknown whether 
this HDI-mediated repression is a global phenomenon occurring within all cancer-derived cell 
lines or is specific to certain cell types.  In addition, the clinical significance of this repression in 
various molecular subtypes of breast cancer has yet to be determined.   
Therefore, to investigate the repression of SRC and MYC in breast cancer-derived cell 
lines (Table 2.1), time course experiments were performed following treatment with various 
HDAC inhibitors (Table 2.2).  It was hypothesised that while histone acetylation and p21
WAF1 
expression are globally induced following drug treatment, HDI-mediated repression of SRC and 
MYC transcription is cell-specific, and thus not ubiquitious across the various cell lines due to 
the heterogenous nature of the cell lines.  In addition, it was hypothesised that RNA pol II-
transcribed miRNA are differentially regulated by these inhibitors in a manner similar to protein-




























Table 2.1.  Molecular features and status for the ERα and PgR, and HER2/neu 
amplification in the selected breast cancer cell lines.  These include the luminal A T47D (ERα- 
and PgR-positive), the mesenchymal Hs578T (triple-negative), the luminal B BT-474 (ERα- and 
PgR-positive with HER2/neu amplification) and the epithelial-like HCC-1419 (HER2-amplified) 
cell lines (Neve et al., 2006; Grigoriadis et al., 2012).   
 
 
Cell Line Subtype ERα and PgR HER2/neu 
T47D luminal A present normal 
Hs578T basal  absent normal 
BT-474 luminal B present amplified 









Table 2.2.  Summary of the HDIs used in the experimental procedures and their associated 
specificity and chemical class.  These include TSA (hydroxamate), Apicidin (cyclic 
tetrapeptide), and Entinostat and Mocetinostat (benzamides).  While TSA is ‘pan-specific’, the 
other three HDIs are specific to class I HDACs.   
 
 
Histone Deacetylase Inhibitor Chemical Class HDAC Specificity  
Trichostatin A (TSA) hydroxamate pan-specific 
Apicidin cyclic tetrapeptide  class I 
Entinostat (MS-275) benzamide class I 










Rationale and Hypothesis: While HDIs are cytotoxic and capable of inducing both histone 
acetylation and p21
WAF1 
expression, only certain classes exhibit the ability to repress SRC and 
MYC.  Additionally, the class-specific and ‘pan-inhibitory’ HDIs can influence the expression of 
RNA pol II-transcribed tumour suppressor miRNA, which translates to miRNA-mediated effects 
on protein-coding genes.  It is our hypothesis that certain classes of HDIs have an advantage over 
others due to their repressive capabilities on the proto-oncogenic SRC and MYC, and induction 
of potential tumour suppressors.    
 
Specific Aims:  
 
1. Determine the relative cytotoxicity and histone acetylation following treatment of ‘pan-
inhibitory’ and class I-specific HDIs on four breast cancer cell lines representative of the 
molecular subtypes. 
 
2. Determine the effects of ‘pan-inhibitory’ and class I-specific HDIs treatment upon the relative 
induction of p21
WAF1
, and repression of proto-oncogenes SRC and MYC. 
 
3. Determine the effects of ‘pan-inhibitory’ and class I-specific HDIs on mature miRNA, and 
examine the protein and mRNA levels of potential mRNA targets in both HDI-treated and 

















3.  MATERIALS AND METHODS 
 
3.1 Reagents, Equipment, Software and Distributors 
 
The distributors of the reagents and commercially available kits used in the following 
procedures are listed in Table 3.1 and Table 3.2, respectively.  The equipment and software 
programmes that have been used to analyse data are correspondingly outlined in Table 3.3 and 
Table 3.4.  The forward and reverse primer sequences for the expression of protein-coding genes, 
purchased from Invitrogen, are reported in Table 3.5 with their annealing temperatures in Table 
3.6.  The gene-specific primer assay kits for miRNA were purchased from Qiagen with catalogue 
number and the mature miRNA sequence listed in Table 3.7.  The synthetic miRNA mimics used 
in transfection experiments were purchased from Qiagen and are listed with their catalogue 
numbers in Table 3.8.  The antibodies and dilutions used in immuno-blotting experiments are 
reported in Table 3.9. 
 
3.2 Cell Lines and Tissue Culture 
 
3.2.1 Culture and Standard Maintenance of Cell Lines 
 
  The human breast cancer cell lines utilised in this study were purchased from the 
American Type Culture Collection (ATCC), and the cell media used to propagate the cell lines 
were purchased from Invitrogen-Gibco Cell Culture Systems.  The metastatic-derived T47D 
mammary ductal carcinoma cell line was cultured in RMPI-1640 media, supplemented with 
insulin; the Hs578T mammary carcinoma cell line was cultured in DMEM media, with 0.01 
mg/mL insulin; the BT-474 ductal mammary carcinoma cell line was cultured in DMEM; the 
HCC-1419 primary ductal carcinoma cell line was cultured in RMPI-1640.  The media contained 
10% foetal bovine serum (FBS) and 1% penicillin-streptomycin, and the cell lines were grown in 
an incubator at 37 ᴼC and with a 5% CO2 atmosphere.  These breast cancer cell lines were chosen 
due to their reported classification (Neve et al., 2006; Grigoriadis et al., 2012), and no 
verification was performed in our laboratory.  Upon propagation and subsequent sub-culturing, 






Table 3.1.  The supplier addresses.   
 
 
Reagent Supplier Location 
Abcam Cambridge, MA. USA 
American Type Culture Collection (ATCC) Manassas, VA, USA 
Applied Biosystems Canada Streetsville, ON, Canada 
Bio-Rad Laboratories, Ltd. Mississauga, ON, Canada 
Cedarlane Laboratories Burlington, Ontario, Canada 
EMD Chemicals Gibbstown, NJ, USA 
Fermentas Canada, Inc. Burlington, ON, Canada 
Fisher Scientific Ottawa, ON, Canada 
Gibco Life Technologies Burlington, ON, Canada 
Invitrogen Canada, Inc. Burlington, ON, Canada 
LICOR Technologies Lincoln, NB, USA 
Millipore  Billerica, MA, USA 
Santa Cruz Biotechnology, Inc. Santa Cruz, CA, USA 
Sigma-Aldrich, Co. Oakville, ON, Canada 
Thermo Scientific Rochester, NY, USA 
Qiagen, Inc. Mississauga, ON, Canada 






Table 3.2.  Suppliers of commercially available kits. 
 
 
Commericially Available Kits Supplier 
miRNeasy Mini Kit Qiagen, Inc. 
iScript cDNA Synthesis Kit Bio-Rad Laboratories, Ltd. 
miScript RT II Kit Qiagen, Inc. 
miScript SybrGreen PCR Kit Qiagen, Inc. 
Total Protein, Micro Lowry Kit  Sigma-Aldrich, Co. 















27 gauge precision glide syringe BD Biosciences 
AccuPower Model 300 Power Supply VWR 
Analogue Vortex Mixer VWR 
Biofuge 13 Heraeus Baxter CanLab 
GeneAmpPCR 2720 Thermal Cycler Applied Biosystems Canada 
LICOR Odyssey Visualisation System LICOR Technologies 
MicroMax Centrifuge IFC 
Mini Protean II cells Bio-Rad Laboratories, Ltd. 
NanoDrop 2000c Spectrophotometer Thermo Scientific 
OWL Electroblotting Unit Thermo Scientific 
Quickseal SA Equipment 
SmartSpec 3000 Spectrophotometer Bio-Rad Laboratories, Ltd. 
Standard Heatblock VWR 
StepOnePlus Real Time PCR System Applied Biosystems Canada 







Table 3.4.  The suppliers for the software programmes used. 
 
 
Software Programmes Suppliers 
Primer Express Version 3.0 Applied Biosystems Canada 
Licor Odyssey Imaging System LICOR Technologies 






Table 3.5.  Forward and reverse primer sequences, purchased from Invitrogen. 
 
 
Primer Forward Sequence (5’-3’) Reverse Sequence (5’-3’) 
p21
WAF1
  GCCTGCCGCCGCCTCTTC GCCGCCTGCCTCCTCCCAACTC 
SRC CAGAGGAGCCCATTTACATCGTC CCCTTGAGAAAGTCCAGCAAACTC 
MYC GGACTTGTTGCGGAAACGA TTACGCACAAGAGTTCCGTAGCT 
RPL13A CAAGGTGTTTGACGGCATCC GCTTTCTCTTTCCTCTTCTCCTCC 
CCND1  GCATGTTCGTGGCCTCTAAGA CGGTGTAGATGCACAGCTTCTC 
c-MYB CCCACTGTTAACAACGACTATTCCT GGTATGGAACATGACTGGAGACATT 
CHEK1 GAGTACCGCACTCTGAGGTTTACA CCACCGGACAGGACTGTGA 











SRC  55 ᴼC 
MYC  60 ᴼC 
p21
WAF1
   60 ᴼC 
c-Myb  59 ᴼC 
ERα  59 ᴼC 
CCND1  60 ᴼC 





Table 3.7.  miScript Primer Assays obtained from Qiagen. 
 
 
miRNA Assay Name Mature miRNA Sequence 
Catalogue 
Number 
miR-129-5p Hs_miR-129_1 CUUUUUGCGGUCUGGGCUUGC MS00006643 
miR-424 Hs_miR-424_1 CAGCAGCAAUUCAUGUUUUGAA MS00004186 
miR-9-3p Hs_miR-9*_1 AUAAAGCUAGAUAACCGAAAGU MS00006510 










Table 3.8.  miScript miRNA Mimics obtained from Qiagen. 
 
 
miRNA Assay Name 
Catalogue 
Number 
Guide Strand (Mature miRNA) 
miR-129-5p Syn-hsa-miR-129-5p MSY0000242 CUUUUUGCGGUCUGGGCUUGC 
miR-424 Syn-hsa-miR-424-5p MSY0001341 CAGCAGCAAAACAUGUUUUGAA 
miR-9-3p Syn-hsa-miR-9* MSY0000442 AUAAAGCUAGAUAACCGAAAGU 










Table 3.9.  Antibodies used in immuno-blotting experiments. 
 
 
Antibody  Company Cat No. 
Chek1 Santa Cruz Biotechnology sc-377231 
HDAC5 Abcam ab11969 
Cyclin D1 Abcam ab6152 
ERα Abcam ab75635 
Histone H3Ac (K9, K18, K23, K27) Abcam ab47915 
Histone H3K9Ac Abcam ab4441 
Histone H3 Abcam ab1791 





3.2.2 Histone Deacetylase Inhibitor Treatments 
 
  Prior to drug treatments, all cell lines were trypsinised, sub-cultured and grown for 36-48 
hours to 70-75% confluency.  
 
3.2.2.1 Time Course Experiments 
 
  The media were aspirated and the T47D, Hs578T, BT-474 and HCC-1419 cell lines were 
grown over 24 hr in fresh media containing 1 µM TSA, 2 µM Apicidin, 2 µM Entinostat or 1 µM 
Mocetinostat.  The Hs578T cell lines were also treated with 2 µM TSA, 5 µM Apicidin, 5 µM 
Entinostat or 5 µM Mocetinostat over 24 hr.   The cells were harvested for RNA in Qiazol™ 
Lysis Buffer or protein in 2X Laemmli sample buffer (10% [v/v] glycerol, 5% [v/v] β-
mercaptoethanol, 2% [w/v] SDS, 65 mM Tris-HCl [pH 7.0] and 0.05% [w/v] bromophenol blue) 
at subsequent time intervals of 1 hr, 3 hr, 6 hr, 12 hr and 24 hr.  Ethanol (EtOH) and dimethyl 
sulphoxide (DMSO) drug vehicle controls and untreated controls were also harvested at this time.  
 
3.2.2.2 Dose Response Experiments 
  
  The media were aspirated and the T47D, Hs578T, BT-474 and HCC-1419 cell lines were 
grown in fresh media containing 0.25 µM, 0.5 µM, 1 µM, 2 µM or 5 µM TSA, Apicidin, 
Entinostat or Mocetinostat.  The cells were harvested for protein 2X Laemmli sample buffer 
(10% [v/v] glycerol, 5% [v/v] β-mercaptoethanol, 2% [w/v] SDS, 65 mM Tris-HCl [pH 7.0] and 
0.05% [w/v] bromophenol blue) after 12 hr; EtOH and DMSO drug vehicle controls and 
untreated controls were also harvested.   
 
3.2.3 miRNA Mimic Transfection Experiments 
 
  The Hs578T and T47D cells were seeded at 1 x 10
4
 or 2 x 10
4
 cells in 24- or 12-well 
plates, respectively, and allowed to grow for 24-36 hr prior to transfections. 300 nM synthetic 
miRNA Mimics purchased from Qiagen (miR-424, miR-19-5p or miR-9-3p) were incubated with 
Lipofectamine 2000 for 4h, followed by the addition of an equal amount of DMEM or RPMI-
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1640 media containing 20% FBS.  RNA and/or protein were harvested as previously described 
over 6 hr, 12 hr, 24 hr, 36 hr, 48 hr or 72 hr.  Untreated, mock, scrambled and miR-1 controls 
were also harvested at this time.   
  
3.3 Real Time Polymerase Chain Reaction 
 
3.3.1 Total RNA Purification from Cultured Cells 
 
  Total RNA, including small non-coding RNAs and mRNA, were isolated utilising 
Qiagen’s miRNeasy Mini Kit.  Following HDI treatments, cells were harvested directly from the 
plate in 700 µL of Qiazol™ Lysis Buffer and homogenised by passing through a 4 gauge-syringe.  
The sample lysates were stored at -80 ᴼC until total RNA was to be extracted.  The lysates were 
thawed to room temperature and incubated for 5 min prior to the addition of 140 µL chloroform 
and subsequent vortexing.  Following centrifugation at 12,000 x g for 15 min, the aqueous phase 
was passed through a miRNeasy Mini column and treated with 1 unit DNase-I for 15 min at room 
temperature to digest contaminating genomic DNA.  The sample RNA was then purified 
according to the manufacturer’s protocol.  The concentration of the RNA was determined by 
measuring the absorbance at 260 nm on a SmartSpec 3000 Spectrophotometer or a NanoDrop 
2000c Spectrophotometer, with the A260 reading equal to 1 = 40 μg/mL RNA.  The purification 
and quality of the RNA was identified by an A260:A280 ratio between 1.6 and 2.0, and the RNA 
quality was further assessed by agarose gel electrophoresis, with visual assessment of the 28S 
and 18S ribosomal subunits by ethidium bromide fluorescence.   
 
3.3.2 mRNA Procedures 
 
3.3.2.1 Synthesise of Complementary DNA 
         
  Following purification and quality determination, 1 µg of total RNA was used to 
synthesise complementary DNA (cDNA), according to Bio-Rad’s iScript reverse transcriptase 
procedure.  cDNA amplification was performed in a GeneAmpPCR System 2700, programmed 
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to the following protocol: 5 min at 25 ᴼC, 30 min at 42 ᴼC and 5 min at 85 ᴼC.  cDNA was stored 
at -20 ᴼC until required. 
 
3.3.2.2 Real Time PCR for mRNA Quantification 
 
  Real Time PCR was performed to analyse mRNA expression following HDI-treatment or 
miRNA transfection.  Reactions were set up with 0.3 µL cDNA to a final volume of 10 µL with 5 
µL QuantiFast SSO SybrGreen and 66 ng of gene-specific primers designed with Primer 
Express® version 3.0 software purchased from Applied Biosystems, or primers previously 
designed and tested in the Bonham Lab (Table 3.5).  Triplicate reactions were performed on an 
Applied Biosystems StepOnePlus Real Time machine, according to the manufacturer’s 
instructions and analysed with StepOne™ Software v2.2.2.  The PCR cycling programme was set 
for an  initial 20 sec at 95 ᴼC followed by 40 cycles of 95 ᴼC for 3 sec and an appropriate primer-
specific annealing temperature for 30 sec (Table 3.9).  A melting curve was performed following 
amplification of the Real Time assays and product specificity was assessed by calculating the 
melting temperature of the amplicon.  The samples were analysed in at least two technical repeats 
in three biological repeats, and the fold changes were calculated by the ΔΔCt method using 
RPL13A as an internal control.   
 
3.3.3 microRNA Procedures 
 
3.3.3.1 Synthesise of Complementary DNA 
 
  cDNA was synthesised from 2 µg total RNA according to the manufacturer’s protocol in 
the miScript RT II kit acquired from Qiagen. cDNA amplification was completed in a 
GeneAmpPCR System 2700 set to the following protocol: 25 ᴼC for 5 min, 37 ᴼC for 60 min and 







3.3.3.2 Real Time PCR for miRNA Quantification 
 
  Real Time PCR was carried out with 2.5 µL cDNA per reaction, 2.5 µL 1X universal 
miScript primer, 2.5 µL 1X miRNA-specific primer (Table 3.6) and 12.5 µL SybrGreen in a final 
volume of 25 µL.  Reactions were performed in triplicate on an Applied Biosystems StepOnePlus 
Real Time machine according to the manufacturer’s instructions and analysed with StepOne™ 
Software v2.2.2.  The PCR cycling programme was run at 95 ᴼC for 15 min, followed by 40 
cycles at 15 sec at 94 ᴼC, 30 sec at 55 ᴼC and 30 sec at 70 ᴼC.  The fold changes were calculated 
by the ΔΔCt method using RNU6 as an internal control and the samples were analysed in at least 
three technical repeats in three biological repeats.  A melting curve was performed following 
amplification of the Real Time assays to assess product specificity.  In addition, a no-template 
control and a positive miRNA control were also included in the Real Time experiments to assess 
possible false-positive amplifications.  Products were commonly subjected to electrophoresis on a 
3% agarose gel. 
   
3.4 Cytotoxic Assays 
The anti-proliferative and cytotoxic activities of the HDIs were determined by the MTT 
assay.  The T47D, Hs578T, BT-474 and HCC-1419 cells were seeded in 96-well plates at a 
concentration of 1 x 10
4
 cells and allowed to grow under normal growth conditions for 36-48 
hours.  The cells were subsequently treated for 48h with 0.01 µM, 0.1 µM, 1 µM, 5 µM, 10 µM, 
50 µM and 100 µM of TSA, Apicidin, Entinostat or Mocetinostat.  Untreated, and EtOH and 
DMSO vehicle controls were also included at a concentration equal to that in the drug-treated 
cells.  The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reagent was 
added at a final 0.5 mg/mL concentration and incubated for 4h at 37 ᴼC, and the formed formazan 
crystals were solubilised with isopropanol alcohol and 0.4 N HCl.  The absorbance at 
wavelengths 540 nm and 630 nm were recorded on a SpectraMax ELISA plate reader.  The 
experiments were repeated in triplicate for three independent assays and the cell viability 
calculated compared to untreated control.  The concentration required to inhibit 50% cellular 





3.5 Western Blot 
 
3.5.1 Protein Isolation from Cultured Cells and Lowry Protein Assay 
  
  Following HDI treatments, cells were harvested directly from the plate in 2X Laemmli 
sample buffer containing 10% (v/v) glycerol, 5% (v/v) β-mercaptoethanol, 2% (w/v) SDS, 65 
mM Tris-HCl (pH 7.0) and 0.05% (w/v) bromophenol blue.  Samples were boiled for 5 min and 
homogenised by passing through a 27-gauge syringe.  Protein concentrations were calculated 
utilising a Total Protein, Micro Lowry Kit purchased from Sigma-Aldrich, according to the 
manufacturer’s protocol.  The absorbances at 750 nm were read on a SmartSpec 3000 
Spectrophotometer and the concentrations were determined alongside a standard curve. 
  
3.5.2 Immuno-Blot Procedure 
 
3.5.2.1 SDS-PAGE Gel Electrophoresis 
 
 Protein samples were subjected to electrophoresis on 10% or 15% polyacrylamide 
resolving gels (29.2% acrylamide to 0.8% bis-acrylamide, 375 mM Tris-HCl [pH 8.8], 0.1% 
[v/v] SDS, 0.1% [w/v] ammonium persulfate and 0.04% [w/v] N,N,N',N'-
tetramethylethylenediamine [TEMED]) and a 5% polyacrylamide stacking gel (29.2% 
acrylamide to 0.8% bis-acrylamide, 130 mM Tris-HCl, 0.1% [w/v] SDS, 0.1% [w/v] ammonium 
persulfate and 0.04% [w/v] TEMED) (Sambrook et al., 1989).  Prior to electrophoresis, protein 
samples were boiled for 5 min at 100 ᴼC and 25 µg protein resolved on the SDS-PAGE gels.  
Procedures were performed with the Mini Protean II cells at 140-160V for approximately 90-120 
min. 
 
3.5.2.2 Nitrocellulose Membrane Transfer 
 
  The gels were saturated with transfer buffer containing 10 mM Tris, 15 mM NaCl, 0.5% 
(v/v) TWEEN-20 for 15 min.  The resolved proteins were transferred by semi-dry transfer to a 
nitrocellulose membrane for 15 min at 400 mA, utilising an OWL electroblotting unit.  Protein 
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transfer was confirmed by Ponceau-S (0.1% [w/v] Ponceau-S in 5% [v/v] acetic acid) staining, 
followed by stain removal with distilled water and 1X PBS (137 mM NaCl, 10 mM Na2HPO4, 
1.8 mM KH2PO4, 2.7 mM KCl, pH 7.4).  The membranes were then blocked for 1 hr in one part  




  Primary antibodies were incubated overnight at 4 ᴼC following by washing in 1X PBST 
(PBS and 0.5% TWEEN-20) and secondary antibody incubation for 1 hr at room temperature, 
followed by 1X PBST and 1X PBS washes.  The primary antibodies, catalogue numbers and 
dilutions in Odyssey blocking buffer with 0.05% TWEEN-20 are listed in Table 3.8.  The goat 
secondary antibodies were labelled with IR680 or IR800 dye, and incubated at a 1:30,000 
dilution in Odyssey blocking buffer and 0.05% TWEEN-20.  The membranes were visualised 
using fluorescence on a LICOR Odyssey visualisation system and associated software.  In certain 
cases, the membranes were stripped for 5 min in Licor Odyssey stripping buffer and three parts 
PBS, prior to being re-probed overnight in a different primary antibody.  In all immuno-blot 
assays, the total protein levels of histone H3 and/or GAPDH were assessed as loading controls 
and to further demonstrate that total H3 levels remained static in acetylation experiments. 
 
3.6 Statistical Analysis 
   
  All statistical analyses were performed using the SigmaStat software version 12.2, with a 
p-value equal to or less than 0.05 considered to be statistically significant.  The p-values were 
based on a one-way analysis of variance (ANOVA) by the Holm-Sidak method (Sidak, 1967; 
Holm, 1979; Seaman et al., 1991; Aickin and Gensler, 1996), and the represented graphs are the 
mean of at least two technical repeats in three independent experiments, +/- SEM.  Statistically 





4.  RESULTS 
 
4.1 The Effect of Histone Deacetylase Inhibitors on Breast Cancer Cell Viability, Histone 




 Class- and isoform-specific HDIs have been shown to exhibit cytotoxic, apoptotic and/or 
anti-proliferative properties in a variety of human cancer-derived cell lines.  In addition, 
treatment leads to increased acetylation of histone and non-histone proteins, eliciting cellular 
processes such as induction of the cell cycle inhibitor p21
WAF1
 (Vigushin et al., 2001; Glaser et 
al., 2003; Beckers et al., 2007; Ueda et al., 2007; Im et al., 2008; Fournel et al., 2008; Khan et 
al., 2008; Ahn et al., 2009; Kelly and Cowley, 2013).  Nonetheless, while the cellular effects of 
class-specific drugs can be similar, they have also demonstrated diversity in the subset of genes 
targeted and in their anti-proliferative or cytotoxic properties.  In addition, apoptotic pathways 
can be activated in diverse ways through the activation of different pro-apoptotic pathways.  It is 
thought that this diversity is partially responsible for the differential cellular effects observed 
within certain cell lines (Chatterjee et al., 2013). 
 Therefore, the effects of four structurally-diverse HDIs on cell viability, histone 
acetylation and gene expression were investigated in four cell lines representative of the 
heterogenous nature of breast cancer.  These cell lines were chosen based on their status of the 
oestrogen receptor-α (ERα), progesterone receptor (PgR) and HER2/neu amplification, and 
included the ERα- and PgR-positive T47D cell line, the triple-negative Hs578T cell line, the 
ERα- and PgR-positive and HER2-amplified BT-474 cell line, and the HER2-amplified HCC-
1419 cell line (Neve et al., 2006; Grigoriadis et al., 2012).  Additionally, the selection of HDIs 
used in this study were based upon their class-specificity and diverse chemical structures; these 
included the hydoxamic acid TSA, the cyclic tetrapeptide Apicidin, and the benzamides, 
Entinostat and Mocetinostat.   
 
4.1.1 The Cytotoxic Influence of Histone Deacetylase Inhibitors in Breast Cancer Cell Lines 
 
To determine the anti-proliferative properties these compounds have on the various breast 
cancer-derived cell lines, MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) 
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assays were performed.  The cell lines were then analysed for cellular viability following 48h 
administration with increasing concentrations of the compounds.  The assays were performed in 
triplicate in at least three independent experiments, and were completed by Kyoo Yoon Choi, an 
honours project student under my supervision. 
These HDIs exhibited anti-proliferative properties in the four breast cancer cell lines in a 
dose-dependent manner (Figure 4.1 and 4.2).  In general, the cell lines had reduced viability 
following HDI treatment; however, the range of concentrations indicated that HDI-mediated 
cytotoxicity varied between the cell lines (Table 4.1).  The IC50 values for the T47D cell line 
were calculated to be 0.20 µM (TSA), 0.25 µM (Apicidin), 2.5 µM (Entinostat) and 2.5 µM 
(Mocetinostat).  TSA and the benzamides were less toxic to the Hs578T cell lines, with IC50 
values of 2.2 µM (TSA), 0.2 µM (Apicidin), 2.5 µM (Entinostat) and 202 µM (Mocetinostat).  
TSA and Apicidin exhibited greater cytotoxicity than the benzamides in the BT-474 cell line; the 
IC50 values were 0.2 µM (TSA), 0.25 µM (Apicidin), 2.2 µM (Entinostat) and 5.0 µM 
(Mocetinostat).  Entinostat had less effect in the HCC-1419 cell line, and the IC50 values were 
calculated to be 0.4 µM (TSA), 0.3 µM (Apicidin), 25 µM (Entinostat) and 12 µM 
(Mocetinostat).   
Apicidin treatment resulted in similar cytotoxic profiles, whereas TSA and the 
benzamides exhibited a greater range of cytotoxic effects in the cell lines.  TSA resulted in 
significantly reduced viability with low IC50 concentrations, with the exception of the Hs578T 
cells.  Generally, the benzamides possessed the lowest cytotoxicity of the tested compounds, with 
BT-474 and HCC-1419 cell lines being less sensitive to Mocetinostat and Entinostat, 
respectively.   Thus, it was observed that HDI-treatment resulted in reduced cell viability in a 
dose-dependent manner. 
 
4.1.2 Dose-Dependent and Time-Dependent Histone H3 Acetylation Following Histone 
Deacetylase Inhibitor Treatment  
 
To assess the extent of HDI-mediated histone acetylation, immuno-blotting for acetylated 
histone H3 (H3Ac) was performed.  Dose responses were used to compare concentration-
dependent HDI-mediated histone acetylation in the cell lines.  In addition, treatments were 













Figure 4.1.  Decreased viability of breast cancer cells following HDI treatment.  As 
indicated, 10
4
 (A) T47D, (B) Hs578T, (C) BT-474 or (D) HCC-1419 were seeded in 96-well 
plates and treated with 0.01 µM, 0.1 µM, 1 µM, 5 µM, 10 µM, 50 µM and 100 µM TSA, 
Apicidin, Entinostat or Mocetinostat for 48 hr.  The cell viability was assessed by the MTT assay.  






















Figure 4.2.  Histone deacetylase inhibitors result in decreased cell viability in breast cancer 
cells.  10
4
 cells were seeded in 96-well plates and treated with 0.01 µM, 0.1 µM, 1 µM, 5 µM, 10 
µM, 50 µM and 100 µM (A) TSA, (B) Apicidin, (C) Entinostat or (D) Mocetinostat for 48 hr.  
The cell viability was assessed by the MTT assay.  Data shown are the average cell viability from 



























T47D 0.2 0.25 2.5 2.5 
Hs578T 2.2 0.2 2.5 2.0 
BT-474 0.2 0.2 2.5 5.0 








(H3K9Ac) over time.  The immuno-blotting procedures were repeated in two independent 
experiments; each assay exhibited consistent results. The data in the forthcoming section is 
representative of these results. 
HDI treatment increased histone H3 acetylation in a dose-dependent manner in the four 
cell lines tested (Figure 4.3).  While the higher drug concentrations enhanced acetylation to a 
greater extent, certain HDIs were less effective.  The T47D, BT-474 and HCC-1419 cell lines 
were highly responsive to HDI administration, with acetylation induced at the 0.25 µM dosage.  
However, in the Hs578T cell line, the 2 µM TSA, 5 µM Entinostat and 5 µM Mocetinostat 
concentrations led to only modest H3 acetylation.  Furthermore, the benzamides had similar 
profiles in each cell line and gradually induced histone acetylation in a dose-dependent manner. 
Based on these observations, the concentrations for further experiments involving the 
Hs578T cell line were 2 µM TSA and 5 µM Apicidin, Entinostat and Mocetinostat.  The T47D, 
BT-474 and HCC-1419 cell lines were treated with 1 µM TSA, 2 µM Apicidin, 2 µM Entinostat 
and 1 µM Mocetinostat.  These reflect the enhanced histone acetylation observed, and confirms 
that the cell lines are treated with HDI concentrations that induce similar levels of histone 
acetylation.  Therefore, any differences observed between the cell lines due to inconsistencies in 
the HDI administration can be eliminated. 
In addition to these dose-dependent observations, immuno-blotting against H3K9 
illustrated that acetylation increased in a time-dependent manner upon HDI administration in the 
cell lines (Figure 4.4).  TSA treatment in the T47D cell line increased acetylation after 3 hr 
treatment, while Apicidin, Entinostat and Mocetinostat lead to acetylation at 12 hr.  These effects 
were still observed following 24 hr treatment.  The Hs578T and BT-474 cells were less 
responsive to class I-specific HDIs and acetylation increased after 6 hr to 12 hr treatment, 
whereas TSA enhanced H3K9 acetylation as early as 3 hr.  While histone acetylation mediated 
through TSA treatment exhibited transient properties within the Hs578T, BT-474 and HCC-1419 
cell lines, with its effects eliminated 24 hr after treatment, the class I-specific HDIs sustained 
enhanced acetylation over the 24 hr period.  HDI treatment in the HCC-1419 cell line induced 
acetylation as early as 1 hr treatment.  Similarly, the effects of TSA were transient.  These 
experiments were also repeated with a pan-acetylated H3 antibody and gave similar results, and 







Figure 4.3.  Increased histone H3 acetylation following HDI treatment.  T47D, Hs578T, BT-
474 or HCC-1419 cells were treated for 12 hr with the indicated concentrations of TSA, 
Apicidin, Entinostat or Mocetinostat.  Treated cells were harvested in 2X Laemmli sample buffer 
and 25 µg protein lysate was resolved via SDS-PAGE, followed by immuno-blotting against 
acetylated H3 (H3Ac), total H3 and GAPDH as a loading control.  The data shown is 










Figure 4.4.  Increased H3K9 acetylation upon HDI treatment.  T47D, Hs578T, BT-474 and 
HCC-1419 cells were treated with 1 µM TSA, 2 µM Apicidin, 2 µM Entinostat or 1 µM 
Mocetinostat at the indicated time points.  Cells were harvested in 2X Laemmli sample buffer 
and 25 µg protein resolved via SDS-PAGE.  Immuno-blotting against acetylated lysine 9 of H3 
(H3K9Ac) and GAPDH as a loading control was performed.  The data shown is representative of 




Therefore, in addition to their anti-proliferative properties, the three chemical classes of 
HDIs enhance histone acetylation in both a dose-dependent and time-dependent manner.   
Minimal cell-specific responses were observed between the diverse compounds, highlighted with 
the transient nature of TSA in the Hs578T and HCC-1419 cell lines and the low responsiveness 
of the benzamides in the Hs578T cell line.  However, they generally act to enhance histone H3 
acetylation within the four cell lines.   
 
4.1.3 Histone Deacetylase Inhibitors Induce p21
WAF1
 Expression   
 
It has been extensively reported in the literature that p21
WAF1 
is universally up-regulated 
following HDI treatment in numerous cancer-derived cell lines (Ocker and Scheider-Stock, 2007; 
Gartel and Tyner, 2002).  In addition, studies performed in the Bonham Lab have shown that 
p21
WAF1
 expression is generally up-regulated following TSA and NaB treatment in colorectal, 
hepatocarcinoma and breast cancer cell lines (Hirsch and Bonham, 2004).  Therefore, HDI-
mediated p21
WAF1 
induction was assessed in the four cell lines to set a baseline to compare 
differential effects of these drugs on proto-oncogene expression, in addition to verify the activity 
of compounds.  Following an HDI time course, reverse transcriptase quantitative PCR (RT-
qPCR) was performed with p21
WAF1
-specific primers.  
Induction of p21
WAF1 
mRNA was observed in all four cell lines after HDI treatment 
(Figure 4.5).  However, the degree and duration of p21
WAF1
 expression varied significantly 
between them, indicating cell-specific responses.  TSA (1 µM) induced p21
WAF1
 expression 8.01 
fold (p<0.001) in the T47D cell line, while 2 µM Apicidin, 2 µM Entinostat and 1 µM 
Mocetinostat increased expression 3.97 fold (p<0.001), 5.03 fold (p<0.001) and 3.09 fold 
(p<0.001), respectively.  The effects of TSA and Apicidin were transient and p21
WAF1
 expression 
returned to control levels after 24 hr treatment. 
TSA (2 µM) administration resulted in the greatest induction in the Hs578T cell line, with 
an 11.21 fold change (p<0.001) after 12 hr treatment.  Apicidin (5 µM) resulted in a 4.68 fold 
(p<0.01) induction at 6 hr, while Entinostat and Mocetinostat (5 µM) induced expression 5.45 
fold (p<0.001) and 5.14 fold (p<0.001) at 24 hr, respectively.  The up-regulation of p21
WAF1
 was 
moderate in the Hs578T cells treated with 2 µM TSA and 5 µM Apicidin, Entinostat or 




Figure 4.5.  p21
WAF1 
mRNA induction following HDI treatment.  T47D, Hs578T, BT-474 or 
HCC-1419 cells were treated with (A) TSA, (B) Apicidin, (C) Entinostat or (D) Mocetinostat and 
collected in Qiazol Lysis Buffer at the time points indicated.  Total RNA was purified and 
mRNA reverse transcribed, and p21
WAF1 
levels were assessed with gene specific primers using 
RT-qPCR normalised against RPL13A.  Fold changes were calculated by the ∆∆Ct method, data 
represent the mean of three independent experiments done in triplicate, +/- SEM.  Asterisks 
indicate significance at p<0.05 (*), p<0.01 (**) and p<0.001 (***).   
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µM TSA, 2 µM Apicidin, 2 µM Entinostat and 1 µM Mocetinostat) still induced p21
WAF1
 
expression, albeit to a lesser degree (data not shown).  
The BT-474 cell line exhibited rapid p21
WAF1 
induction, with a biphasic response to 2 µM 
Entinostat, while TSA (1 µM), Apicidin (2 µM) and Mocetinostat (1 µM) transiently increased 
expression.  The maximal mRNA levels were observed at 6 hr in TSA-treated cells (19.93 fold 
[p<0.001]), 3 hr in Apicidin-treated cells (10.00 fold [p<0.001]), 3 hr in Entinostat-treated cells 
(13.14 fold [p<0.001]) and 3 hr in Mocetinostat treated cells (12.65 fold [p<0.001]).  Despite 
enhanced histone acetylation, these compounds only transiently induced p21
WAF1
 in this cell line.  
 The expression of p21
WAF1 
in the HCC-1419 cell line increased following HDI treatment; 
1 µM TSA and 2 µM Apicidin-mediated induction was transient whereas 2 µM Entinostat and 1 
µM Mocetinostat had longer effects.  The induction following TSA treatment was 14.87 fold 
(p<0.001) at 12 hr, 4.87 fold (p<0.001) at 6 hr in Apicidin treated cells, and 7.91 fold (p<0.001) 
and 3.01 fold (p<0.001) in Entinostat- and Mocetinostat-treated cells, respectively.   
In general, the effects following the class I-specific HDI treatments were less striking than 
those observed with the ‘pan-specific’ TSA.  With the exception of the BT-474 cell line, the 
benzamides sustained p21
WAF1 
induction over 24 hr; in addition, this cell line had the maximum 
p21
WAF1 
induction following HDI treatment.  Furthermore, Entinostat and Mocetinostat exhibited 




The data indicate these HDIs are anti-proliferative, lead to acetylated histones and induce 
p21
WAF1
 expression in the breast cancer cell lines; however, several differences can be 
highlighted between them.  While these compounds similarly enhanced the acetylation of 
histones in a dose-dependent and time-dependent manner in each the four cell lines, Entinostat 
and Mocetinostat treatment required a higher concentration to decrease cell viability by 50%.  In 
fact, with the exception of TSA treatment in the Hs578T cells, the cell lines required higher 
dosages of the benzamides to induce cytotoxicity. In addition, the cell viability profiles from 
Apicidin-treated cells were similar between the cell lines.  p21
WAF1
 induction was rapid and 
transient in the BT-474 cell line; in addition, the effect of Entinostat-mediated up-regulation was 
biphasic.  TSA showed the maximal induction of p21
WAF1
 in the four cell lines, while the 




4.2 The Response of SRC and MYC to Histone Deacetylase Inhibitor Treatment 
 
It has been previously established that SRC gene expression is repressed following TSA 
and NaB treatment in many cancer-derived cell lines (Kostyniuk et al., 2002).  This 
transcriptional repression has also been observed for the proto-oncogene MYC (Wang et al., 
1998; Sasakawa et al., 2003; Xu et al. 2005; Ierano et al., 2013, Leone et al., 2015; Raha et al., 
2015; Bonham and Beaton-Brown, unpublished data). In addition, class- and isoform-specific 
HDIs have been shown to exhibit differential effects on gene expression (Glaser et al., 2003; 
Halsall et al., 2012; Chatterjee et al., 2013).  It has been demonstrated that HDI-mediated 
repression is not a universal phenomenon.  For example, benzamide treatment had no effect on 
SRC and MYC expression (Bonham and Beaton-Brown, unpublished data).  The extent of HDI-
mediated repression of these proto-oncogenes in various cancer-derived cell lines is unclear.  
Therefore, SRC and MYC expression were analysed following HDI treatment, in order to 
examine the characteristics of this transcriptional repression.  
 
4.2.1 Relative Steady-State Levels of SRC and MYC 
 
  To better assess the response of SRC and MYC transcription to HDI treatment, the 
relative steady-states of transcripts for these proto-oncogenes were assessed in the breast cancer 
cell lines (Figure 4.6).  The data was normalised to the BT-474 cell lines and the relative level of 
transcript of SRC and MYC determined between these four cell lines.  The T47D cells exhibited 
high SRC mRNA levels and moderate MYC expression relative to the other three cell lines.  The 
reciprocal was observed in the Hs578T cell line; MYC levels were highest and SRC levels were 
intermediate.  The BT-474 cells exhibited minimal SRC and MYC relative to the other cell lines, 
while the HCC-1419 cell line had moderate MYC and low SRC transcript levels.   
 
  4.2.2 The Expression of SRC Differed in the Breast Cancer Cell Lines 
 
The ability of the compounds to repress SRC at the transcript level differed between the 








Figure 4.6.  Relative SRC and MYC mRNA levels in T47D, Hs578T, BT-474 and HCC-1419 
breast cancer cell lines.  Total RNA was harvested in Qiazol Lysis Buffer and cDNA 
synthesized from purified RNA.  (A) SRC and (B) MYC levels were assessed with gene-specific 
primers using RT-qPCR normalised against RPL13A.  The relative expressions were calculated 
by the ∆∆Ct method relative to the BT-474 cell line, and data represent the mean of three 






Figure 4.7.  Differential SRC expression upon HDI treatment.  T47D, Hs578T, BT-474 or 
HCC-1419 cells were treated with (A) 1 µM TSA, (B) 2 µM Apicidin, (C) 2 µM Entinostat or 
(D) 1 µM Mocetinostat at the indicated time points and collected in Qiazol Lysis Buffer.  Total 
RNA was purified and reverse transcribed.  SRC levels were assessed with SRC-specific primers 
using RT-qPCR normalised against RPL13A.  The fold changes were calculated by the ∆∆Ct 
method, and data represent the mean of at least two independent experiments done in triplicate, 
+/- SEM.  Asterisks indicate significance at p<0.05 (*), p<0.01 (**) and p<0.001 (***).  
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with 1 µM TSA and 2 µM Apicidin treatment, whereas 2 µM Entinostat and 1 µM Mocetinostat 
had no effect. While Apicidin treatment sustains SRC repression after 24 hr treatment at 0.33 fold 
(p<0.001), TSA exhibits transient properties; the maximal repression is 0.18 fold (p<0.001) at 12 
hr.  Comparable results were observed in the Hs578T cell line.  Both 2 µM TSA and 5 µM 
Apicidin maintained SRC repression after 24 hr treatment (0.19 fold [p<0.001] and 0.39 fold 
[p<0.001]).  While 5 µM benzamide treatment did not result in statistical significance, repression 
is observed at following 12 hr treatment.  It is interesting to note that lower concentrations of 
TSA and Apicidin (1 µM and 2 µM, respectively) down-regulated SRC expression, although not 
to the extent observed with the higher doses (data not shown).  In addition, a lower concentration 
of the benzamides (2 µM Entinostat and 1 µM Mocetinostat) had no effect on SRC mRNA in the 
Hs578T cell line (data not shown). 
In the BT-474 cell line, TSA and Apicidin repressed SRC expression, and Apicidin 
repressed SRC to a greater extent than TSA.  Modest SRC repression was also observed after 
Entinostat and Mocetinostat treatment.  The effects of TSA and the benzamides in the BT-474 
cell line were transient; maximal down-regulation was observed at 6 hr treatment (0.20 fold 
[p<0.001]) in TSA-treated cells, and at 6 hr treatment (0.49 fold [p<0.001] and 0.51 fold 
[p<0.001]) in both Entinostat- and Mocetinostat-treated cells.  The effects of Apicidin were not 
transient and repression maintained after 24 hr treatment (0.24 fold [p<0.001]). 
SRC expression in the HCC-1419 cells was increased with Entinostat and Mocetinostat, 
and repressed with TSA and Apicidin.  However, while repression was initially observed 6 hr and 
12 hr (0.36 fold) after TSA treatment, expression rebounded near basal levels at 2.5 fold (p<0.05) 
at 24 hr treatment.  Treatment with Apicidin maintained repression for an extended period of time 
(0.28 fold [p<0.001]), however levels began to rebound at 24 hr.  Interestingly, Entinostat and 
Mocetinostat treatment induced SRC mRNA, with a 2.9 fold (p<0.001) and a 2.4 fold (p<0.001) 
increase at 24 hr.   
 
4.2.3 The Expression of MYC Differed in the Breast Cancer Cell Lines 
 
  The breast cancer cell lines exhibited differential responses of MYC after HDI treatment 
(Figure 4.8).  Following TSA and Apicidin treatment in the T47D cells, the levels of MYC were 





Figure 4.8.  Differential MYC expression following HDI treatment.  T47D, Hs578T, BT-474 
or HCC-1419 cells were treated with (A) 1 µM TSA, (B) 2 µM Apicidin, (C) 2 µM Entinostat or 
(D) 1 µM Mocetinostat and collected in Qiazol Lysis Buffer at the indicated time points.  Total 
RNA was purified and the mRNA reverse transcribed, and MYC levels were assessed with 
MYC-specific primers using RT-qPCR normalised against RPL13A.  The fold changes were 
calculated by the ∆∆Ct method, and data represent the mean of at least two independent 
experiments done in triplicate, +/- SEM.  Asterisks indicate significance at p<0.05 (*), p<0.01 
(**) and p<0.001 (***).   
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lived, TSA repressed expression 0.08 (p<0.001) at 12 hr treatment.  The benzamides induced 
MYC initially at 1 hr and/or 3 hr treatment, but otherwise had little effect.   
  HDI-mediated effects on MYC expression were absent in the Hs578T cells; in fact, 
treatment modestly increased expression over 24 hr.  In addition, treatment with the lower 
concentrations of the drugs (1 µM TSA, 2 µM Apicidin, 2 µM Entinostat and 1 µM 
Mocetinostat) in the Hs578T cell line did not significantly differ from the MYC expression 
profiles obtained with the higher concentrations (data not shown). 
  TSA repressed MYC in the BT-474 cell line, whereas Apicidin, Entinostat and 
Mocetinostat initially induced expression at 1 hr (1.91 fold [p<0.001], 2.56 fold [p<0.001] and 
2.38 fold [p<0.001], respectively) without a long-term effect.  In addition, the effects of TSA 
were transient and the maximal repression observed was 0.24 fold (p<0.0001) after 12 hr 
treatment.   
  The HCC-1419 cell line initially exhibited MYC induction following HDI treatment.  
This transient induction was observed after 1 hr to 3 hr treatment at 2.31 fold (p<0.01), 2.12 fold 
(p<0.001), 4.14 fold (p<0.001) and 5.03 fold (p<0.001) in TSA, Apicidin, Entinostat and 




  While SRC and MYC are generally down-regulated following TSA and NaB treatment in 
multiple cancer-derived cell lines (Kostynuik et al., 2002), the data illustrates that the HDI-
mediated repression of these proto-oncogenes is not a universal effect in the four breast cancer 
cell lines tested.  SRC repression was confirmed following TSA and Apicidin treatment, with the 
exception of induction at 24 hr treatment in the HCC-1419 cell line.  Likewise, it was confirmed 
that the benzamides either had no effect or induced expression in three cell lines (T47D, Hs578T 
and HCC-1419), but only repressed SRC in the BT-474 cells.       
  The response of MYC did not mimic that observed with SRC expression following HDI 
treatment.  While the benzamides either induced or had no effect on MYC expression in all these 
cell lines, TSA and/or Apicidin only repressed expression in the T47D and BT-474 cell lines.  
Furthermore, the Hs578T cell line exhibited the least response to HDI-mediated MYC induction 
or repression; this could reflect minimal histone acetylation following class I-specific treatment 
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or the increased steady-state MYC levels.  In addition, the different subtypes of breast cancer 
cells respond differently to HDI treatment.  The MYC locus is amplified in the triple-negative 
Hs578T and HER2-amplified HCC-1419 cell lines (Kao et al., 2009), and the data indicate that 
these two subclasses could not clinically benefit from HDI treatment, as the ERα-positive cell 
lines (T47D and BT-474).   
 
4.3 HDI Treatment Induces miRNA Gene Expression 
 
  It has been extensively demonstrated in the literature that oncogenic and/or tumour 
suppressive miRNA are altered upon HDI treatment (Scott et al., 2006; Lu et al., 2005; Tsai et 
al., 2011; Saito et al., 2006).  For example, miR-409 and miR-127 were up-regulated following 
HDI treatment in cancer-derived cell lines (Tsai et al., 2011; Saito et al., 2006).  It has also been 
demonstrated that miRNA are subjected to differential effects following class- and/or isoform-
specific drug administration; in fact, it has been established that Entinostat induced expression of 
miR-125a and miR-126b in HER2-enriched cell lines, whereas hydroxamate treatment had no 
effect (Wang et al., 2013).  Therefore, it was hypothesised that miRNA could be differentially 
regulated by HDI treatment in the four breast cancer cell lines.  In order to assess this, cell lines 
were treated with 1 µM TSA, 2 µM Apicidin, 2 µM Entinostat or 1 µM Mocetinostat, and the 
expression of miRNA implicated in breast cancer progression were analysed by RT-qPCR.  It 
was observed that three miRNA genes, miR-129-5p, miR-424 and miR-9-3p, were induced in the 
T47D, Hs578T and/or HCC-1419 cell lines upon HDI treatment. 
 
4.3.1 miR-129-5p, miR-424 and miR-9-3p Induction 
 
  Differential effects upon miRNA induction were observed in the four breast cancer cell 
lines following HDI treatment.  In the T47D cell line, Entinostat and TSA treatment induced 
miR-129-5p expression, whereas Apicidin and Mocetinostat has no effect (Figure 4.9).  TSA and 
Entinostat treatment up-regulated miR-129-5p expression 5.72 fold (p<0.001) and 4.46 fold 
(p<0.01), respectively.  This miRNA was not increased with treatment in the other cell lines.   
  miR-424 expression was induced over time with TSA and benzamide treatment in both 











Figure 4.9.  miR-129-5p induction following HDI treatment in the T47D cell line.  Total 
RNA from untreated and 1 μM TSA, 2 μM Apicidin, 2 μM Entinostat or 1 μM Mocetinostat 
treated T47D cells were collected at the indicated time points.  Samples were subjected to RT-
qPCR with miR-129-5p-specific primer, and the fold changes calculated by the ∆∆Ct method.  
Data shown is the averaged results of three independent experiments with at least three technical 
repeat(s) +/- SEM, and asterisks indicate significance at p<0.05 (*), p<0.01 (**) and p<0.001 






Figure 4.10.  miR-424 induction in HDI-treated T47D and Hs578T cell lines.  Total RNA 
from untreated and 1 μM TSA, 2 μM Apicidin, 2 μM Entinostat or 1 μM Mocetinostat treated (A) 
T47D or (B) Hs578T cells were collected at the indicated time points.  Samples were subjected to 
RT-qPCR with miR-424-specific primers, and the fold changes calculated by the ∆∆Ct method.  
Data shown is the averaged results of three independent experiments with at least three technical 
repeat(s) +/- SEM, and asterisks indicate significance at p<0.05 (*), p<0.01 (**) and p<0.001 
(***).   
 106 
 
regulated expression 4.55 fold (p<0.001) and 3.42 fold (p<0.01) while TSA induced expression 
2.69 fold (p<0.05) at 24 hr treatment in the T47D cells.  In the Hs578T cell line, 24 hr treatment 
with TSA induced expression 4.16 fold (p<0.001), while Entinostat and Mocetinostat up-
regulated expression 2.11 fold (p<0.01) and 2.43 fold (p<0.01), respectively.  
HDI treatment induced miR-9-3p expression in the T47D, Hs578T and HCC-1419 cell 
lines (Figure 4.11).  In the T47D cell line, TSA increased expression 20.70 fold (p<0.001) at 24 
hr treatment, while Apicidin and the benzamides only up-regulated expression 3.88 fold (p<0.01), 
5.64 fold (p<0.01) 3.14 fold (p<0.01), respectively.  miR-9-3p expression increased 12.94 fold 
(p<0.001) following 24 hr TSA treatment, while Apicidin, Entinostat and Mocetinostat induced 
expression 2.14 fold (p<0.05), 2.65 fold (p<0.05) and 2.40 fold (p<0.05) in the Hs578T cells.  
Similarly in the HCC-1419 cell line, TSA induced expression 3.82 fold (p<0.001), while the class 
I-specific HDIs had no effect after 24 hr. 
 
4.3.2 Down-Regulation of miRNA Gene Targets  
 
miRNA-mediated gene regulation involves the decay of mRNA transcripts and/or 
translational inhibition dependent upon the complementary binding of the seed sequence to the 
mRNA (Bartel et al., 2004; Bagga et al., 2005).  Thus, utilising the bioinformatic programmes 
miRanda, TargetScan and Diana, which predict miRNA:mRNA interactions based on 
computorial algorithms (Enright et al., 2003; Betel et al., 2008, 2010; Vlachos et al., 2014), 
miRNA target genes with potential oncogenic processes in breast cancer were validated.  The 
binding of miRNA to the 3’ UTR of their target mRNA are discussed in more detail in the 
following sections.  These targets were analysed for mRNA and/or protein expression following 
HDI-mediated miRNA induction and miRNA transfection.  It was hypothesised that the 
biologically significant induction of miRNA down-regulated their gene targets at the mRNA 
and/or protein expression levels.  
In order to eliminate HDI-mediated effects independent of miRNA induction, the cell 
lines were additionally transfected with synthetic mature miRNA obtained from Qiagen.  These 
are synthetically produced double-stranded RNA molecules that are processed into mature 
miRNA by the RISC machinery and able to exert effects within the cells.  It has been illustrated 








Figure 4.11.  miR-9-3p induction upon HDI treatment in T47D, Hs578T and HCC-1419 cell 
lines.  Total RNA from untreated and 1 μM TSA, 2 μM Apicidin, 2 μM Entinostat or 1 μM 
Mocetinostat treated (A) T47D, (B) Hs578T or (C) HCC-1419 cells were collected at the 
indicated time points.  Samples were subjected to RT-qPCR with miR-9-3p-specific primers, and 
the fold changes calculated by the ∆∆Ct method.  Data shown is the averaged results of three 
technical repeat(s) +/- SEM, and asterisks indicate significance at p<0.05 (*), p<0.01 (**) and 




expression (Ghosh et al., 2010; Roccaro et al., 2010).  Thus, protein expression of their 
respective gene targets were subsequently analysed in the transfected cells, to further validate 
them as potential miRNA targets.  
 
4.3.2.1 The Down-Regulation of ERα, a miR-129-5p Gene Target, in the T47D Cell Line 
 
The miRanda and TargetScan miRNA:mRNA interaction databases indicate that the ERα 
gene (ESR1) is a potential target for miR-129-5p, which is induced following TSA and Entinostat 
treatment in the T47D cell line.  ERα possesses three potential miR-129-5p binding sequences 
spaced closely together at the middle region of the 3’ UTR (Figure 4.12).  Although miR-129-5p 
had been induced in both the T47D and Hs578T cell lines following HDI treatment, ERα mRNA 
and protein expression were only examined in the ERα-positive T47D cells. 
 The transcript levels of ERα were down-regulated -10 fold (p<0.0001) over 24 hr with 
TSA treatment (Figure 4.13), whereas Apicidin and Entinostat were transient in nature and 
maximally repressed expression -2 fold (p<0.001) after 12 hr and -2 fold (p<0.001) after 6 hr 
treatment, respectively.  Mocetinostat did not affect ERα expression.  However, this repression 
did not reflect the induction of miR-129-5p in the T47D cell line; while TSA and Entinostat 
treatment resulted in the highest miR-129-5p induction, only TSA significantly reduced ERα 
transcript levels.    
 In addition, the protein expression of ERα reflected the mRNA data; TSA treatment 
down-regulated ERα (Figure 4.14), whereas expression was not altered with Apicidin and 
benzamide treatment (data not shown).  It has previously been demonstrated in the literature that 
treatment with ‘pan-specific’ HDIs such as TSA and Vorinostat represses ERα expression, by 
mechanisms which include enhanced acetylation of the protein and subsequent degradation 
(Fiskus et al., 2007; Kim et al., 2010).  Thus, it is possible that HDI-mediated mechanisms 
independent to or in addition to miR-129-5p induction are responsible for the repression.  
To test this, miR-129-5p was transfected into T47D cells, and the protein expression of ERα 
determined.  Following a 24 hr transfection, immuno-blot analysis indicated that the protein 
levels of ERα were unaltered (data not shown).  Therefore, it is likely that the HDI-mediated 
repression of ERα is due to varying downstream effects of the drugs, rather than induction of 












Figure 4.12.  miR-129-5p binding sites in the 3’ UTR of the ESR1 gene.  A schematic 
representation of the (A) human ESR1 3’ UTR with miR-129-5p binding sites.  The nucleotide 
sequence numbers within the 3’ UTR are labelled above.  (B) The nucleotide duplex formation 
between the miRNA and mRNA.  The vertical lines indicate predicted base pairing and colons 











Figure 4.13.  ERα expression following HDI treatment.  T47D cells were treated with 1 µM 
TSA, 2 µM  Apicidin, 2 µM Entinostat or 1 µM Mocetinostat and collected in Qiazol Lysis 
Buffer at the indicated times.  Untreated and drug vehicle controls were also harvested at this 
time.  Total RNA was purified and the mRNA reverse transcribed, and ERα levels were assessed 
with ERα-specific primers using RT-qPCR normalised against an internal control.  The fold 
changes were calculated by the ∆∆Ct method, and data represent the mean of one independent 















Figure 4.14.  ERα expression in TSA-treated T47D cells.  The cells were treated with 1 µM 
TSA over a period of 24 hr and collected in 2X Laemmli sample buffer at the indicated time 
points.  Following SDS-PAGE electrophoresis, 25 µg protein was transferred to a nitrocellulose 
membrane and incubated with an anti- Rα antibody.  GAPDH is included as a loading control.  





4.3.2.2 Chek1, a miR-424 and miR-129-5p Target, is Repressed in T47D and Hs578T Cells 
 
 It has recently been demonstrated that miR-424 targets the 3’ UTR of Chek1 to decrease 
protein levels in cervical cancer cell lines (Xu et al., 2012).  In addition, miRanda and TarBase 
miRNA:mRNA interaction databases (Enright et al., 2003; Betel et al., 2008, 2010; Vlachos et 
al., 2014) predict that Chek1 mRNA is a target for both miR-424 and miR-129-5p.  It possesses 
one potential binding site for each miRNA in the 3’ UTR (Figure 4.15); the miR-424 site is 
located near the beginning of the 3’ UTR while the miR-129-5p site is located two-thirds from 
the proximal end.   
To validate Chek1 as a potential miR-424 and/or miR-129-5p target in these cell lines, 
HDI-treated and miRNA-transfected cells were examined for mRNA and protein expression.  
While no effect on CHEK1 mRNA stability was observed, protein levels were down-regulated 
following TSA and/or Apicidin in the T47D (Figure 4.16 A) and Hs578T (Figure 4.16 B) cell 
lines.  However, these patterns do not reflect the HDI-mediated induction of miR-129-5p and 
miR-424 in the cell lines; Apicidin repressed Chek1 protein in the T47D cell line, but had no 
effect on the expression of either miR-129-5p or miR-424.  In addition, Entinostat induced miR-
424 4.5 fold (p<0.001), but treatment did not affect Chek1 protein levels (data not shown).   
Therefore, it was unclear whether protein down-regulation was due to the presence of 
miRNA within the cell; the biological effects of the HDIs could be responsible.  In order to test 
this, synthetic miR-424 was transfected into the T47D and Hs578T cell lines.  Transfection of 
miR-424 down-regulated Chek1 protein expression over 24 hr in the T47D cell line (Figure 
4.17).  Although Chek1 contained a potential seed sequence in the 3’ UTR, miR-129-5p 
transfection had no effect on Chek1 protein levels.  This indicates that miR-424, but not miR-
129-5p, can bind to the 3’ UTR of Chek1 mRNA to inhibit translation in the T47D cell line.  It is 
possible that both miR-424 and certain HDIs contribute to the regulation of Chek1.   
 
4.3.2.3 c-MYB, a miR-424 Target, is Repressed by HDIs in T47D and Hs578T Cell Lines  
 
  c-MYB is the cellular homologue of the avian myeloblastosis viral oncogene and is a 
potential target for miR-424.  The c-MYB gene encodes a proto-oncogenic transcription factor 










Figure 4.15.  miR-129-5p and miR-424 binding sites in the 3’ UTR of the Chek1 gene.  A 
schematic representation of the (A) human Chek1 3’UTR with indicated miR-129-5p and miR-
424 binding sites.  The nucleotide sequence numbers within the 3’ UTR are labelled above.  (B) 
The nucleotide duplex formation between the miRNA and mRNA.  The vertical lines indicate 
predicted base pairing and colons indicate wobble base pairing.  The seed sequence of miR-129-














Figure 4.16.  Chek1 protein expression following HDI treatment.  (A) T47D or (B) Hs578T 
cells were treated with 1 µM TSA or 2 µM Apicidin over the indicated time points.  Cells were 
harvested in 2X Laemmli sample buffer and 25 µg protein was resolved via SDS-PAGE.  
Immuno-blotting against Chek1 and GAPDH as a loading control was performed.  The data 


















Figure 4.17.  miR-424 transfection repressed Chek1 levels in T47D cells.  The cells were 
seeded at 2 x 10
4
 cells in 12-well plates and incubated with 300 nM synthetic miR-424 and 
Lipofectamine 2000 for 4 hr.  RPMI-1640 media containing 20% FBS was added to the cells, and 
they were harvested over 24 hr in 2X Laemmli sample buffer.  25 µg of protein was resolved on a 
SDS-PAGE gel and immuno-blotting against Chek1 was performed.  A mock control containing 







subtypes.  It is regulated in part by ERα, and therefore c-MYB plays a crucial role in the 
proliferation of these ERα-positive breast cancer cells and has the ability to repress differentiation 
and apoptosis (Miao et al., 2011).  Due to its contributory role in the cellular growth of cancer 
cells, the expression of c-MYB mRNA and protein levels following HDI-mediated induction of 
miR-424 were investigated.  It was hypothesised that the up-regulation of miR-424 translated to 
c-Myb protein and/or c-MYB mRNA repression.   
  c-MYB has two potential, conserved binding sequences for miR-424 in the 3’ UTR 
(Figure 4.18) (Enright et al., 2003; Betel et al., 2008, 2010; Vlachos et al., 2014).  The seed 
sequence binds to two adjacent locations in the 3’ UTR of the mRNA.  c-MYB expression was 
down-regulated following HDI-treatment in both the T47D and Hs578T cells (Figure 4.19).  In 
the T47D cell line, c-MYB was repressed -5.71 fold [p<0.0001] with TSA and -3.3 fold 
[p<0.001] with Apicidin, while Entinostat and Mocetinostat had no effect.  However, in the 
Hs578T cells, benzamide-mediated repression (-2.5 fold [p<0.001]) of c-MYB was comparable 
to -5 fold (p<0.0001) and -2.5 fold (p<0.001) repression following TSA and Apicidin, 
respectively.  Immuno-blot analysis of c-Myb protein in HDI-treated or miR-424 transfected cells 
were inconclusive.   
  It should be noted that the repression of c-MYB levels did not correlate with the observed 
induction pattern of miR-424 in either cell line.  Apicidin treatment down-regulated c-MYB 
expression in both cell lines, despite exhibiting no effect on miR-424 induction.  In addition, 
Entinostat and Mocetinostat treatment induced miR-424 to a greater extent than TSA in the T47D 
cell line, but TSA maximally repressed c-MYB levels whereas the benzamides had only modest 
effects.     
   
4.3.2.4 Cyclin D, a miR-424 Target, is Repressed Following miR-424 Induction 
 
 CCND1 and its protein product cyclin D are frequently over-expressed in many cancers, 
including breast cancer, and controls the G1/S transition of the cell cycle via binding to CDK4/6 
(Grillo et al., 2006; Liu et al., 2008).  It has been demonstrated with luciferase assays that the 3’ 
UTR of CCND1 can be regulated post-transcriptionally by the miR-16 family members, which 
includes miR-424 (Liu et al., 2008).  The 3’ UTR of CCND1 contains one miR-424 binding site 













Figure 4.18.  miR-424 binding sites in the 3’ UTR of the c-MYB gene.  A schematic 
representation of the (A) human c-MYB 3’UTR with indicated miR-424 binding sites.  The 
nucleotide sequence numbers within the 3’ UTR are labelled above.  (B) The nucleotide duplex 
formation between the miRNA and mRNA.  The vertical lines indicate predicted base pairing and 










Figure 4.19.  c-MYB repression in HDI-treated T47D and Hs578T cells.  Total RNA from 
untreated and 1 μM TSA, 2 μM Apicidin, 2 μM Entinostat or 1 μM Mocetinostat treated T47D 
cells were collected at the indicated time points.  Samples were subjected to Real Time PCR with 
gene-specific primers, and the fold changes calculated by the ∆∆Ct method.  Data shown is the 
averaged results of one technical repeat done in triplicate.  The error bars represent the standard 
















Figure 4.20.  miR-424 binding sites in the 3’ UTR of the CCNDI gene.  A schematic 
representation of the (A) human CCND1 3’UTR with the indicated miR-424 binding site.  The 
nucleotide sequence numbers within the 3’ UTR are labelled above.  (B) The nucleotide duplex 
formation between the miRNA and mRNA (B).  The vertical lines indicate predicted base pairing 
and colons indicate wobble base pairing.  The seed sequence of miR-424 is underlined in purple 




CCND1 translation and/or led to mRNA decay, the protein expression and transcript levels were 
assessed in the two cell lines.  
 While the mRNA levels of CCND1 decreased in the T47D cell line (Figure 4.21) 
following HDI treatment, this repression did not correlate with the HDI-mediated induction of 
miR-424; Apicidin had no effect on miR-424 induction, although treatment with the cyclic 
peptide down-regulated CCND1 expression.  TSA and the class I-specific Apicidin sustained 
repression (-10 fold [p<0.0001] and -3.3 fold [p<0.001]) over 24 hr, whereas the benzamides 
exhibited modest repression, -2.5 fold (p<0.001) and -2.5 fold (p<0.001) after 24 hr treatment.  
Immuno-blot analysis of HDI-treated cells indicated that cyclin D protein levels were down-
regulated only following TSA treatment (Figure 4.22).  While these protein levels reflect the 
mRNA repression observed with TSA treatment, discrepancies were observed following 
treatment with the class I-specific drugs.  The protein levels were not significantly altered with 
Apicidin, Entinostat and Mocetinostat treatments (data not shown), despite mRNA down-
regulation.   
However, it has been previously reported in the literature that CCND1 transcription is 
also decreased with HDI treatment (Jin et al., 2012; Zhang et al., 2012) as well as by miR-424 
(Liu et al., 2008).  It cannot be concluded that the decrease is solely due to increased miR-424 
expression, rather than other contributing mechanisms.  Therefore, T47D cells were transfected 
with exogenous miR-424.  It was observed that the protein levels of cyclin D were repressed 24 
hr after transfection (Figure 4.23), suggesting that miR-424 targets the 3’ UTR to inhibit protein 
synthesis and/or initiate mRNA decay in this cell line.   
 
4.3.2.5 HDAC5, a miR-9-3p Target, is Down-Regulated Following HDI treatment 
 
 It has been implicated in the literature that miR-9-3p has a role in acetylation and 
deacetylation processes, and represses the class IIa HDACs 4 and 5.  In B-cell lymphoma lines, 
up-regulation of miR-9-3p leads to a reduction of these HDACs and increased acetylation 
(Roccaro et al., 2010).  Therefore, the mRNA and protein expression of these HDACs were 
analysed following HDI-mediated up-regulation of miR-9-3p. 
The mRNA levels of these enzymes were induced or not significantly altered within 24 hr 









Figure 4.21.  CCND1 repression in HDI-treated T47D breast cancer cells.  Total RNA from 
untreated and 1 μM TSA, 2 μM Apicidin, 2 μM Entinostat or 1 μM Mocetinostat treated T47D 
cells were collected at the indicated time points.  Samples were subjected to Real Time PCR with 
gene-specific primers, and the fold changes calculated by the ∆∆Ct method.  Data shown is the 




















Figure 4.22.  Cyclin D expression in TSA-treated T47D cells.  The cells were treated with 1 
µM TSA over a period of 24 hr and collected in 2X Laemmli sample buffer at the indicated time 
points.  Following SDS-PAGE electrophoresis, 25 µg protein was transferred to a nitrocellulose 
membrane and incubated with anti-cyclin D antibody.  GAPDH was assessed as a loading 












Figure 4.23.  miR-424 transfection repressed cyclin D levels in T47D cells.  The cells were 
seeded at 2 x 10
4
 cells in 12-well plates and incubated with 300 nM synthetic miR-424 and 
Lipofectamine 2000 for 4 hr.  RPMI-1640 media containing 20% FBS was added to the cells, and 
they were harvested over 24 hr in 2X Laemmli sample buffer.  25 µg of protein was resolved on a 
SDS-PAGE gel and immuno-blotting against cyclin D was performed.  A mock control 





reduced in T47D and Hs578T cells (Figure 4.24), whereas expression was induced in the HCC 
1419 cell line (data not shown).  It is interesting to note that Apicidin, a class I-specific HDI 
thought not to target class II HDACs, resulted in modest repression of HDAC5 protein.       
To eliminate HDI-mediated repression of HDAC5 protein levels, miR-9-3p was 
transfected into the T47D and Hs578T cell lines.  The protein expression of HDAC5 in the 
Hs578T cell line was induced within 24 hr of miR-9-3p transfection, while data from the T47D 
cells demonstrated that miR-9-3p transfection had no effect on expression (data not shown).  
Therefore, it is likely that the observed HDAC5 repression observed within the HDI-treated cells 




The miRNA data further highlights the differential cellular effects HDIs have upon gene 
expression in the four representative breast cancer cell lines.  The expression of miR-129-5p, 
miR-424 and/or miR9-3p expression increased in the T47D, Hs578T and HCC-1419 cell lines.  
Therefore, our results indicate that certain HDIs lead to induction of these tumour suppressive 
miRNA genes in a cell-specific manner.  This induction of miRNA correlated with decreased 
mRNA stability and/or translational inhibition of certain targets.  miRNA transfections validated 









Figure 4.24.  HDAC5 expression in HDI-treated T47D or Hs578T cells.  (A) T47D or (B) 
Hs578T cells were treated with 1 µM TSA or 2 µM Apicidin over a period of 24 hr.  Cells were 
harvested in 2X Laemmli sample buffer and 25 µg protein was resolved via SDS-PAGE.  
Immuno-blotting against Chek1 and GAPDH as a loading control was performed.  The data 






5.  DISCUSSION 
 
  Histone deacetylase inhibitors are a novel class of anti-neoplastic drugs that mediate 
apoptosis, inhibit cell cycle progression, induce mitotic abnormalities and up-regulate gene 
expression in a wide variety of cancer-derived cell lines.  While they were traditionally thought to 
act by inhibiting HDAC enzymes and increasing histone acetylation, the additional mechanisms 
by which HDIs exert their cellular effects are poorly understood.  The inhibition of HDACs are 
widely associated with gene activation, however HDI treatment activates only a small percentage 
of human genes (2-10%), and an equal percentage are also repressed upon treatment (Van Lint et 
al., 1996; Gray et al., 2004; Marks et al., 2004; Mitsiades et al., 2004; Peart et al., 2005; Ropero 
and Esteller, 2007; LeBonte et al., 2009). 
  The FDA has approved two chemotherapeutic HDIs, Vorinostat in 2006 and Romidepsin 
in 2009, for the treatment of cutaneous T-cell lymphoma (Mann et al., 2007; Slingerland et al., 
2013).  Furthermore, following a recent phase II clinical study, the FDA has designated 
Entinostat as a ‘breakthrough therapy’ in ERα-positive metastatic breast cancers when combined 
with the aromatase inhibitor exemestane (Yardley et al., 2013).  Numerous additional HDIs have 
exhibited promising clinical responses in animal studies and phase I/II clinical trials (Piekarz et 
al., 2007; Lee et al., 2008; Jagannath et al., 2010; Munster et al., 2011; Yardley et al., 2013). 
  Research completed in the Bonham Lab has demonstrated that TSA- and NaB-dependent 
repression of the proto-oncogene SRC is mediated through both the 1A and 1α promoters.  This 
phenomenon has been observed in many cancer-derived cell lines, as well as in response to 
Apicidin treatment.  While TSA is considered a ‘pan-specific’ HDI and inhibits both class I and 
class II enzymes, Apicidin is specific for class I (HDACs 1-3, 8) (Fournel et al., 2002; Furumai et 
al., 2002; Haggarty et al., 2003; Khan et al., 2008).  ChIP analysis of the SRC promoter 
following TSA treatment indicated increased RNA pol II presence with increased H3 acetylation 
and H3K4 tri-methylation.  In contrast, H3K36 tri-methylation, a marker of elongation, decreased 
across the coding region of the gene while occupancy of NELF increased at the promoter.  It is 
thought that this HDI-dependent repression is mediated through promoter proximal pausing, 
although the exact mechanism behind this has yet to be determined.  Interestingly, two class I-
specific benzamides, Entinostat and Mocetinostat, were unable to down-regulate SRC expression, 
despite these compounds inducing the cyclin-dependent kinase inhibitor p21
WAF1
.  This 
potentially indicates that HDI-mediated repression of gene expression is not due to histone 
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acetylation, but rather non-transcriptional effects of the inhibitors, and highlights the potential 
complex nature of this class of drugs. 
  Therefore, to determine whether the repression of SRC and MYC is a cell-specific or a 
ubiquitous event, the responses of these proto-oncogenes to various classes of HDIs were 
surveyed in a panel of breast cancer cell lines.  These inhibitors included the ‘pan-inhibitory’ 
TSA (hydroxamate) and three class I-specific drugs, Apicidin (cyclic tetrapeptide), Entinostat 
(benzamide) and Mocetinostat (benzamide).  In addition, breast cancer cell lines were chosen 
based on their diverse molecular subtypes; this included T47D (ERα- and PgR-positive), Hs578T 
(triple-negative), BT-474 (ERα- and PgR-positive, and HER2-amplified) and HCC-1419 (HER2-
amplified) (Neve et al., 2006; Grigoriadis et al., 2012).   
 
5.1 The Response of Breast Cancer Cell Lines to Histone Deacetylase Inhibitors 
 





  It has been demonstrated widely in the literature that HDIs induce cytotoxicity, histone 
acetylation and p21
WAF1
 expression in cancer-derived cell lines (Vigushin et al., 2001; Glaser et 
al., 2003; Beckers et al., 2007; Ueda et al., 2007; Im et al., 2008; Fournel et al., 2008; Khan et 
al., 2008; Ahn et al., 2009; Kelly and Cowley, 2013).  The cellular effects of these class-specific 
drugs shared several properties in the four breast cancer cell lines, inducing histone H3 
acetylation and expression of the cyclin-dependent kinase inhibitor p21
WAF1
, while decreasing 




  The cell viability profiles illustrate that HDIs exert their cytotoxic effects 48 hr following 
treatment.  The efficacy of Entinostat has been demonstrated in phase II clinical studies and it has 
been considered ‘breakthrough therapy’ in ERα-positive metastatic breast cancer (Yardley et al., 
2013).  Reflecting the value of this compound in ERα-positive breast cancers, it was 
demonstrated that the cytotoxic properties of Entinostat in ERα-negative and/or HER2-amplified 
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cell lines were not as effective.  In addition, while Apicidin is also a class I-specific HDI, its 
cytotoxic profile more closely resembled that of TSA in the majority of the cell lines.  Therefore, 
even similar class I-specific HDIs such as Apicidin, Entinostat and Mocetinostat exhibit 
differential cytotoxic properties between cell lines.   
  Furthermore, the HER2-enriched HCC-1419 cell line was less sensitive to the cytotoxic 
effects mediated by these four compounds.  Cellular signalling cascades mediated through the 
HER2/neu receptor could be responsible for this divergence; thus, treatment of non-HER2-
enriched breast cancers with these chemotherapeutics could harbour greater clinical efficacy 
compared to treatment in HER2-amplified cancers.  In addition, it has been reported in the 
literature that ERα-negative cell lines are less susceptible than ERα-positive cell lines to TSA-
mediated growth inhibition (Margueron et al., 2004).  Similar results were found in this study, 
with the Hs578T cell line exhibiting less sensitivity toward the cytotoxic effects of TSA. 
  These data indicate that the cell lines differentially respond to the various inhibitors, and 
that certain drugs possess higher potency to induce cancer-cell death.  It has previously been 
established in the literature that these inhibitors can activate genes associated with different 
cellular functions (Halsall et al., 2012; Chatterjee et al., 2013).  It is likely that, through HDAC 
inhibition or the acetylation of pro-apoptotic and cell cycle regulators, these compounds can 
influence the stability and downstream effects of a diverse set of proteins.  This would ultimately 
lead to diverse responses in the cell following HDI treatment.  In addition, the pharmacokinetics 
of these individual compounds and the presence or absence of efflux drug pumps on cellular 
surfaces may further influence the cellular response to these drugs.  
 
5.1.1.2 Histone Acetylation 
 
  The induction of histone H3 acetylation following treatment illustrated that these 
compounds increased acetylation in a time- and dose-dependent manner in the four cell lines.  
While the relative HDI-mediated acetylation cannot be directly compared between the cell lines, 
several divergent responses can be highlighted.  The transient properties of TSA in the Hs578T 
and HCC-1419 cell lines potentially indicate the rapid metabolism of the hydroxamate, whereas 
class I-specific inhibitors could have a longer half-life within the cells.  The prolonged effects of 
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Apicidin, Entinostat and Mocetinostat may potentially lead to secondary responses in gene 
expression and/or cellular signalling.   
  While the benzamides inhibit the same complement of HDAC enzymes and had similar 
cytotoxic profiles in the Hs578T cell line, 0.5 µM Mocetinostat increased the acetylation of 
histones, whereas a 5 µM dose of Entinostat was required for enhanced histone acetylation.  This 
potentially implicates Mocetinostat as an advantageous chemotherapeutic agent compared to 
Entinostat for in ERα-negative cancers, although additional studies would be required to validate 
this observation.  In addition, Mocetinostat treatment induced cytotoxic effects at a lower 
concentration than Entinostat in this particular cell line, further suggesting the advantageous 






  It has been demonstrated extensively in the literature that p21
WAF1 
is induced in many-
cancer-derived cell lines upon HDI treatment (Sowa et al., 1997; Huang et al., 2000; Lagger et 
al., 2003; Ocker and Scheider-Stock, 2007; Gartel and Tyner, 2002; Simboeck et al., 2010).  The 
expression of p21
WAF1
 was therefore examined in these cell lines following drug treatment.  
While the drugs globally induced p21
WAF1
 over 24 hr, it is interesting to note the BT-474 cells 
responded with an immediate rapid, albeit transient, induction of expression unique to this cell 
line.  While p21
WAF1
 expression returned to control levels after 6 hr or 12 hr treatment, Entinostat 
exhibited a biphasic response.  This may be due to secondary effects within the cell mediated by 
Entinostat that result in the up-regulation of p21
WAF1
 expression, such as the activation of 
downstream signalling pathways that could stabilise mRNA expression or induce transcription.  
In contrast, p21
WAF1
 expression in the T47D, Hs578T and HCC-1419 cell lines exhibited 
sustained induction over 12 hr or 24 hr treatment.  p21
WAF1
 has been implicated in the anti-
proliferative effects of HDIs (Sherr and Roberts, 1999; Gartel and Tyner, 2002), and therefore 
anti-neoplastic agents drugs that exhibit prolonged p21
WAF1
 induction could be therapeutically 
beneficial compared to those that have short-term effects.   
  The data also indicates that certain classes of HDIs are poor inducers of p21
WAF1
 
expression in certain breast cancer cell lines.  While the benzamides share a similar structure, 
Entinostat induced p21
WAF1
 to a greater extent than Mocetinostat in the T47D, Hs578T and HCC-
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1419 cell lines.  The induction of p21
WAF1
 is dependent on the phosphorylation of H3S10 prior to 
acetylation of H3K14 (Simboeck et al., 2010), and therefore it is probable that these drugs do not 
activate the p21
WAF1 
promoter as efficiently as other compounds.  In addition, the Ing2 subunit of 
the Sin3A co-repressor complex has been demonstrated to be disrupted by Vorinostat treatment 
(Smith et al., 2010; Sardiu et al., 2014).  Vorinostat shares a highly similar structure to TSA, and 
it is possible that while TSA could dissociate Ing2 from Sin3A, the benzamides are unable to and 
thus do not effect p21
WAF1
 expression in the same manner.  Furthermore, it has been shown that 
inhibiting Ing2 induces p21
WAF1 
(Larrieu et al., 2010). 
  In addition, treatment with the lower concentrations of 1 µM TSA, 2 µM Apicidin, 2 µM 
Entinostat or 1 µM Mocetinostat in the Hs578T cell line, which did not induce significant histone 
acetylation, exhibited moderate p21
WAF1
 induction.  Recent research has illustrated that global 
histone acetylation is a poor marker of HDI-mediated gene induction (Halsall et al., 2012).  It has 
also been suggested that HDI treatment results in transient acetylation of genes poised in the 
transcriptionally active state (Rada-Iglesias et al., 2007; Wang et al., 2009).  Therefore, the 
acetylation of histones could be a poor indicator of the cellular activity of HDIs within certain 
cell lines.  The data also supports the induction of p21
WAF1
 expression despite poorly enhanced 
histone acetylation following treatment.  However, it remains to be determined if the minor up-
regulation of p21
WAF1
 expression, albeit statistically significant, is biologically significant.  ERα-
negative cell lines, such as the Hs578T cell line, have been demonstrated to exhibit differential 
sensitivity to HDAC inhibitors than ERα-positive cell lines (Margueron et al., 2004), and the data 
obtained from this study potentially indicates that this differential sensitivity may also be 
observed with gene induction.  While the HDIs increased p21
WAF1 
mRNA in a dose-dependent 
manner in this cell line, experiments using more concentrations would be required to confirm this 
trend. 
 
5.1.2 Histone Deacetylase Inhibitors Differentially Impact SRC and MYC Expression 
 
While widespread HDI-mediated enhanced histone acetylation and induction of p21
WAF1
 
expression has been determined in these cell lines, it has become increasingly demonstrated in the 
literature that these inhibitors affect numerous cellular processes independent of histone 
acetylation and transcriptional up-regulation (Vigushin et al., 2001; Butler et al., 2002; Glaser et 
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al., 2003; Noh et al., 2003; Bolden et al., 2006; Rosato et al., 2006; Ma et al., 2009; Chatterjee et 
al., 2013).  Although it had generally been accepted that HDI-mediated induction of transcription 
resulted from increased histone acetylation at gene promoters (Tsai et al., 2001), recent reports 
have revealed that many HDI-induced genes are in fact protected from enhanced acetylation 
(Halsall et al., 2012).  Therefore, it has become increasingly evident that the effects of these 
compounds are not as straight-forward as initially thought.  In addition, the various mechanisms 
of HDI-mediated transcriptional repression have yet to be fully elucidated.   
In order to examine HDI-mediated effects on gene repression, SRC and MYC transcript 
levels were analysed following drug treatment in the four breast cancer cell lines.  These two 
proto-oncogenes are frequently over-expressed in cancer (Dubik et al., 1987; Bonilla et al., 1988; 
Garcia et al., 1989; Cartwright et al., 1989, 1990; Dehm and Bonham, 2004; Wheeler et al., 
2009; Horiuchi et al., 2012), and it is thought that certain classes of these chemotherapeutics 
could have a clinical advantage compared to other compounds due to their ability to repress SRC 
and MYC.  It has previously been demonstrated in the Bonham Lab that SRC is repressed upon 
HDI treatment in many cancer-derived cell lines (Dehm et al., 2001); however, the extent of this 
HDI-mediated repression is unclear.  In addition, these inhibitors cannot universally repress SRC 
and MYC levels, and treatment with the benzamides had no effect on expression (Bonham and 
Beaton-Brown, unpublished data).  While SRC and MYC share similar promoter elements 
(Henricksson and Luscher, 1996; Facchini and Penn, 1998; Xiao et al., 1998; Bonham et al., 
2003, 2000; Levens, 2008), the mechanisms of HDI-mediated transcriptional repression between 
these two proto-oncogenes are unique.  The data presented in this thesis suggests that SRC and 
MYC are not globally repressed following HDI treatment in these breast cancer-derived cell 
lines.   
 
5.1.2.1 The Amplification and/or Rearrangement of the MYC Locus and HDI-Mediated 
Repression 
 
While MYC expression is repressed following HDI treatment in many cancer-derived cell 
lines (Wang et al., 1998; Sasakawa et al., 2003; Xu et al. 2005; Ierano et al., 2013, Leone et al., 
2015; Raha et al., 2015), this down-regulation was not observed following treatment in the 
Hs578T and HCC-1419 cell lines.  The MYC gene is amplified in many triple-negative breast 
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cancer cell lines, and the Hs578T and HCC-1419 cell lines both possess an amplified MYC 
genomic region as well as numerous other genomic alterations (Kao et al., 2009); this 
amplification is also reflected in the elevated steady-state levels of MYC in these cell lines.  The 
rearrangement and/or amplification of the MYC locus could alter the normal response of the 
promoter to these inhibitors, and is likely responsible for the abnormal expression of MYC 
following treatment in these two cell lines.  The T47D and BT-474 cell lines do not harbour 
MYC amplification and/or rearrangement at the genomic level, although the steady-state 
expression of MYC is comparable to the HCC-1419 cell line.  This increased expression could be 
due to enhanced transcription without genomic amplification.   
While it is more likely that the rearrangement of the MYC locus is responsible for the 
abnormal response to the HDIs, it is also possible that the inhibition of class II HDACs and/or the 
cellular signalling pathways activated or inactivated by these inhibitors could differentially 
influence transcription.  Furthermore, the possible detrimental effects of MYC induction in breast 
cancer patients with a rearranged and/or amplified MYC locus remain unclear, and therefore 
further studies with MYC-amplified cell lines are required.  In fact, it is possible that in certain 
oncogenic backgrounds with MYC over-expression, the induction of p21
WAF1
 could lead to cell 
cycle progression rather than cell cycle arrest through the enhancement of cyclin D (Bearss et al., 
2002).  Additionally, experiments involving more cell lines with abnormal MYC loci would 
verify the altered response of MYC in cell lines or tumours with genomic rearrangements.   
 
5.1.2.2 The Effects of HDAC Inhibition on SRC and MYC Repression 
 
 The inhibitors utilised in this study target different classes of HDAC enzymes; Apicidin 
and the two benzamides, Entinostat and Mocetinostat, inhibit the class I HDACs with varying 
specificities, while TSA is ‘pan-inhibitory’ and targets class I, II and IV HDACs (Fournel et al., 
2002; Furumai et al., 2002; Haggarty et al., 2003; Khan et al., 2008).  It is possible that these 
distinct properties contribute to the HDI-specific effects on SRC and MYC expression between 
the cell lines.  For example, while the benzamides and Apicidin are class I-specific HDAC 
inhibitors and can catalytically inhibit HDAC1, HDAC2 and HDAC3, they differentially 
impacted SRC and/or MYC activation and/or repression.  However, these differences were not 
consistent between the various cell lines, and determining the specific HDAC responsible is 
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challenging.   
In addition, it has been demonstrated that benzamides preferentially inhibit the HDAC3-
containing complex NCoR/SMRT, while the HDAC1/2-containing Sin3 complex is targeted by 
the hydroxamates and cyclic tetrapeptides.  While these inhibitors can inhibit the catalytic 
activity of the HDAC subunit, it is becoming increasingly apparent that HDIs interact 
differentially with these multi-protein co-repressors complexes (Bantscheff et al., 2011).  These 
differences in selective targeting and enhanced binding to certain co-repressors may also account 
for the differential responses observed following HDI treatment.  Furthermore, the cell lines 
could express a unique complement of HDAC complexes and/or protein subunits, modifying the 
impact that the same HDI could have within different cell lines.   
It is also probable that the differential effects of these compounds are due to the 
acetylation and destabilisation of transcription factors and/or protein complexes associated with 
HDAC co-repressors, rather than direct HDAC inhibition.  TSA and Apicidin could induce 
acetylation of transcription factors, whereas Entinostat and Mocetinostat have no effect, resulting 
in varied downstream responses.  Furthermore, TSA has been shown to disrupt HDAC and 
protein phosphatase complexes (Chen et al., 2008), and this could alter the chromatin-reading 
proteins at the promoters of genes, thereby altering gene expression following HDI treatment in 
these cells.  In addition, down-regulating the Sin3A co-repressor complex leads to the repression 
of MYC-target genes (McDonel et al., 2011); it is likely that the compounds which disrupt this 
complex (Sardiu et al., 2014) contribute to this process.  While the specific HDAC(s) or 
complex(es) responsible for repression and/or activation of these proto-oncogenes following HDI 
treatment cannot be determined, it is apparent that the actions of these inhibitors are widespread 
and unpredictable.   
 
5.1.2.3 The Pharmacokinetics of HDIs in the Breast Cancer Cell Lines  
 
The pharmacokinetics of these drugs within the cells could impact their effects on gene 
expression.  The transient nature of HDI-mediated SRC repression in certain cell lines could be 
due to the rapid metabolism and/or clearance from the cells.  For instance, the BT-474 cell line 
exhibited transient histone H3 acetylation and SRC repression following TSA treatment, and 
therefore this inhibitor may have a short half-life within this cell line.  A rapid clearance of TSA 
 134 
 
from the cell could account for its transient nature.  It is also possible that these cells uptake the 
drugs with various affinities, and this could impact the HDI-mediated effects observed in gene 
expression, as well as cytotoxicity and histone acetylation.   
 
5.1.2.4 HDI-Mediated Promoter Proximal Pausing  
 
Work from the Bonham Lab has indicated that TSA-mediated repression of SRC and 
MYC in the T47D cell line is likely due to promoter proximal pausing of RNA pol II (Bonham 
and Beaton-Brown, unpublished data).  The chromatin markers associated with the gene 
promoters following drug treatment supports this hypothesis.  While the data presented in this 
thesis further support TSA-mediated SRC repression in the Hs578T, BT-474 and HCC-1419 
breast cancer cell lines, MYC is not subjected to the same regulatory mechanisms in these cell 
lines.  While this could be due to the rearrangement and/or amplification of the MYC locus in the 
Hs578T and HCC-1419 cell lines, as previously mentioned, it is also probable that these drugs 
possess different cellular targets in the diverse cell lines.  The data suggest the repression of these 
proto-oncogenes are potentially due to multiple mechanisms, and are cell-specific and not a 
universal phenomenon. 
 
5.1.2.5 The Clinical Relevance of SRC and MYC Repression in Molecular Subtypes of 
Breast Cancer 
 
These cell lines represent the different molecular subtypes of breast cancer (Neve et al., 
2006; Grigoriadas et al., 2012), and it has been demonstrated that cell lines recapitulate the 
heterogeneous nature of breast cancer (Neve et al., 2006).  In addition, the down-regulation of 
SRC expression has been associated with reduced tumorigenic potential (Ishizawar et al., 2004; 
Hiscox et al., 2006; Park et al., 2008; Vandyke et al., 2009; Montero et al., 2011) in cell lines.   
The SRC expression data obtained in this study suggest that prolonged exposure to the 
benzamides in the HER2/neu-amplified HCC-1419 cell line could mediate induction of SRC, 
activating Src-dependent signalling pathways downstream.  This could indicate cell-specific 
control of SRC transcription dependent upon specific signalling cascades that result from 
enhanced HER2/neu activity.  However, the BT-474 cell line also over-expresses HER2/neu, but 
their response to the compounds are divergent from that observed in the HCC-1419 cells.  This 
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could be due to additional HDI-mediated, non-transcriptional effects on cellular signalling, which 
are present in the ERα-positive BT-474 cells but absent from the ERα-negative HCC-1419 cells.  
Therefore, additional experiments with HER2-amplified cell lines as well as in vivo studies 
would need to be performed to identify any clinical disadvantages of Entinostat and Mocetinostat 
in this particular subtype. 
In addition, the BT-474 cell line exhibited the lowest steady-state levels of SRC and 
MYC expression.  Therefore, the down-regulation of these proto-oncogenes may not be 
biologically significant in this cell line, or clinically significant in primary tumours with lower 
SRC and MYC expression.  In contrast, the T47D cell line expressed high levels of SRC mRNA, 
and repression observed following TSA and Apicidin treatment, whereas Entinostat and 
Mocetinostat, two benzamides currently used in ERα-positive tumour treatment and in phase I/II 
clinical trials, had no effect on expression.  This suggests that certain classes of these 
chemotherapeutics are advantageous compared to others due to their ability to repress these genes 
in certain subtypes of breast cancer.   
Furthermore, while the T47D and BT-474 cell lines are both ERα-positive, they exhibited 
differential repression of SRC following Mocetinostat and Entinostat treatment.  In contrast, the 
expression of MYC following treatment with these benzamides showed similar results between 
the two cell lines.  The presence or absence of ERα had no apparent influence on the HDI-
mediated repression of these proto-oncogenes.   
The data presented in this thesis indicate that different molecular subtypes of breast 
cancer could clinically benefit from treatment with certain chemotherapeutics.  While TSA 
repressed SRC in all four cell lines, MYC repression was only observed in the ERα-positive cell 
lines, potentially indicating that ‘pan-specific’ inhibitors related to this compound have an 
advantage over benzamide-derived compounds.  Entinostat and Mocetinostat induced or had no 
effect on MYC expression, which could be clinically disadvantageous.  However, it should be 
clarified that although these trends were observed within the ERα-positive, triple-negative or 
HER2/neu amplified cell lines, it cannot be determined if these are universal effects common to 
all breast cancer cell lines of these subtypes.  Investigations in additional cell lines would be 





5.2 Histone Deacetylase Inhibitors Mediate miRNA Expression 
 
miRNA genes are located within genomic regions associated with cancer and can act in a 
tumour suppressive or oncogenic manner (Lu et al., 2005; Ma et al., 2007; Babashah and 
Soleimani, 2011; Tsai et al., 2011).  Furthermore, HDI treatment has repressed or induced 
miRNA gene expression in many cancer-derived cell lines (Scott et al., 2006; Lu et al., 2005; 
Tsai et al., 2011).  It was hypothesised that these compounds differentially affected miRNA 
expression in the breast cancer cell lines.  While miRNA expression was up-regulated with HDI 
treatment, these observations were not recapitulated from each cell line.   
 
5.2.1 miR-424 and miR-129-5p Induction 
 
Both miR-424 and miR-129-5p are anti-proliferative tumour suppressor miRNA, and are 
frequently down-regulated in cancers (Wu et al., 2010; Xu et al., 2012).  In fact, miR-129-5p is 
repressed in many malignancies (Dyrskjøt et al., 2009; Wu et al., 2010), and induction has been 
demonstrated with TSA and Vorinostat treatment (Bandres et al., 2009; Brest et al., 2011).  The 
data presented in this thesis demonstrate similar results, wherein several of these inhibitors 
induced miR-129-5p expression, particularly TSA and Entinostat treatment in the T47D cells.  
Furthermore, recent research in thyroid cancer cells indicates that miR-129-5p is necessary for 
HDI-mediated cell death (Brest et al., 2011).  Therefore, HDI-mediated induction of miR-129-5p 
in the T47D cell line could be therapeutically beneficial and lead to apoptosis, suggesting an 
advantage over those inhibitors which do not induce miR-129-5p.   
In addition, miR-424 is also a tumour suppressor (Lui et al., 2008; Pallasch et al., 2009; 
Xu et al., 2012), and its induction could likewise be clinically beneficial.  In fact, it has been 
illustrated in the literature that miR-424 up-regulation in cervical cancer cell lines leads to 
apoptosis and cell cycle arrest.  The inhibition of the cell cycle at the G1/S phase is likely 
mediated by the down-regulation of the protein checkpoint kinase Chek1.  (Xu et al., 2012).  
Similar results were obtained in the T47D cell line, wherein miR-424 transfection decreased 
Chek1 protein levels.  This suggests a putative role for miR-424 as a tumour suppressor miRNA 
in certain breast cancers.  Therefore, the ability of Entinostat and TSA to significantly induce 
miR-424 in the T47D cell line could contribute to the anti-tumorigenic effects these HDIs exhibit 
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in cancerous cells.   
The induction of these tumour suppressors could be clinically advantageous in certain 
breast cancers, and chemotherapeutics which induce miR-129-5p and/or miR-424 may be better 
candidates in cancer treatment.  Entinostat has shown promising results in ERα-positive breast 
cancers, and treatment induced miR-424 and miR-129-5p expression in an ERα-positive cell line.  
Interestingly, miRNA expression in two HER2/neu amplified cell lines (BT-474 and HCC-1419) 
were not induced with the inhibitors, and therefore miR-424 and/or miR-129-5p induction could 
be an important therapeutic avenue in non-HER2/neu amplified breast cancers.  It is also possible 
that HER2/neu signalling has a role in the transcription and/or biogenesis of these miRNA, and 
contributes to their repression.  Furthermore, while Apicidin, Entinostat and Mocetinostat are 
class I-specific drugs and inhibit the same HDAC enzymes, they did not have similar effects on 
miRNA expression.  This discrepancy could be due to the inhibitors targeting different co-
repressor subunits or through altered miRNA biogenesis. 
  While HDI-mediated up-regulation of miR-424 and miR-129-5p correlated with 
repression of their gene targets (cyclin D, Chek1, ERα and c-MYB) in the T47D and/or Hs578T 
cell lines, the expression of other validated targets were not down-regulated.  The time course 
experiments were terminated at 24 hr due to the cytotoxicity of the HDIs and resultant poor 
quality of the samples at 48h.  It is possible that this 24 hr time period is too brief to observe 
miRNA-mediated protein down-regulation.  However, analysis of cells transfected with miRNA 
was extended to 72h to allow the biogenesis of the miRNA molecules and downstream effects.  
The cyclin D and Chek1 proteins were down-regulated following transfection and therefore 
confirmed as miR-424 targets (Wu et al., 2010; Xu et al., 2012) in the T47D cell line.   
  It has been demonstrated in the literature that cyclin D expression is down-regulated 
following both HDI treatment (Alao et al., 2006; Zhang et al., 2012; Jin et al., 2012) and miR-
424 induction (Wu et al., 2010).  It is therefore probable that multiple regulatory mechanisms 
exist to repress cyclin D, and miR-424 only plays a role in this process.  Furthermore, it could be 
concluded that down-regulation of c-MYB and ERα at the mRNA and/or protein level were due 
to either direct HDI-mediated effects, or a combination of direct and miRNA-mediated effects.  
Nonetheless, the up-regulation of these tumour suppressor miRNA by certain HDIs resulted in 





5.2.2 miR-9-3p Induction 
 
  While little is known on the role of miR-9-3p in cancer progression, it was found to be 
down-regulated in B-cell lymphoma and breast cancer cell lines (Roccaro et al., 2010; 
Zawistowski et al., 2013).  Furthermore, it is interesting to note that miR-9-3p targets the 3’ UTR 
of HDAC4 and HDAC5 (Roccaro et al., 2010), both class II(a) HDACs which can be targeted by 
‘pan-specific’ HDIs.  Due to this, it could be postulated that treatment with the ‘pan-specific’ 
TSA would have the highest impact on miR-9-3p expression, and potentially be one mechanism 
by which these drugs down-regulate HDAC class II(a) activity.  Due to the proposed role of miR-
9-3p in acetylation and deacetylation processes (Roccaro et al., 2010), it could be suggested that 
the induction of miR-9-3p is due to class IIa involvement.  This is supported by the ‘pan-specific’ 
TSA substantially inducing expression, whereas the class I-specific inhibitors were more 
moderate in their effects. 
 However, miR-9-3p transfection in the T47D and Hs578T cell lines had either no effect or 
up-regulated HDAC5 protein expression, respectively.  Due to the promiscuous nature of 
miRNA, it has been suggested that these small non-coding molecules exert cell-specific 
regulatory mechanisms on mRNA translation and/or decay (Bartel et al., 2004; Bagga et al., 
2005).  It is possible in these breast cancer cell lines that miR-9-3p preferentially targets the 3’ 
UTR of HDAC4 or has different gene targets.  In addition, it is likely that HDAC5 protein 
repression observed with TSA treatment is due to regulatory mechanisms that are independent to 






6. CONCLUSIONS AND FUTURE STUDIES 
 
  The heterogeneity of breast carcinoma has been demonstrated in studies examining the 
clinical and molecular characterisation of the disease.  These malignancies arise through myriad 
abnormal cellular processes, including imbalances in histone acetylation by the reciprocally 
acting HAT and HDAC enzymes.  The dysregulation of these epigenetic mechanisms represents 
a novel level of gene control, which can be exploited by various chromatin-remodelling 
chemotherapeutics.  Histone deacetylase inhibitors are a novel class of these chemotherapeutics 
that preferentially affect cancerous cells, leading to apoptosis, cell cycle arrest and/or 
differentiation (Mehnert et al., 2007; Ma et al., 2009; Wanczyk et al., 2011).  While these drugs 
were traditionally thought to shift the balance of HAT and HDAC activity, thereby altering 
chromatin modifications and enhancing gene expression, recent evidence suggests that the 
actions of HDIs are more complex than originally thought.  They have been shown to exhibit 
cell-specific and/or differential effects in a variety of cancer-derived cell lines (Gray et al., 2004; 
Ropero and Esteller, 2007; LeBonte et al., 2009; Halsall et al., 2012; Chatterjee et al., 2013).   
  The data presented in this thesis further highlights the complex nature and 
unpredictability of these inhibitors.  It also highlights the clinical advantages that certain drugs 
could have over other chemical classes of these compounds for the treatment of certain breast 
tumours.  It has previously been demonstrated that the SRC proto-oncogene is repressed 
following TSA, NaB and/or Apicidin treatment in many cancerous cell lines, including 
colorectal, breast and hepatocellular (Kostyniuk et al., 2002; Dehm and Bonham, 2004; Hirsch et 
al., 2006; Bonham and Beaton-Brown, unpublished data).  The repression of SRC is mediated 
from both the 1A and 1α promoters despite increased histone acetylation at these regions, and 
does not require de novo protein synthesis.  This HDI-mediated repression was likewise observed 
for the MYC proto-oncogene.  However, Entinostat and Mocetinostat treatment did not down-
regulate SRC and MYC.  These are two benzamides which are currently in clinical trials, and 
Entinostat has also been labelled a ‘breakthrough therapy’ in conjunction with exemestane in the 
treatment of metastatic ERα-positive breast cancers.  It would be expected that 
chemotherapeutics that down-regulate SRC and/or MYC while inducing p21
WAF1
 would be more 
potent drugs to treat breast tumours.  In addition, the up-regulation of tumour suppressor miRNA 
is another avenue that can be exploited to induce cancer cell death and anti-neoplastic effects.   
 140 
 
The data presented in this study indicates that HDAC inhibitors do not universally repress 
SRC or MYC in four cell lines representative of the heterogeneous nature of breast cancer.  
However, these compounds induced cell cytotoxicity, histone H3 acetylation and p21
WAF1
 
expression, indicating that the mechanisms of HDI-mediated repression are particular to certain 
compounds.  While TSA and Apicidin repressed SRC in all cell lines, treatment with the 
benzamides had no effect.  MYC repression was only observed following TSA treatment in the 
BT-474 and T47D cell lines, and the class I-specific inhibitors had either no effect or induced 
expression.     
It has been demonstrated that benzamides are unable to inhibit HDAC activity within the 
Sin3 complex.  In fact, while benzamides such as Entinostat can rapidly inhibit HDAC3 and 
HDAC3-containing co-repressor complexes, they have little effect on the Sin3 components and 
HDAC1/2 enzymes.  However, they are able to inhibit the CoREST and NuRD complexes, which 
contain HDAC1 and/or HDAC2 dimers and HDAC3 (Bantscheff et al., 2011; Becher et al., 
2014).  The inhibition of these complexes can lead to increased histone acetylation and p21
WAF1
 
expression.  In contrast, hydroxamates such as TSA and Vorinostat, rapidly inhibit the three co-
repressor complexes Sin3, NuRD and CoREST (Becher et al., 2014), and therefore can also 
induce histone acetylation and p21
WAF1
.  The distinct kinetics of these inhibitors in affecting the 
HDAC co-repressor complexes could explain the differences in enhanced histone H3 acetylation, 
p21
WAF1
 induction and cytotoxicity observed between the HDIs within the cell lines.   
The divergence in the effects of these compounds on co-repressors and HDAC enzymes 
could also account for the differential effects observed between SRC and MYC repression 
following treatment with similarly structured HDIs.  Certain drugs, such as TSA and/or Apicidin, 
could inhibit HDAC1/2 within the Sin3 complex and/or disrupt complex integrity.  Therefore, it 
is possible that the Sin3 complex could be responsible for HDI-mediated repression of these 
proto-oncogenes.  Indeed, Vorinostat dissociates Ing2 from the Sin3A complex, abrogating its 
activity (Smith et al., 2010).  The mechanism(s) by which TSA and/or Apicidin exert these 
effects are currently unknown; it could be mediated through HDAC inhibition and/or complex 
disruption.  In contrast, Mocetinostat and Entinostat cannot inhibit the HDACs within Sin3, and 
furthermore have no effect on the integrity of the complex (Figure 6.1).  
In order to test whether the Sin3 complex is associated with the SRC and MYC 








Figure 6.1. Model of HDI-mediated inhibition of HDAC co-repressor complexes.  A red 
arrow indicates repression and a green arrow indicates activation.  The benzamides have no effect 
on the Sin3 complex but can inhibit the CoREST, NuRD and NCOR/SMRT complexes.  
Hydroxamates and cyclic tetrapeptides can inhibit the four co-repressor complexes.  Through 
these mechanisms, Entinostat, Mocetinostat, TSA and Apicidin activate gene expression and 





would be expected to be enriched at the promoter regions.  The components of the Sin3 complex 
could be knocked down in cell lines, and the effects on SRC and MYC expression observed 
through RT-qPCR.  These proto-oncogenes would be repressed following Sin3 disruption if the 
complex is involved in regulation.  In addition, HDAC1 and/or HDAC2 can be over-expressed in 
the cell lines and the effect on SRC and MYC expression determined.  While this experiment 
may implicate the HDAC1/2-containing Sin3 complex in gene regulation, it does not eliminate 
the consequences that HDAC over-expression could have in the cell.  These may involve other 
cellular processes, which potentially could lead to differences in MYC and SRC expression.  
Despite the exact mechanism responsible for the HDI-mediated repression of SRC and/or MYC 
in these cell lines, it is evident that these classes of inhibitors are complex and unpredictable in 
nature. 
In addition, it has been shown that RNA pol II-encoded miRNA are induced upon HDI 
treatment (Lu et al., 2005; Scott et al., 2006).  miRNAs are implicated in numerous cellular 
processes important in malignant pathogenic processes and have been shown to have anti-tumour 
activity (Iorio et al., 2005; Lu et al., 2005; Scott et al., 2006; Lowery et al., 2009).  The data 
presented in this thesis demonstrated that HDIs induced miR-129-5p, miR-424 and miR-9-3p 
expression in several breast cancer cell lines.  These tumour suppressor miRNA were not up-
regulated in all cell lines with all the inhibitors, and this further highlights the complexity and 
unpredictability that these compounds have within cell lines.  It is likely that this up-regulation 
observed following TSA, Apicidin, Entinostat and/or Mocetinostat treatment is mediated through 
co-repressor complexes commonly affected by the four inhibitors.  However, it is unclear 
whether the mechanisms of HDI-mediated induction are due to enhanced transcription from the 
miRNA promoters or altered miRNA biogenic processes.  Therefore, analysing the expression of 
pri-miRNA and pre-miRNA through RT-qPCR techniques could eliminate HDI-mediated 
enhancement of miRNA processing.  It is also probable that certain HDIs preferentially target 
certain miRNA for processing by Drosha and Dicer.   
Furthermore, the cyclin D and Chek1 protein were down-regulated following miRNA 
transfection, suggesting that miR-424 targets the 3’ UTR of these transcripts for translational 
inhibition and/or mRNA decay.  To determine the mechanism by which this miRNA regulates 
cyclin D and Chek1 post-transcriptionally, luciferase reporter assays involving the 3’ UTR of 
these transcripts and miRNA transfection can be utilised.  The measurement of the luciferase 
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activity would indicate if the mRNA is degraded following transfection, or if the mechanism of 
regulation is through the inhibition of translation.  miR-424 is involved in cell cycle arrest and 
apoptosis in cervical cancer (Xu et al., 2012), and transfection experiments followed by TUNEL 
assays or Annexin V assays for apoptotic detection can be performed.  This would therefore 
indicate the potential advantages of miR-424 induction in the breast cancer cell lines.  In addition, 
transwell migration and invasion assays following miR-424 and miR-129-5p transfection to 
determine if the induction of these miRNA leads to a decrease in the metastatic properties of 
cells.  It has also been demonstrated that miR-129-5p is required for HDI-mediated apoptosis in 
thyroid cancer cells (Brest et al., 2011).  Transfection of anti-miR-129-5p followed by HDI 
treatment and subsequent apoptotic assays could elucidate whether this miRNA is required for 
the HDI-mediated cytotoxicity observed in the breast cancer cell lines. 
  The field of research into the mechanisms of HDI action has evolved considerably, 
particularly in the last decade.  Recent research has illustrated that these inhibitors influence more 
than merely histone acetylation and gene activation.  The repression of gene expression and non-
transcriptional effects are being demonstrated in many cancer-derived cell lines, and it has 
become apparent that HDIs are more multifaceted than previously thought.  In fact, the 
complexity of these drugs and their unique interaction with HDAC enzymes and the co-repressor 
complexes could hinder the development of novel chemotherapeutics in the treatment of cancers.  
The data presented in this thesis further highlights the complex nature and unpredictability of 
these inhibitors.  Furthermore, it provides a potential framework for the mechanisms by which 
the various HDAC inhibitors act through the co-repressor complexes and highlights the 








Ahn, M.Y., Lee, J., Na, Y.J., Choi, W.S., Lee, B.M., Kang, K.W., and Kim, H.S. (2009). 
Mechanism of apicidin-induced cell cycle arrest and apoptosis in Ishikawa human endometrial 
cancer cells. Chem. Biol. Interact. 179, 169-177. 
 
Aickin, M., and Gensler, H. (1996). Adjusting for multiple testing when reporting research 
results: the Bonferroni vs Holm methods. Am. J. Public Health 86, 726-728. 
 
Alao, J.P., Stavropoulou, A.V., Lam, E.W., Coombes, R.C., and Vigushin, D.M. (2006). Histone 
deacetylase inhibitor, trichostatin A induces ubiquitin-dependent cyclin D1 degradation in MCF-
7 breast cancer cells. Mol. Cancer 5, 8. 
 
Anderson, S.K., Gibbs, C.P., Tanaka, a, Kung, H.J., and Fujita, D.J. (1985). Human cellular src 
gene: nucleotide sequence and derived amino acid sequence of the region coding for the carboxy-
terminal two-thirds of pp60c-src. Mol. Cell. Biol. 5, 1122-1129. 
 
Aulmann, S., Adler, N., Rom, J., Helmchen, B., Schirmacher, P., and Sinn, H.P. (2006). c-myc 
amplifications in primary breast carcinomas and their local recurrences. J. Clin. Pathol. 59, 424-
428. 
 
Ayrapetov, M.K., Wang, Y.H., Lin, X., Gu, X., Parang, K., and Sun, G. (2006). Conformational 
basis for SH2-Tyr(P)527 binding in Src inactivation. J. Biol. Chem. 281, 23776-23784. 
 
Bagga, S., Bracht, J., Hunter, S., Massirer, K., Holtz, J., Eachus, R., and Pasquinelli, A.E. (2005). 
Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation. Cell. 122, 553-563. 
 
Bali, P., Pranpat, M., Swaby, R., Fiskus, W., Yamaguchi, H., Balasis, M., Rocha, K., Wang, 
H.G., Richon, V., and Bhalla, K. (2005). Activity of suberoylanilide hydroxamic acid against 
human breast cancer cells with amplification of Her-2. Clin. Cancer Res. 11, 6382-6389. 
 
Bandres, E., Agirre, X., Bitarte, N., Ramirez, N., Zarate, R., Roman-Gomez, J., Prosper, F., and 
Garcia-Foncillas, J. (2009). Epigenetic regulation of microRNA expression in colorectal cancer. 
Int. J Cancer. 125, 2737-2743.  
 
Bantscheff, M., Hopf, C., Savitski, M.M., Dittmann, A., Grandi, P., Michon, A.M., Schlegl, J., 
Abraham, Y., Becher, I., Bergamini, G., Boesche, M., Delling, M., Dumpelfeld, B., Eberhard, D., 
Huthmacher, C., Mathieson, T., Poeckel, D., Reader, V., Strunk, K., Sweetman, G., Kruse, U., 
Neubauer, G., Ramsden, N.G., and Drewes, G. (2011). Chemoproteomics profiling of HDAC 
inhibitors reveals selective targeting of HDAC complexes.  Nature Biotechnol. 29, 255-265. 
 
Barneda-Zahonero, B., and Parra, M. (2012). Histone deacetylases and cancer. Mol. Oncol. 6, 
579-589. 
 





Bearss, D.J., Lee, R.L., Troyer, D.A., Pestell, R.G., and Windle, J.J. (2002). Differential effects 
of p21WAF1/CIP1 deficiency on MMTV-ras and MMTV-myc mammary tumor properties. 
Cancer Res. 62, 2077-2084.  
 
Becher, I., Dittmann, A., Savitski, M.M., Hopf, C., Drewes, G., and Bantscheff, M. (2014). 
Chemoproteomics reveals time-dependent binding of histone deacetylase inhibitors to 
endogenous repressor complexes. ACS. Chem. Biol. 9, 1736-1746 
 
Beckers, T., Burkhardt, C., Wieland, H., Gimmnich, P., Ciossek, T., Maier, T., and Sanders, K. 
(2007). Distinct pharmacological properties of second generation HDAC inhibitors with the 
benzamide or hydroxamate head group. Int. J. Cancer 121, 1138-1148. 
 
Bicaku, E., Marchion, D.C., Schmitt, M.L., and Munster, P.N. (2008). Selective inhibition of 
histone deacetylase 2 silences progesterone receptor-mediated signalling. Cancer Res. 68, 1513-
1519. 
 
Biscardi, J.S., Tice, D.A. and Parsons S.J. (1999). c-Src, receptor tyrosine kinases, and human 
cancer. Adv. Cancer Res. 76, 61-119. 
Biscardi, J.S., Ishizawar, R.C., Silva, C.M., and Parsons, S.J. (2000). Tyrosine kinase signalling 
in breast cancer: epidermal growth factor receptor and c-Src interactions in breast cancer. Breast 
Cancer Res. 2, 203-210. 
 
Bieliauskas, A.V., and Pflum, M.K. (2008). Isoform-selective histone deacetylase inhibitors. 
Chem. Soc. Rev. 37, 1402-1413. 
Boffa, L.C., Vidali, G., Mann, R.S., and Allfrey, V.G. (1978). Suppression of histone 
deacetylation in vivo and in vitro by sodium butyrate. J. Biol. Chem. 253, 3364-3366. 
 
Boggon, T.J., and Eck, M.J. (2004). Structure and regulation of Src family kinases. Oncogene 23, 
7918-7927. 
 
Bonham, K. and Fujita, D.J. (1993). Organization and analysis of the promoter region and 5' non-
coding exons of the human c-src proto-oncogene. Oncogene 8, 1973-1981. 
 
Bouchalova, K., Cizkova, M., Cwiertka, K., Trojanec, R., and Hajduch, M. (2009). Triple 
negative breast cancer – current status and prospective targeted treatment based on Her1 (EGFR) 
TOP2A and c-Myc gene assessment. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech 
Repub. 153(1), 13-18.   
 
Boumber, Y., Younes, A., and Garcia-Manero, G. (2011). Mocetinostat (MGCD0103): a review 
of an isotype-specific histone deacetylase inhibitor. Expert Opin. Investig. Drugs 20, 823-829. 
Brennecke, J., Stark, A., Russell, R.B., and Cohen, S.M. (2005). Principles of microRNA-target 




Bressi, J.C., Jennings, A.J., Skene, R., Wu, Y., Melkus, R., De Jong, R., O’Connell, S., 
Grimshaw, C.E., Navre, M., and Gangloff, A.R. (2010). Exploration of the HDAC2 foot pocket: 
synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg. Med. Chem. Lett. 20, 
3142-3145.  
 
Brest, P., Lassalle, S., Hofman, V., Bordone, O., Tanga, V.G., Bonnetaud, C., Moreilhon, C., 
Rios, G., Santini, J., Barbry, P., Svanborg, C., Mograbi, B., Mari, B., and Hofman, P. (2011). 
miR-129-5p is required for histone deacetylase inhibitor-induced cell death in thyroid cancer 
cells. Endocr. Relat. Cancer. 18, 711-719.  
 
Brunton, V.G., Ozanne, B.W., Paraskeva, C., Frame, M.C. (1997). A role for epidermal growth 
factor receptor, c-Src and focal adhesion kinase in an in vitro model for the progression of colon 
cancer. Oncogene 17, 283-293. 
 
Butler, K.V. and Kozikowski, A.P. (2008). Chemical origins of isoform selectivity in histone 
deacetylase inhibitors. Curr. Pharm. Des. 14, 505-528.  
 
Cai, X., Hagedorn, C.H., and Cullen, B.R. (2004). Human microRNAs are processed from 
capped, polyadenylated transcripts that can also function as mRNAs. RNA 10, 1957-1966. 
 
Calin, G.A., Dumitru, C.D., Shimizu, M., Bichi, R., Zupo, S., Noch, E., Aldler, H., Rattan, S., 
Keating, M., Rai, K., et al. (2002). Frequent deletions and down-regulation of micro- RNA genes 
miR-15 and miR-16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. U.S.A. 99, 
15524-15529. 
 
Calin, G.A., Sevignani, C., Dumitru, C.D., Hyslop, T., Noch, E., Yendamuri, S., Shimizu, M., 
Rattan, S., Bullrich, F., Negrini, M., et al. (2004). Human microRNA genes are frequently 
located at fragile sites and genomic regions involved in cancers. Proc. Natl. Acad. Sci. U.S.A.  
101, 2999-3004. 
 
Canadian Cancer Society (2014). Canadian Cancer Society’s Advisory Committee on Cancer 
Statistics. Canadian Cancer Statistics 2014. 
 
Candido, E.P.M., Davie, J.R. (1978). Sodium butyrate cultured cells inhibits histone 
deacetylation in cultured cells. Cell 14, 105-113. 
 
Castellano, L., Giamas, G., Jacob, J., Coombes, R.C., Lucchesi, W., Thiruchelvam, P., Barton, 
G., Jiao, L.R., Wait, R., Waxman, J., et al. (2009). The estrogen receptor-alpha-induced 
microRNA signature regulates itself and its transcriptional response. Proc. Natl. Acad. Sci. 
U.S.A. 106, 15732-15737. 
 
Cartwright, C.A., Kamps, M.P., Meisler, A.I., Pipas, J.M., and Eckhart, W. (1989). pp60 c-Src 
activation in human colon carcinoma. J. Clin. Invest. 83, 2025-2033. 
 
Cartwright, C.A., MeInt. J. Mol. Med.isler, A.I., and Eckhart, W. (1990). Activation of the 
pp60c-src protein kinase is an early event in colonic carcinogenesis. Proc. Natl. Acad. Sci. U.S.A. 




Chang, T.C., Wentzel, E.A., Kent, O.A., Ramachandran, K., Mullendore, M., Lee, K.H., 
Feldmann, G., Yamakuchi, M., Ferlito, M., Lowenstein, C.J., Arking, D.E., Beer, M.A., Maitra, 
A., and Mendell, J.T. (2007).  Transactivation of miR-34a by p53 broadly influences gene 
expression and promotes apoptosis. Mol. Cell 26, 745-752. 
 
Chavan, A.V., and Somani, R.R. (2010). HDAC inhibitors – new generation of target specific 
treatment. Mini Rev. Med. Chem. 10, 1263-1276. 
 
Chatterjee, N., Wang, W.L.W., Conklin, T., Chittur, S., and Tennishwood, M. (2013). Histone 
deacetylase inhibitors modulate miRNA and mRNA expression, block metaphase, and induce 
apoptosis in inflammatory breast cancer cells. Cancer Biol. Ther. 14, 658-671. 
 
Chen, Y., and Olopade, O.I. (2008).  MYC in breast tumor progression. Expert Rev. Anticancer 
Ther. 8, 1689-1698. 
 
Chen, H., Pimienta, G., Gu, Y., Sun, X., Hu, J., Kim, M.S., Chaerkady, R., Gucek, M., Cole, 
R.N., Sukumar, S., and Pandey, A. (2010). Proteomic characterization of Her2/neu-
overexpressing breast cancer cells. Proteomics 10, 3800-3810. 
 
Chen, W., Wei, F., Xu, J., Wang, Y., Chen, L., Wang, J., and Guan, X. (2011). Trastuzumab 
enhances the anti-tumor effects of the histone deacetylase inhibitor sodium butyrate on a HER2-
overexpressing breast cancer cell line. Int. J. Mol. Med. 28, 985-991. 
Choudhary, C., Kumar, C., Gnad, F., Nielsen, M.L., Rehman, M., Walther, T.C., Olsen, J. V, 
Mann, M. (2009). Lysine acetylation targets protein complexes and co-regulates major cellular 
functions. Sci. Biochem. Cell Biol. 325, 834-841. 
 
Cicatiello, L., Mutarelli, M., Grober, O.M.V., Paris, O., Ferraro, L., Ravo, M., Tarallo, R., Luo, 
S., Schroth, G.P., Seifert, M., Zinser, C., Chiusano, M.L., Traini, A., de Bortoli, M., and Weisz, 
A. (2010). Estrogen receptor α controls a gene network in luminal-like breast cancer cells 
comprimising multiple transcription factors and microRNAs. Am. J. Pathol. 176, 2113-2130. 
 
Citri, A., and Yarden, Y. (2006). EGF-ERBB signalling: towards the systems level. Nat. Rev. 
Mol. Cell. Biol. 7, 505-516. 
 
Cooper, J.A, Gould, K.L., Cartwright, C.A, and Hunter, T. (1986). Tyr527 is phosphorylated in 
pp60c-src: implications for regulation. Science 231, 1431-1434.  
 
Cooper, J.A., and King, C.S. (1986). Dephosphorylation or antibody binding to the carboxy 
terminus stimulates pp60 c-src. Mol. Cell. Biol. 6, 4467-4477. 
 
Corcoran, D.L., Pandit, K.V., Gordon, B., Bhattacharjee, A., Kaminski, N., and Benos, P.V. 
(2009).  Features of mammalian microRNA promoters emerge from polymerase II chromatin 




Courtneidge, S.A (1985). Activation of the pp60c-src kinase by middle T antigen binding or by 
dephosphorylation. EMBO J. 4, 1471-1477. 
 
Darkin-Rattray, S.J., Gurnett, A.M., Myers, R.W., Dulski, P.M., Crumley, T.M., Allocco, J.J., 
Cannova, C., Meinke, P.T., Colletti, S.L., Bednarek, M. a, Singh, S.B., Goetz, M. a, 
Dombrowski, a W., Polishook, J.D., and Schmatz, D.M. (1996). Apicidin: a novel antiprotozoal 
agent that inhibits parasite histone deacetylase. Proc. Natl. Acad. Sci. U.S.A. 93, 13143-13147. 
 
de Ruijter, T.C., Veeck, J., de Hoon, J.P.J., van Engeland, M., Tjan-Heijnen, V.C. (2011). 
Characteristics of triple-negative breast cancer. J. Cancer Res. Clin. Oncol. 137, 183-192.  
 
Dehm, S.M., and Bonham, K. (2004). SRC gene expression in human cancer: the role of 
transcriptional activation. Biochem. Cell Biol. 82, 263-274. 
 
Dejligbjerg, M., Grauslund, M., Litman, T., Collins, L., Qian, X., Jeffers, M., Lichenstein, H., 
Jensen, P.B., and Sehested, M. (2008). Differential effects of class I isoform histone deacetylase 
depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells. Mol. Cancer 7, 
70. 
 
Delcuve, G., Khan, D.H., and Davie, J.R. (2013). Targeting class I histone deacetylases in cancer 
therapy. Expert Opin. Ther. Targets. 17, 29-41. 
 
Di Leva, G., Gasparini, P., Piovan, C., Ngankeu, A., Garofalo, M., Taccioli, C., Iorio, M.V., Li, 
M., Volinia, S., Alder, H., Nakamura, T., Nuovo, G., Liu, Y., Nephew, K.P., and Croce, C.M. 
(2010). MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer.  J. 
Natl. Cancer Inst. 102, 706-721. 
 
Doerks, T., Copley, R.R., Schultz, J., Ponting, C.P., and Bork, P. (2002). Systematic 
identification of novel protein domain families associated with nuclear functions. Genome Res. 
12, 47-56. 
 
Dokmanovic, M., Clarke, C., and Marks, P.A. (2007). Histone deacetylase inhibitors: overview 
and perspectives. Mol. Cancer Res. 5, 981-989. 
Dubik, D., Dembinski, T.C., and Shiu, R.P.C. (1987). Stimulation of c-Myc oncogene expression 
associated with estrogen-induced proliferation of human breast cancer cells. Cancer Res. 47, 
6517-6521. 
 
Dyrskjot, L., Ostenfeld, M.S., Bramsen, J.B., Silahtaroglu, A.N., Lamy, P., Ramanathan, R., 
Fristrup, N., Jensen, J.L., Andersen, C.L., Zieger, K., Kauppinen, S., Ulhoi, B.P., Kjems, J., 
Borre, M., and Orntoft, T.F. (2009). Genomic profiling of microRNAs in bladder cancer: miR-
129 is associated with poor outcome and promotes cell death in vitro. Cancer Res. 69, 4851-
4860. 
 
el-Deiry, W.S., Tokino, T., Velculescu, V.E., Levy, D.B., Parsons, R., Trent, J.M., Lin, D., 
Mercer, W.E., Kinzler, K.W., Vogelstein, B. (1993). WAF1 a potential mediator of p53 tumor 




Elias, A.D. (2010). Triple-negative breast cancer: a short review. Am. J. Clin. Oncol. 33(6), 637-
645. 
 
Ellis, D.J., Lawman, Z.K., and Bonham, K. (2008). Histone acetylation is not an accurate 
predictor of gene expression following treatment with histone deacetylase inhibitors. Biochem. 
Biophys. Res. Commun. 367, 656-662. 
Elston, E.W., Ellis, I.O., 1993. Method for grading breast cancer. J. Clin. Pathol. 46, 189-190.  
 
Eot-Houllier, G., Fulcrand, G., Watanabe, Y., Magnaghi-Jaulin, L., and Jaulin, C. (2008).  
Histone deacetylase 3 is required for centromeric H3K4 deacetylation and sister chromatid 
cohesion.  Genes Dev. 22, 2639-2644. 
 
Espada, J., Ballestar, E., Fraga, M.F., Villar-Garea, A., Juarranz, A., Stockert, J.C., Robertson, 
K.D., Fuks, F., and Esteller, M. (2004). Human DNA methyltransferase 1 is required for 
maintenance of the histone H3 modification pattern. J. Biol. Chem. 279, 37175-37184. 
Fan, J., Yin, W.J., Lu, J.S., Wang, L., Wu, J., Wu, F.Y., Di, G.H., Shen, Z.Z., and Shao, Z.M. 
(2008). ER alpha negative breast cancer cells restore response to endocrine therapy by 
combination treatment with both HDAC inhibitor and DNMT inhibitor. J. Cancer Res. Clin. 
Oncol. 134, 883-890. 
 
Felsenfeld, G. (1992). Chromatin as an essential part of the transcriptional mechanism. Nature 
355, 219-224. 
 
Ferguson, L.R., Tatham, A.L., Lin, Z., and Denny, W.A. (2011). Epigenetic regulation of gene 
expression as an anticancer drug target. Curr. Cancer Drug Targets 11, 199-212.  
 
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D.M., 
Forman, D., and Bray F. (2015).  Cancer incidence and mortality worldwide: sources, methods 
and major patterns in GLOBOCAN 2012. Int. J. Cancer 136, E359-E386. 
 
Finn, R.S., Dering, J., Ginther, C., Wilson, C.A., Glaspy, P., Tchekmedyian, N., and Slamon, D.J. 
(2007). Dasatinib, an orally active small molecule inhibitor of both the Src and Abl kinases, 
selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in 
vitro. Breast Cancer Res. and Treat. 105, 319-326. 
 
Fiskus, W., Hembruff, S.L., Rao, R., Sharma, P., Balusu, R., Venkannagari, S., Smith, J.E., Peth, 
K., Peiper, S.C., and Bhalla, K.N. (2012). Co-treatment with vorinostat synergistically enhances 
activity of Aurora kinase inhibitor against human breast cancer cells. Breast Cancer Res. Treat. 
135, 433-444. 
 
Fleury, L., Gerus, M., Lavigne, A.C., Richard-Foy, H., and Bystricky, K. (2008). Eliminating 
epigenetic barriers induces transient hormone-regulated gene expression in estrogen receptor 




Frame, M.C., 2004. Newest findings on the oldest oncogene; how activated Src does it. J. Cell 
Sci. 117, 989-998.  
 
Fournel, M., Bonfils, C., Hou, Y., Yan, P.T., Trachy-Bourget, M.C., Kalita, A., Liu, J., Lu, A.H., 
Zhou, N.Z., Robert, M.F., et al. (2008). MGCD0103, a novel isotype-selective histone 
deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol. Cancer 
Ther. 7, 759-768. 
Fuino, L., Bali, P., Wittmann, S., Donapaty, S., Guo, F., Yamaguchi, H., Wang, H., Atadja, P., 
Bhalla, K. (2003). Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes 
human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone. Mol. Cancer 
Ther. 2, 971-985. 
Gabrielli, B. and Brown, M. (2012). Histone deacetylase inhibitors disrupt the mitotic spindle 
assembly checkpoint by targeting histone and nonhistone proteins. Adv. Cancer Res. 116, 1-37. 
Garcia, I., Dietrich, P.Y., Aapro, M., Vauthier, G., Vadas, L., Engel, E. (1989). Genetic 
alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human 
breast carcinomas. Cancer Res. 49, 6675-6679. 
 
Gartel, A.L., and Tyner, A.L. (2002). The role of the cyclin-dependent kinase inhibitor p21 in 
apoptosis. Mol. Cancer Ther. 1, 639-649. 
 
Ghosh, G., Subramanian, I.V., Adhikari, N., Zhang, X., Joshi, H.P., Basi, D., Chandrashekhar, 
Y.S., Hall, J.L., Roy, S., Zeng, Y., and Ramakrishnan, S. (2010). Hypoxia-induced miRNA-424 
expression in human endothelial cells regulates HIF-α isoforms and promotes angiogenesis. J. 
Clin. Invest. 120, 4141-4154. 
 
Glaser, K.B., Staver, M.J., Waring, J.F., Stender, J., Ulrich, R.G., Davidsen, S.K. (2003). Gene 
expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene 
set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol. Cancer Ther. 2, 
151-163.  
 
Glaser, K.B., Li, J., Pease, L.J., Staver, M.J., Marcotte, P.A., Guo, J., Frey, R.R., Garland, R.B., 
Heyman, H.R., Wada, C.K., et al. (2004). Differential protein acetylation induced by novel 
histone deacetylase inhibitors. Biochem. Biophys. Res. Commun. 325, 683-690. 
Gregoire, S., Xiao, L., Nie, J., Zhang, X., Xu, M., Li, J., Wong, J., Seto, E., and Yang, X.J. 
(2007). Histone deacetylase 3 interacts with and deacetylates myocyte enhancer factor 2. Mol. 
Cell. Biol. 27, 1280-1295. 
 
Grigoriadis, A., Mackay, A., Noel, E., Wu, P.J., Natrajan, R., Frankum, J., Reis-Filho, J.S., and 
Tutt, A. (2012). Molecular characteristics of cell line models for triple-negative breast cancers. 




Grimson, A., Farh, K.K., Johnston, W.K., Garrett-Engele, P., Lim, L.P., and Bartel, D.P. (2007). 
MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol. Cell 27, 
91-105. 
Goldberg, G.S., Alexander, D.B., Pellicena, P., Zhang, Z.Y., Tsuda, H., and Miller, W.T. (2003). 
Src phosphorylates Cas on tyrosine 253 to promote migration of transformed cells. J. Biol. Chem. 
278, 46533-46540.  
 
Grozinger, C.M., Hassig, C.A., and Schreiber, S.L. (1999). Three proteins define a class of 
human histone deacetylases related to yeast Hda1p. Proc. Natl. Acad. Sci. U.S.A. 96, 4868-4873. 
Grozinger, C.M., and Schreiber, S.L. (2000). Regulation of histone deacetylase 4 and 5 and 
transcriptional activity by 14-3-3-dependent cellular localization. Proc. Natl. Acad. Sci. U.S.A. 
97, 7835-7840. 
Gu, W., Roeder, R.G. (1997). Activation of p53 sequence-specific DNA binding by acetylation 
of the p53 c-terminal domain. Cell 90, 595–606. 
Gu, T.J., Yi, X., Zhao, X.W., Zhao, Y., and Yin, J.Q. (2009). Alu-directed transcriptional 
regulation of some novel miRNAs. BMC Genomics 10, 563. 
Gui, C.Y., Ngo, L., Xu, W.S., Richon, V.M., and Marks, P.A. (2004). Histone deacetylase 
(HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, 
including HDAC1. Proc. Natl. Acad. Sci. U.S.A. 101, 1241-1246. 
 
Halsall, J., Gupta, V., O’Neill, L.P., Turner, B.M., and Nightingale, K.P. (2012). Genes are often 
sheltered from the global histone hyperacetylation induced by HDAC inhibitors. PLoS One. 7, 
e33453. 
 
Hanahan, D., and Weinberg R.A. (2000). The hallmarks of cancer. Cell 100, 57-70. 
Harms, K.L., and Chen, X. (2007). Histone deacetylase 2 modulates p53 transcriptional activities 
through regulation of p53-DNA binding activity. Cancer Res. 67, 3145-3152. 
Harper, J.W., Adami, G.R., Wei, N., Keyomarsi, K., Elledge, S.J. (1993). The p21 cdk-
interacting protein Cipl Is a potent inhibitor of Gl cyclin-dependent kinases. Cell 75, 805-816. 
Hirsch, C.L., Smith-Windsor, E.L., and Bonham, K. (2006). Src family kinase members have a 
common response to histone deacetylase inhibitors in human colon cancer cells. Int. J. Cancer 
118, 547-554. 
Hirsch, C.L., and Bonham, K. (2004). Histone deacetylase inhibitors regulate p21WAF1 gene 
expression at the post-transcriptional level in HepG2 cells. FEBS Lett. 570, 37-40. 
Hiscox, S., Morgan, L., Green, T., and Nicholson, R.I. (2006). Src as a therapeutic target in anti-




Hoffman, Y., Dahary, D., Bublik, D.R., Oren, M., and Pilpel, Y. (2013). The majority of 
endogenous microRNA targets within Alu elements avoid the microRNA machinery. 
Bioinformatics. 29, 894-902. 
Holm, S. (1979). A simple sequentially rejective multiple test procedure. Scand. J. Stat. 6, 65-70. 
Hondermarck, H. (2003). Breast cancer: when proteomics challenges biological complexity. Mol. 
Cell. Proteomics. 2, 281-291. 
 
Horiuchi, D., Kusdra, L., Huskey, N.E., Chandriani, S., Lenburg, M.E., Gonzalez-Angulo, A.M., 
Creasman, K.J., Bazarov, A.V., Smyth, J.W., Davis, S.E., Yaswen, P., Bills, G.B., Esserman, 
L.J., and Goga, A. (2012). MYC pathway activation in triple-negative breast cancer is synthetic 
lethal with CDK inhibition. J. Exp. Med. 209, 679-696. 
 
Hua, F., Sun, J., Guo, F., Yin, S., Zhang, Q., Zhang, W. (2014). Effect of downregulated histone 
deacetylase 2 expression on cell proliferation and cell cycle in cervical cancer. J. BUON. 19, 497-
501. 
Huang, L., Sowa, Y., Sakai, T., Pardee, A.B. (2000). Activation of the p21 WAF1 / CIP1 
promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic 
acid (SAHA) through the Sp1 sites. Oncogene 19, 5712-5719. 
Huang, X., Wang, S., Lee, C.K., Yang, X., and Liu, B. (2011). HDAC inhibitor SNDX-275 
enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits 
potential to overcome trastuzumab resistance. Cancer Lett. 307, 72-79. 
Huang, V., Zheng, J., Qi, Z., Wang, J., Place, R.F., Yu, J., Li, H., and Li, L.C. (2013). Ago1 
Interacts with RNA polymerase II and binds to the promoters of actively transcribed genes in 
human cancer cells. PLoS Genet. 9, e1003821. 
Ierano, C., Chakraborty, A.R., Nicolae, A., Bahr, J.C., Zhan, Z., Pittaluga, S., Bates, S.E., and 
Robey, R.W. (2013). Loss of the proteins Bak and Bax prevents apoptosis mediated by histone 
deacetylase inhibitors. Cell Cycle 12, 2829-2838. 
Im, J.Y., Park, H., Kang, K.W., Choi, W.S., and Kim, H.S. (2008). Modulation of cell cycles and 
apoptosis by apicidin in estrogen receptor (ER)-positive and-negative human breast cancer cells. 
Chem. Biol. Interact. 172, 235-244. 
Inoue, A. and Fujimoto, D. (1969). Enzymatic deacetylation of histone. Biochem. Biophys. Res. 
Commun. 36(1), 146-150. 
Iorio, M.V., Ferracin, M., Liu, C.G., Veronese, A., Spizzo, R., Sabbioni, S., Magri, E., Pedriali, 
M., Fabbri, M., Campiglio, M., Menard, S., Palazzo, J.P., Rosenberg, A., Musiani, P., Volinia, S., 
Nenci, I., Calin, G.A., Querzoli, P., Negrini, M., and Croce, C.M. (2005). MicroRNA gene 
expression deregulation in human breast cancer. Cancer Res. 65, 7065-7070. 
 153 
 
Iorio, M.V., Visone, R., Di Leva, G., Donati, V., Petrocca, F., Casalini, P., Taccioli, C., Volinia, 
S., Liu, C.G., Alder, H., et al. (2007). MicroRNA signatures in human ovarian cancer. Cancer 
Res. 67, 8699-8707. 
Irby, R.B., Mao, W., Coppola, D., Kang, J., Loubeau, J.M., Trudeau, W., Karl, R., Fujita, D.J., 
Jove, R., and Yeatman, T.J. (1999). Activating SRC mutation in a subset of advanced human 
colon cancers. Nature Genet. 21, 187-190.  
 
Irby, R.B., and Yeatman, T.J. (2000). Role of Src expression and activation in human cancer. 
Oncogene. 19, 5636-5642.  
 
Iravani S., Mao, W., Fu, L., Karl, R., Yeatman, T., Jove, R. and Coppola, D. (1998). Elevated c-
Src protein expression is an early event in colonic neoplasia. Lab. Invest. 78, 365-371.  
 
Jamerson, M.H., Johnson, M.D., and Dickson, R.B. (2004). Of mice and Myc: c-Myc and 
mammary tumorigenesis. J. Mammary Gland Biol. Neoplasia. 9, 27-37. 
 
Jin, J.S., Tsao, T.Y., Sun, P.C., Yu, C.P., and Tzao, C. (2012). SAHA inhibits the growth of 
colon tumours by decreasing histone deacetylase and the expression of cyclin D1 and survivin. 
Pathol. Oncol. Res. 18, 713-720.  
 
Jones, P.L., Veenstra, G.J.C., Wade, P.A., Vermaak, D., Kass, S.U., Landsberger, N., 
Strouboulis, J., Wolffe, A.P. (1998). Methylated DNA and MeCP2 recruit histone deacetylase to 
repress transcription. Nature Genet. 19, 187-192. 
Kaluza, D., Kroll, J., Gesierich, S., Manavski, Y., Boeckel, J.N., Doebele, C., Zelent, A., Rossig, 
L., Zeiher, A.M., Augustin, H.G., et al. (2013). Histone deacetylase 9 promotes angiogenesis by 
targeting the antiangiogenic microRNA-17-92 cluster in endothelial cells. Arterioscler. Thromb. 
Vasc. Biol. 33, 533-543. 
Kao, J., Salari, K., Bocanegra, M., Choi, Y.L., Girard, L., Gandhi, J., Kwei, K.A., Hernandez-
Boussard, T., Wang, P., Gazdar, A.F., et al. (2009). Molecular profiling of breast cancer cell lines 
defines relevant tumor models and provides a resource for cancer gene discovery. PloS One 4, 
e6146. 
Karagianni, P., and Wong, J. (2007). HDAC3: taking the SMRT-N-CoRrect road to repression. 
Oncogene 26, 5439-5449. 
 
Karginov, F.V., Conaco, C., Xuan, Z., Schmidt, B.H., Parker, J.S., Mandel, G., and Hannon, G.J. 
(2007). A biochemical approach to identifying microRNA targets. Proc. Natl. Acad. Sci. U.S.A. 
104(49), 19291-19296. 
 
Kawai, H., Li, H., Avraham, S., Jiang, S., and Avraham, H.K. (2003). Overexpression of histone 
deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen 
receptor alpha. Int. J. Cancer 107, 353-358. 
 154 
 
Katzenellenbogen, B.S. (1991). Antiestrogen resistance: mechanisms by which breast cancer 
cells undermine the effectiveness of endocrine therapy. J. Natl. Cancer Inst. 83, 1434-1435. 
 
Keen, J.C., Yan, L., Mack, K.M., Pettit, C., Smith, D., Sharma, D., and Davidson, N.E. (2003). A 
novel histone deacetylase inhibitor, Scriptaid, enhances expression of function estrogen receptor 
α (ER) in ER negative human breast cancer cells in combination with 5-aza 2’-deoxycytidine. 
Breast Cancer Res. Treat. 81, 177-186.  
 
Kelly, R.D.W., and Cowley, S.M. (2013). The physiological roles of histone deacetylase 
(HDAC) 1 and 2: complex co-stars with multiple leading parts. Biochem. Soc. Trans. 41, 741-
749. 
 
Khan, N., Jeffers, M., Kumar, S., Hackett, C., Boldog, F., Khramtsov, N., Qian, X., Mills, E., 
Berghs, S.C., Carey, N., et al. (2008). Determination of the class and isoform selectivity of small-
molecule histone deacetylase inhibitors. Biochem. J. 409, 581-589. 
 
Khan, O., and La Thangue, N.B. (2012). HDAC inhibitors in cancer biology: emerging 
mechanisms and clinical applications. Immuno. Cell Biol. 90, 85-94. 
 
Khorasanizadeh, S. (2004). The nucleosome : from genomic organization to genomic regulation. 
Cell 116, 259-272. 
 
Kim, S.C., Sprung, R., Chen, Y., Xu, Y., Ball, H., Pei, J., Cheng, T., Kho, Y., Xiao, H., Xiao, L., 
et al. (2006). Substrate and functional diversity of lysine acetylation revealed by a proteomics 
survey. Mol. Cell 23, 607-618. 
Kim, Y.-K. and Kim, V.N. (2007). Processing of intronic microRNAs. EMBO J. 26, 775-783.  
Kim, I.A., No, M., Lee, J.M., Shin, J.H., Oh, J.S., Choi, E.J., Kim, I.H., Atadja, P., and Bernhard, 
E.J. (2009). Epigenetic modulation of radiation response in human cancer cells with activated 
EGFR or HER-2 signalling: potential role of histone deacetylase 6. Radiother. Oncol. 92, 125-
132. 
Kim, I.Y., Yong, H.Y., Kang, K.W., and Moon, A. (2009). Overexpression of ErbB2 induces 
invasion of MCF10A human breast epithelial cells via MMP-9. Cancer Lett. 275, 227-233. 
 
Kim, S.H., Kang, H.J., Na, H., and Lee, M.O. (2010). Trichostatin A enhances acetylation as well 
as protein stability of ERα through induction of p300 protein. Breast Cancer Res. 12, R22-R30. 
 
Kmiecik, T.E., Johnson, and P.J., Shalloway, D. (1988). Regulation by the autophosphorylation 
site in overexpressed pp60c-src. Mol. Cell. Biol. 8, 4541-4546.  
 
Kodack, D.P., Chung, E., Yamashita, H., Incio, J., Duyverman, A.M.M.J., Song, Y., Farrar, C.T., 
Huang, Y., Ager, E., Kamoun, W., Goel, S., Snuderl, M., Lussiez, A., Hiddingh, L., Mahmood, 
S., Tannous, B.A., Eichler, A.F., Fukumura, D., Engelman, J.A., and Jain, R.K. (2012). 
Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast 




Kramer, O.H., Mahboobi, S., and Sellmer, A. (2014). Drugging the HDAC6-HSP90 interplay in 
malignant cells. Trends Pharmacol. Sci. 35, 501-509. 
 
LaBonte, M.J., Wilson, P.M., Fazzone, W., Groshen, S., Lenz, H.J., and Ladner, R.D. (2009). 
DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors 
vorinostat and LBH589 in colon cancer cell lines. BMC Med. Genomics 2, 67. 
Lagger, G., O'Carroll, D., Rembold, M., Khier, H., Tischler, J., Weitzer, G., Schuettengruber, B., 
Hauser, C., Brunmeir, R., Jenuwein, T., and Seiser, C. (2002). Essential function of histone 
deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J. 21, 2672–2681.  
Lagger, G., Doetzlhofer, A., Schuettengruber, B., Haidweger, E., Simboeck, E., Tischler, J., 
Chiocca, S., Suske, G., Rotheneder, H., Wintersberger, E., et al. (2003). The tumor suppressor 
p53 and histone deacetylase 1 are antagonistic regulators of the cyclin-dependent kinase Inhibitor 
p21/WAF1/CIP1 gene. Mol. Cell. Biol. 23, 2669-2679. 
Lamond, N.W., and Younis, T. (2014). Pertuzumab in human epidermal growth-factor receptor 
2-positive breast cancer: clinical and economic considerations. Int. J. Womens Health 6, 509-521. 
Lapidus, R.J., Nass, S.J., Butash, K.A., Pari, F.F., Weitzman, S.A., Graff, G.J., Herman, J.G. and 
Davidson, N.E. (1998). Mapping of ER gene CpG island methylation by methylation-specific 
polymerase chain reaction. Cancer Res. 58, 2515-2519. 
Larrieu, D., Ythier, D., Brambilla, C., and Pedeux, R. (2014). ING2 controls the G1to S-phase 
transition by regulating p21 expression. Cell Cycle 9, 3984-3990. 
Lee, Y., Kim, M., Han, J., Yeom, K.-H., Lee, S., Baek, S.H., and Kim, V.N. (2004). MicroRNA 
genes are transcribed by RNA polymerase II. EMBO J. 23, 4051-4060.  
 
Lee, A.Y.H., Paweletz, C.P., Pollock, R.M., Settlage, R.E., C, J., Secrist, J.P., Miller, T. a, 
Stanton, M.G., Kral, A.M., S, N.D., Meng, F., Yates, N.A, Richon, V., Hendrickson, R.C., Cruz, 
J.C., and Ozerova, N.D.S. (2008). Quantitative analysis of histone deacetylase-1 selective histone 
modifications by differential mass spectrometry quantitative analysis of histone deacetylase-1 
selective histone modifications by differential mass apectrometry. J. Proteome Res. 7, 5177-5186.  
 
Lee, M.J., Kim, Y.S., Kummar, S., Giaccone, G., and Trepel J.B. (2008). Histone deacetylase 
inhibitors in cancer therapy. Curr. Opin. Oncol. 2), 639-649. 
 
Lee, J.H., Jeong, E.G., Choi, M.C., Kim, S.H., Park, J.H., Song, S.H., Park, J., Bang, Y.J., and 
Kim, T.Y. (2010). Inhibition of histone deacetylase 10 induces thioredoxin-interacting protein 
and causes accumulation of reactive oxygen species in SNU-620 human gastric cancer cells. Mol. 
Cell 30, 107-112. 
Lee, J., Bartholomeusz, C., Mansour, O., Humphries, J., Hortobagyi, G.N., Ordentlich, P., and 
Ueno, N.T. (2014). A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy 
in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression. Breast 
Cancer Res. Treat. 146, 259-272. 
 156 
 
Lengauer, C., Kinzler, K.W., and Vogelstein, B. (1998). Genetic instabilities in human cancers. 
Nature 396, 643-649. 
Leone, A., Roca, M.S., Ciardiello, C., Terranova-Barberio, M., Vitagliano, C., Ciliberto, G., 
Mancini, R., Di Gennaro, E., Bruzzeze, F., and Budillon A. (2015). Vorinostat synergizes with 
EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial 
porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway. Free Radic. Biol. Med. 89, 
287-299. 
Levens, D. (2008). How the c-myc promoter works and why it sometimes does not. J. Natl. 
Cancer Inst. Monographs 39, 41-43. 
Li, J., Wang, J., Nawaz, Z., Liu, J.M., Qin, J., and Wong, J. (2000). Both corepressor proteins 
SMRT and N-CoR exist in large protein complexes containing HDAC3. EMBO J. 19, 4342-
4350.  
Li, X., Shen, Y., Ichikawa, H., Antes, T., and Goldberg, G.S. (2009). Regulation of miRNA 
expression by Src and contact normalization: effects on nonanchored cell growth and migration. 
Oncogene 28, 4272-4283. 
 
Li, Y., Yuan, Y., Meeran, S.M., and Tollefsbol. T.O. (2010). Synergistic epigenetic reactivation 
of estrogen receptor-alpha (ERα) by combined green tea polyphenol and histone deacetylase 
inhibitor in ERα-negative breast cancer cells. Mol. Cancer. 14, 274-286. 
 
Li, Z., and Zhu, W.G. (2014). Targeting histone deacetylases for cancer therapy: from molecular 
mechanisms to clinical implications. Int. J. Biol. Sci. 10, 757-770. 
Lint, V., Emiliani, S. and Verdin E. (1996). The expression of a small fraction of cellular genes is 
changed in response to histone hyperacetylation. Gene Expr. 5, 245-253. 
Little, C.D., Nau, M.M., Carney, D.N., Gazdar, A.F., and Minna, J.D. (1983). Amplification and 
expression of the c-myc oncogene in human lung cancer cell lines. Nature 306, 194-196. 
 
Lowery, A.J., Miller, N., Devaney, A., McNeill, R.E., Davoren, P.A., Lemetre, C., Benes, V., 
Schmidt, S., Blake, J., Ball, G., and Kerin, M.J. (2009).  MicroRNA signatures predict oestrogen 
receptor, progesterone receptor and HER2/neu receptor statuts in breast cancer. Breast Cancer 
Res. 11, R27. 
 
Lu, Z., Liu, M., Stribinskis, V., Klinge, C.M., Ramos, K.S., Colburn, N.H., and Li, Y. (2008). 
MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. 
Oncogene 27, 4373-4379. 
Lujambio, A., Ropero, S., Ballestar, E., Fraga, M.F., Cerrato, C., Setien, F., Casado, S., Suarez-
Gauthier, A., Sanchez-Cespedes, M., Git, A., et al. (2007). Genetic unmasking of an 
epigenetically silenced microRNA in human cancer cells. Cancer Res. 67, 1424-1429. 
Ma, X., Ezzeldin, H.H., and Diasio, R.B. (2009). Histone deacetylase inhibitors: current status 
and overview of recent clinical trials. Drugs. 69, 1911-1934. 
 157 
 
Maa, M.C., Leu, T.H., McCarley, D.J., Schatzman, R.C., and Parsons, S.J. (1995). Potentiation of 
epidermal growth factor receptor-mediated oncogenesis by c-Src: implications for the etiology of 
multiple human cancers. Proc. Natl. Acad. Sci. U.S.A. 92, 6981-6985.  
 
Malhotra, G.K., Zhao, X., Band, H., and Band, V. (2014). Histological, molecular and functional 
subtypes of breast cancers. Cancer Biol. Ther. 10, 955-960. 
Margueron, R., Duong, V., Castet, A., and Cavailles, V. (2004). Histone deacetylase inhibition 
and estrogen signalling in human breast cancer cells. Biochem. Pharmacol. 68, 1239-1246. 
Marmorstein, R. and Zhou M.M (2014). Writers and readers of histone acetylation: structure, 
mechanism, and inhibition. Cold Spring Harb. Perspect Biol. 6, a018762. 
 
Martinet, N., and Bertrand, P. (2011). Interpreting clinical assays for histone deacetylase 
inhibitors. Cancer Manag. Res. 3, 117-141.  
 
Mateo, F., Vidal-Laliena, M., Canela, N., Busino, L., Martinez-Balbas, M.A., Pagano, M., Agell, 
N., and Bachs, O. (2009). Degradation of cyclin A is regulated by acetylation. Oncogene 28, 
2654-2666. 
McDonel, P., Demmers, J., Tan, D.W., Watt, F., and Hendrich, B.D. (2012). Sin3a is essential for 
the genome integrity and viability of pluripotent cells. Dev. Biol. 363, 62-73. 
Mehnert, J.M., and Kelly, K. (2007). Histone deacetylase inhibitors: biology and mechanisms of 
action.  Cancer J. 13, 23-29. 
Mitsiades, C.S., Mitsiades, N.S., McMullan, C.J., Poulaki, V., Shringarpure, R., Hideshima, T., 
Akiyama, M., Chauhan, D., Munshi, N., Gu, X., et al. (2004). Transcriptional signature of 
histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc. 
Natl. Acad. Sci. U.S.A. 101, 540-545. 
Montero, J.C., Seoane, S., Ocana, A., and Pandiella, A. (2011). Inhibition of SRC family kinases 
and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin. Cancer 
Res. 17, 5546-5552. 
 
Morlando, M., Ballarino, M., Gromak, N., Pagano, F., Bozzoni, I., and Proudfoot, N.J. (2008). 
Primary microRNA transcripts are processed co-transcriptionally. Nat. Struct. Mol. Biol. 15, 902-
909. 
 
Mu, P., Han, Y.C., Betel, D., Yao, E., Squatrito, M., Ogrodowski, P., de Stanchina, E., D'Andrea, 
A., Sander, C., and Ventura, A. (2009). Genetic dissection of the miR-17~92 cluster of 
microRNAs in Myc-induced B-cell lymphomas. Genes Dev. 23, 2806-2811. 
 
Munster, P.N., Thurn, K.T., Thomas, S., Raha, P., Lacevic, M., Miller, A., Melisko, M., Ismail-
Khan, R., Rugo, H., Moasser, M., and Minton, S.E. (2011). A phase II study of the histone 
deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with 




Nan, X., N.H., Johnson, C.A., Laherty, C.D., Turner, B.M., Eisenman, R.N., Bird, A. (1998). 
Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone 
deacetylase complex. Nature 393, 386-389. 
 
Nass, S.J., and Dickson, R.B. (1997). Defining a role for c-Myc in breast tumorigenesis. Breast 
Cancer Res. Treat. 44, 1-22. 
 
Nebbioso, A., Aversana, C.D., Bugge, A., Sarno, R., Valente, S., Rotili, D., Manzo, F., Teti D., 
Mandrup, S., Ciana, P., Maggi, A., Mai, A., Gronemeyer, H., and Altucci, L. (2010). HDACs 
class II-selective inhibition alters nuclear receptor-dependent differentiation. J. Mol. Endocrinol. 
45, 219-228. 
 
Neve, R.M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F.L., Fevr, T., Clark, L., Bayani, N., 
Coppe, J.P., Tong, F., Speed, T., Spellman, P.T., DeVries, S., Lapuk, A., Wang, N.J., Kuo, W.L., 
Stilwell, J.L., Pinkel, D., Albertson, D.G., Waldman, F.M., McCormick, F., Dickson, R.B., 
Johnson, M.D., Lippman, M., Ethier, S., Gazdar, A., and Gray, J.W. (2006). A collection of 
breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 10, 
515-527. 
 
O'Sullivan, C.C and Connolly R.M. (2014). Pertuzumab and its accelerated approval: evolving 
treatment paradigms and new challenges in the management of HER2-positive breast cancer. 
Oncology 28, 186-194.  
 
Ocker, M., and Schneider-Stock, R. (2007).  Histone deacetylase inhibitors: signalling towards 
p21
CIP1/WAF1
. Int. J. Biochem. Cell Biol. 39, 1367-1374.  
 
Okada, M. and Nakagawa, H. (1989). A protein tyrosine kinase involved in regulation of pp60c-
src function. J. Biol. Chem. 264, 20886-20893. 
 
Okada, M. (2012). Regulation of the SRC family kinases by Csk. Int. J. Biol. Sci. 8, 1385-1397. 
 
Olzmann, J.A., Li, L., Chudaev, M.V., Chen, J., Perez, F.A., Palmiter, R.D., and Chin, L.S. 
(2007). Parkin-mediated K63-linked polyubiquitination targets misfolded DJ-1 to aggresomes via 
binding to HDAC6. J. Cell Biol. 178, 1025-1038. 
 
Ottaviano, Y.L., Issa, J.P., Parl, F.F., Smith, H.S., Baylin, S.B., and Davidson, N.E. (1994). 
Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression 
in human breast cancer cells. Cancer Res. 54, 2552-2555. 
 
Ottenhoff-Kalff, A.E., Rijksen, G., van Beurden, E.A., Hennipman, A., Michels, A.A., and Staal, 
G.E. (1992). Characterization of protein tyrosine kinases from human breast cancer: involvement 
of the c-Src oncogene product. Cancer Res. 52, 4773-4778. 
 
Owens, D.W., McLean, G.W., Wyke, a W., Paraskeva, C., Parkinson, E.K., Frame, M.C., and 
Brunton, V.G. (2000). The catalytic activity of the Src family kinases is required to disrupt 




Pang, Y., Young, C.Y.F., and Yuan, H. (2010). MicroRNAs and prostate cancer.  Acta. Biochim. 
Biophys. Sin. 42, 363-369.  
 
Pathiraja, T.N., Stearns, V., and Oesterreich, S. (2010). Epigenetic regulation in estrogen receptor 
positive breast cancer – role in treatment response. J. Mammary Gland Biol. Neoplasia. 15, 35-
47.  
 
Parbin, S., Kar, S., Shilpi, A., Sengupta, D., Deb, M., Rath, S.R., and Patra, S.K. (2013). Histone 
deacetylases: a saga of perturbed acetylation homeostasis in cancer. J. Histochem. Cytochem. 62, 
11-33. 
 
Peart, M.J., Smyth, G.K., van Laar, R.K., Bowtell, D.D., Richon, V.M., Marks, P.A., Holloway, 
A.J., and Johnstone, R.W. (2005). Identification and functional significance of genes regulated by 
structurally different histone deacetylase inhibitors. Proc. Natl. Acad. Sci. U.S.A. 102, 3697-
3702. 
 
Peng, L., and Seto, E. (2011). Deacetylation of nonhistone proteins by HDACs and the 
implications in cancer. Handb. Exp. Pharmacol. 206, 39-56.  
 
Perez, E.A., Romond, E.H., Suman, V.J., Jeong, J.H., Davidson, N.E., Geyer, C.E., Jr., Martino, 
S., Mamounas, E.P., Kaufman, P.A., and Wolmark, N. (2011). Four-year follow-up of 
trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-
positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J. Clin. 
Oncol. 29, 3366-3373. 
 
Perou, C.M., Sùrlie, T., Eisen, M.B., Rijn, M. Van De, Jeffrey, S.S., Rees, C.A., Pollack, J.R., 
Ross, D.T., Johnsen, H., Akslen, L.A., Fluge, I., Pergamenschikov, A., Williams, C., Zhu, S.X., 
Lùnning, P.E., Brown, P.O., Botstein, D., Grant, S. (2000). Molecular portraits of human breast 
tumours. Nature 406, 747-752. 
 
Place, R.F., Li, L.C., Pookot, D., Noonan, E.J., and Dahiya, R. (2007). MicroRNA-373 induces 
expression of genes with complementary promoter sequences. Proc. Natl. Acad. Sci. U.S.A. 105, 
1608-1613. 
 
Podo, F., Buydens, L.M., Degani, H., Hilhorst, R., Klipp, E., Gribbestad, I.S., van Huffel, S., van 
Laarhoven, H.W., Luts, J., Monleon, D., Postma, G.J., Schneiderhan-Marra, N., Santoro, F., 
Wouters, H., Russnes, H.G., Sorlie, T., Tagliabue, E., Borresen-Dale, A.L. (2010). Triple-
negative breast cancer: present challenges and new perspectives. Mol. Oncol. 4, 209-229. 
 
Polo, S.E., and Almouzni, G. (2005). Histone metabolic pathways and chromatin assembly 
factors as proliferation markers. Cancer Lett. 220, 1-9. 
 
Raha, P., Thomas, S., Thurn K.T., Park, J., and Munster, P.N. (2007). Combined histone 
deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer 
models, by reversing Bcl-2 overexpression. Breast Cancer Res. 17, 1-16. 
 160 
 
Rakha, E.A., El-Sayed, M.E., Green, A.R., Lee, A.H., Robertson, J.F., and Ellis, I.O. (2007). 
Prognostic markers in triple-negative breast cancer. Cancer 109, 25-32. 
Rao, R., Balusu, R., Fiskus, W., Mudunuru, U., Venkannagari, S., Chauhan, L., Smith, J.E., 
Hembruff, S.L., Ha, K., Atadja, P., et al. (2012). Combination of pan-histone deacetylase 
inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast 
cancer cells. Mol. Cancer Ther. 11, 973-983. 
 
Reichert, N., Choukralleh, M.A., and Matthias, P. (2012). Multiple roles of class I HDACs in 
proliferation, differentiation and development. Cell. Mol. Life Sci. 69, 2173-2187.  
 
Renoir, J.M. (2012), Estradiol receptors in breast cancer cells: associated co-factors as targets for 
new therapeutic approaches. Steriods. 77, 1249-1261.  
 
Renoir, J.M., Marsaud, V., and Lazennec, G. (2013). Estrogen receptor signalling as a target for 
novel breast cancer therapeutics. Biochem. Pharmacol. 85, 449-465. 
 
Roccaro, A.M., Sacco, A., Jia, X., Azab, A.K., Paiso, P., Ngo, H.T., Azab, F., Runnels, J., 
Quang, P., and Ghobrial, I.M. (2010). MicroRNA-dependent modulation of histone acetylation in 
Waldenstrom macroglobulinemia. Blood 116, 1506-1514.  
 
Rodriguez, A., Griffiths-Jones, S., Ashurst, J.L., and Bradley, A. (2004). Identification of 
mammalian microRNA host genes and transcription units. Genome Res. 14, 1902-1910.  
 
Ropero, S., Fraga, M.F., Ballestar, E., Hamelin, R., Yamamoto, H., Biox-Chornet, M., Caballero, 
R., Alaminos, M., Setien, F., Paz, M.F., Herranz, M., Palacios, J., Arango, D., Orntoft, T.F., 
Aaltonen, L.A., Schwartz, S., and Esteller, M. (2006). A truncating mutation of HDAC2 in 
human cancers confers resistance to histone deacetylase inhibition. Nat. Genet. 38, 566-569.   
 
Ropero, S., and Esteller, M. (2007). The role of histone deacetylases (HDACs) in human cancer. 
Mol. Oncol. 1, 19-27. 
 
Roskoski, R., Jr. (2004). Src protein-tyrosine kinase structure and regulation. Biochem. Biophys. 
Res. Commun. 324, 1155-1164. 
 
Rous, P. (1911). A sarcoma of the fowl transmissible by an agent separable from the tumor cells. 
J. Exp. Med. 2, 696-705. 
 
Rubinsztein, D.C. (2006). The roles of intracellular protein-degradation pathways in 
neurodegeneration. Nature 443, 780-786. 
 
Saal, L.H., Holm, K., Maurer, M., Memeo, L., Su, T., Wang, X., Yu, J.S., Malmström, P.O., 
Mansukhani, M., Enoksson, J., Hibshoosh, H., Borg, Å., and Parsons, R. (2005). PIK3CA 
mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually 




Saal, L.H., Gruvberger-saal, S.K., Persson, C., Lövgren, K., Staaf, J., Jönsson, G., Pires, M.M., 
Maurer, M., Holm, K., Koujak, S., Subramaniyam, S., Vallon-, J., Olsson, H., Su, T., Memeo, L., 
Ludwig, T., Ethier, P., Krogh, M., Szabolcs, M., Murty, V.V.V.S., Isola, J., Hibshoosh, H., 
Parsons, R., and Borg, Å. (2011). Recurrent gross mutations of the PTEN tumor suppressor gene 
in breast cancers with deficient DSB repair. Nature Genet. 40, 102-107. 
 
Sabnis, G.J., Goloubeva, O., Chumsri, S., Nguyen, N., Sukumar, S., and Brodie, A.M.H. (2011). 
Functional activation of the estrogen receptor alpha and aromatase by the HDAC inhibitor 
entinostat sensitizes ER-negative tumors to letrozole. Cancer Res. 71, 1893-1903. 
 
Saji, S., Kawakami, M., Hayashi, S., Yoshida, N., Hirose, M., Horiguchi, S., Itoh, A., Funata, N., 
Schreiber, S.L., Yoshida, M., et al. (2005). Significance of HDAC6 regulation via estrogen 
signalling for cell motility and prognosis in estrogen receptor-positive breast cancer. Oncogene 
24, 4531-4539. 
 
Saito, Y., Liang, G., Egger, G., Friedman, J.M., Chuang, J.C., Coetzee, G.A., and Jones, P.A. 
(2006). Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 
by chromatin-modifying drugs in human cancer cells. Cancer Cell. 9, 435-443.  
 
Sambasivarao, S. V., Qian, Y., and Chen, X. (2010). Examination of the expanding pathways for 
the regulation of p21 expression and activity. Cell. Signal. 22, 1003-1012. 
 
Sampath, D., Liu, C., Vasan, K., Sulda, M., Puduvalli, V.K., Wierda, W.G., and Keating, M.J. 
(2012). Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic 
lymphocytic leukemia. Blood 119, 1162-1172. 
 
Sardiu, M.E., Smith, K.T., Groppe, B.D., Gilmore, J.M., Saraf, A., Edigy, R., Peak, A., Seidel, 
C., Florens, L., Workman, J.L., and Washburn, M.P. (2014). SAHA induced dynamics of a 
human histone deacetylase protein interacton network. Mol. Cell Proteomics. 13, 3114-3125. 
Saumet. A., Vetter, G., Bouttier, M., Antoine, E., Roubert, C., Orsetti, B., Theillet, C., and 
Lecellier, C.H. (2012). Estrogen and retinoic acid antagonistically regulate several microRNA 
genes to control aerobic glycolysis in breast cancer cells. Mol. BioSyst. 8, 3242-3253. 
Sasakawa, Y, Naoe, Y., Inoue, T., Sasakawa, T., Matsuo, M., Manda, T., and Mutoh, S. (2003). 
Effects of FK228, a novel histone deacetylase inhibitor, in tumor growth and expression of p21 
and c-myc genes in vivo. Cancer Lett. 195, 161-168. 
 
Schanen, B.C., and Li, X. (2011). Transcriptional regulation of mammalian miRNA genes. 
Genomics. 97, 1-8. 
 
Schuetz, A., Min, J., Allali-Hassani, A., Schapira, M., Shuen, M., Loppnau, P., Mazitschek, R., 
Kwiatkowski, N.P., Lewis, T.A., Maglathin, R.L., et al. (2008). Human HDAC7 harbors a class 
IIa histone deacetylase-specific zinc binding motif and cryptic deacetylase activity. J. Biol. 




Scott, G.K., Mattie, M.D., Berger, C.E., Benz, S.C. and Benz, C.C. (2006). Rapid alteration of 
microRNA levels by histone deacetylase inhibition. Cancer Res. 66, 1277-1281. 
 
Seaman, M.A., Levin, J.R., and Serlin, R.C. (1991). New Developments in pairwise multiple 
comparisons: Some powerful and practical procedures. Psychol. Bull. 110, 577-586. 
 
Sen, G.L., and Blau, H.M. (2005). Argonaute 2/RISC resides in sites of mammalian mRNA 
decay known as cytoplasmic bodies. Nat. Cell Biol. 7, 633-636. 
 
Shah, P., Gau, Y., and Sabnis, G. (2014). Histone deacetylase inhibitor entinostat reverses 
epithelial to mesenchymal transition of breast cancer cells by reversing the repression of E-
cadherin. Breast Cancer Res. Treat. 143, 99-111. 
 
Shih, K.K., Qin, L.X., Tanner, E.J., Zhou, Q., Bisogna, M., Dao, F., Olvera, N., Viale, A., 
Barakat, R.R., and Levine, D.A. (2011). A microRNA survival signature (MiSS) for advanced 
ovarian cancer. Gynecol. Oncol. 121, 444-450.   
 
Shalloway, D., Coussens, P.M., and Yaciuk, P. (1984). Overexpression of the c-src protein does 
not induce transformation of NIH 3T3 cells. Proc. Natl. Acad. Sci. U.S.A. 81, 7071-7075. 
 
Shao, Y., Gao, Z., Marks, P.A., and Jiang, X. (2004). Apoptotic and autophagic cell death 
induced by histone deacetylase inhibitors. Proc. Natl. Acad. Sci. U.S.A. 101, 18030-18035. 
 
Sharma, D., Saxena, N.K., Davidson, N.E., and Vertino, P.M. (2006). Restoration of tamoxifen 
sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER 
recruits distinctive corepressor complexes. Cancer Res. 66, 6370-6378. 
 
Shenouda, S.K., and Alahari, S.K. (2009). microRNA function in cancer: oncogene or a tumor 
suppressor? Cancer Metastasis Rev. 28, 369-378. 
 
Shin, N.Y., Dise, R.S., Schneider-Mergener, J., Ritchie, M.D., Kilkenny, D.M., and Hanks, S.K. 
(2004). Subsets of the major tyrosine phosphorylation sites in Crk-associated substrate (CAS) are 
sufficient to promote cell migration. J. Biol. Chem. 279, 38331-38337. 
 
Si, M.L., Zhu, S., Wu, H., Lu, Z., Wu, F., and Mo, Y.Y. (2007). miR-21-mediated tumor growth. 
Oncogene 26, 2799-2803. 
 
Sidak, Z., (1967). Rectangular confidence regions for the means of multivariate normal 
distributions. J. Am. Stat. Assoc. 62, 626-633. 
Simboeck, E., Sawicka, A., Zupkovitz, G., Senese, S., Winter, S., Dequiedt, F., Ogris, E., Di 
Croce, L., Chiocca, S., and Seiser, C. (2010). A phosphorylation switch regulates the 
transcriptional activation of cell cycle regulator p21 by histone deacetylase inhibitors. J. Biol. 
Chem. 285, 41062-41073. 
Singh, B.N., Zhang, G., Hwa, Y.L., Li, J., Dowdy, S.C., and Jiang, S.W. (2010). Nonhistone 
protein acetylation as cancer therapy targets. Expert Rev. Anticancer Ther. 10, 935-954. 
 163 
 
Singhi, A.D., Cimino-Mathews, A., Jenkins, R.B., Lan, F., Fink, S.R., Nassar, H., Vang, R., 
Fetting, J.H., Hicks, J., Sukumar, S., et al. (2012). MYC gene amplification is often acquired in 
lethal distant breast cancer metastases of unamplified primary tumors. Mod. Pathol. 25, 378-387. 
 
Slingerland, M., Guchelaar, H.J., and Gelderblom, H. (2013). Histone deacetylase inhibitors: an 
overview of the clinical studies in solid tumors. Anticancer Drugs. 25, 140-149.  
 
Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Press, M., Mackey, J., 
Glaspy, J., Chan, A., Pawlicki, M., et al. (2011). Adjuvant trastuzumab in HER2-positive breast 
cancer. New. Engl. J. Med. 365, 1273-1283. 
Slezak-Prochazka, I., Kluiver, J., de Jong, D., Kortman, G., Halsema, N., Poppema, S., Kroesen, 
B.J., and van den Berg, A. (2013). Cellular localization and processing of primary transcripts of 
exonic microRNAs. PloS One 8, e76647. 
Smith, K.T., Martin-Brown, S.A., Florens, L., Washburn, M.P., and Workman, J.L. (2010). 
Deacetylase inhibitors dissociate the histone-targeting ING2 subunit from the Sin3 complex. 
Chem. Biol. 17, 65-74. 
Sorlie, T., Perou, C.M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M.B., 
van de Rijn, M., Jeffrey, S.S., et al. (2001). Gene expression patterns of breast carcinomas 
distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U.S.A. 98, 10869-
10874. 
Stark, K., Burger, A., Wu, J., Shelton, P., Polin, L., and Li, J. (2013). Reactivation of estrogen 
receptor alpha by vorinostat sensitizes mesenchymal-like triple-negative breast cancer to 
aminoflavone, a ligand of the aryl hydrocarbon receptor. PloS One 8, e74525. 
Stearns, V., Zhou, Q., and Davidson, N.E. (2007). Epigenetic regulation as a new target for breast 
cancer therapy. Cancer Invest. 25, 659-665. 
Struski, S., Doco-fenzy, M., Cornillet-lefebvre, P. (2002). Compilation of published comparative 
genomic hybridization studies. Cancer Genet. Cytogenet. 135, 63-90. 
Sun, J.M., Chen, H.Y., Moniwa, M., Litchfield, D.W., Seto, E., and Davie, J.R. (2002). The 
transcriptional repressor Sp3 is associated with CK2-phosphorylated histone deacetylase 2. J. 
Biol. Chem. 277, 35783-35786. 
 
Sun, Z., Feng, D., Fang, B., Mullican, S.E., You, S.H., Lim, H.W., Everett, L.J., Nabel, C.S., Li, 
Y., Selvakumaran, V., Won, K.J., and Lazar, M.A. (2013). Deacetylase-independent function of 
HDAC3 in transcription and metabolism requires nuclear receptor corepressor.  Mol. Cell. 52, 
769-782.  
 
Tagliabue, E., Balsari, A., Campiglio, M., and Pupa, S.M. (2010). HER2 as a target for breast 
cancer therapy. Expert Opin. Biol. Ther. 10, 711-724. 
 164 
 
Tate, C.R., Rhodes, L.V., Segar, H.C., Driver, J.L., Pounder, F.N., Burow, M.E., and Collins-
Burow, B.M. (2012). Targeting triple-negative breast cancer cells with the histone deacetylase 
inhibitor panobinostat. Breast Cancer Res. 14, R79. 
Takai, N., Ueda, T., Nishida, M., Nasu, K., and Narahara, H. (2008). Beta-
hydroxyisovalerylshikonin has a profound anti-growth activity in human endometrial and ovarian 
cancer cells. Gynecol. Oncol. 109, 107-114.  
 
Talamonti, M.S., Roh, M.S., Curley, S.A., and Gallick, G.E. (1993). Increase in activity and level 
of pp60c-src in progressive stages of human colorectal cancer. J. Clin. Invest. 91, 53-60.  
 
Taunton, J., Hassig, C.A., Schreiber, S.L. (1996). A mammalian histone deacetylase related to the 
yeast transcriptional regulator Rpd3p. Science 272, 408-411. 
 
Thomas, S.M., and Brugge, J.S. (1997). Cellular functions regulated by Src Family Kinases. Ann. 
Rev. Cell Dev. Biol. 13, 513-609. 
 
Thomas, S., and Munster, P.N. (2009). Histone deacetylase inhibitor induced modulation of anti-
estrogen therapy. Cancer Lett. 280, 184-191. 
 
Thomas, S., Thurn, K.T., Bicaku, E., Marchion, D.C., and Munster, P.N. (2011). Addition of a 
histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which 
is opposed by the induction of autophagy. Breast Cancer Res. Treat. 130, 437-447.  
 
Tice, D., Biscardi, J.S., Nickles, A.L., and Parsons, S.J. (1999). Mechanism of biological synergy 
between cellular Src and epidermal growth factor receptor. Proc. Natl. Acad. Sci. U.S.A. 96, 
1415-1420.  
 
Timp, W., and Feinberg, A.P. (2013). Cancer as a dysregulated epigenome allowing cellular 
growth advantage at the expense of the host. Nat. Rev. Cancer. 13, 497-510.  
 
Tsai, H.C., and Baylin, S.B. (2011). Cancer epigenetics: linking basic biology to clinical 
medicine. Cell Res. 21, 502-517. 
 
Tsai, K.W., Wu, C.W., Hu, L.Y., Li, S.C., Liao, Y.L., Lai, C.H., Kao, H.W., Fang, W.L., Huang, 
K.H., Chan, W.C., and Lin, W.C. (2011). Epigenetic regulation of miR-34b and miR-129 
expression in gastric cancer. Int. J. Cancer 129, 2600-2610.  
 
Trivedi, C.M., Luo, Y., Yin, Z., Zhang, M., Zhu, W., Wang, T., Floss, T., Goettlicher, M., 
Noppinger, P.R., Wurst, W., et al. (2007). Hdac2 regulates the cardiac hypertrophic response by 
modulating Gsk3 beta activity. Nat. Med. 13, 324-331. 
Tu, Y., Hershman, D.L., Bhalla, K., Fiskus, W., Pellegrino, C.M., Andreopoulou, E., Makower, 
D., Kalinsky, K., Fehn, K., Fineberg, S., et al. (2014). A phase I-II study of the histone 
deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-
cyclophosphamide in locally advanced breast cancer. Breast Cancer Res. Treat. 146, 145-152. 
 165 
 
Valenzuela-Fernandez, A., Cabrero, J.R., Serrador, J.M., and Sanchez-Madrid, F. (2008). 
HDAC6: a key regulator of cytoskeleton, cell migration and cell-cell interactions. Trends. Cell 
Biol. 18, 291-297. 
Valero, V. (2014). Carboplatin for early triple-negative breast cancer?  Lancet Oncol. 15, 676-
678. 
Vidal-Laliena, M., Gallastegui, E., Mateo, F., Martinez-Balbas, M., Pujol, M.J., and Bachs, O. 
(2013). Histone deacetylase 3 regulates cyclin A stability. J. Biol. Chem. 288, 21096-21104. 
Vidanes, G.M., Bonilla, C.Y., and Toczyski, D.P. (2005). Complicated tails: histone 
modifications and the DNA damage response. Cell 121, 973-976. 
Vigushin, D.M., Ali, S., Pace, P.E., Mirsaidi, N., Ito, K., Adcock, I., and R.C. (2001). 
Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast 
cancer in vivo. Clin. Cancer Res. 7, 971–976. 
 
von Minckwitz, G., Schneeweiss, A., Loibl, S., Salat, C., Denkert, C., Rezai, M., Blohmer, J.U., 
Jackisch, C., Paepke, S., Gerber, B., et al. (2014). Neoadjuvant carboplatin in patients with triple-
negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 
trial. Lancet Oncol. 15, 747-756. 
 
Wanczyk, M., Roszczenko, K., Marcinkiewicz, K., Bojarczuk, K., Kowara, M., and Winiarska, 
M. (2011). HDACi – going through the mechanisms. Front. Biosci. 16, 340-359. 
 
Wang, G., Wang, Y., Shen, C., Huang, Y., Huang, K., Huang, T.H.M., Nephew, N.P., Li, L., and 
Liu, Y. (2010). RNA polymerase II binding patterns reveal genomic regions involved in 
microRNA gene regulation. PLoS One. 5, e13798.  
 
Wang, S., Huang, J., Lyu, H., Lee, C.K., Tan, J., Wang, J., and Liu B. (2013). Functional 
cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of 
erbB2/erbB3 and apoptosis in breast cancer cells. Cell Death Dis. 4, e556.  
 
Warfel, N.A., and el-Deiry, W.S. (2013). p21WAF1 and tumourigenesis: 20 years after. Curr. 
Opin. Oncol. 25, 52-58. 
Warrener, R., Chia, K., Warren, W.D., Brooks, K., and Gabrielli, B. (2010). Inhibition of histone 
deacetylase 3 produces mitotic defects independent of alterations in histone H3 lysine 9 
acetylation and methylation. Mol. Pharmacol. 78, 384-393. 
Weigelt, B., Horlings, H.M., Kreike, B., Hayes, M.M., Hauptmann, M., Wessels, L.F., de Jong, 
D., Van de Vijver, M.J., Van't Veer, L.J., and Peterse, J.L. (2008). Refinement of breast cancer 
classification by molecular characterization of histological special types. J. Pathol. 216, 141-150. 




Wirapati, P., Sotiriou, C., Kunkel, S., Farmer, P., Pradervand, S., Haibe-Kains, B., Desmedt, C., 
Ignatiadis, M., Sengstag, T., Schutz, F., et al. (2008). Meta-analysis of gene expression profiles 
in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis 
signatures. Breast Cancer Res. 10, R65. 
Wolffe A.P. (1994). Transcription: in tune with the histones. Cell 77, 13-16. 
 
Wong, P., Iwasaki, M., Somervaille, T.C.P., Ficara, F., Carico, C., Arnold, C., Chen, C.Z., and 
Cleary, M.L. (2010). The miR-17-92 microRNA polyciston regulates MLL leukemia stem cell 
potential by modulating p21 expression. Cancer Res. 70, 3833-3842.   
 
Wrobel, C.N., Debnath, J., Lin, E., Beausoleil, S., Roussel, M.F., and Brugge, J.S. (2004). 
Autocrine CSF-1R activation promotes Src-dependent disruption of mammary epithelial 
architecture. J. Cell Biol. 165, 263-273. 
 
Wu, Z. and Yu, Q (2009). E2F1-mediated apoptosis as a target of cancer therapy. Current Mol. 
Pharmacol. 2(2),149-160. 
Xu, Y., Harrison, S.C., and Eck, M.J. (1997). Three-dimensional structure of the tyrosine kinase 
c-Src. Nature 385(6617), 595-602. 
Xu, Y., Voelter-Mahlknecht, S., and Mahlknecht, U., (2005). The histone deacetylase inhibitor 
suberoylanilide hydroxamic acid down-regulates expression levels of Bcr-Abl, c-Myc and 
HDAC3 in chronic myeloid leukemia cell lines. Int. J. Mol. Med. 15(1), 169-172. 
Xu, W.S., Parmigiani, R.B., and Marks, P.A. (2007). Histone deacetylase inhibitors: molecular 
mechanisms of action. Oncogene 26, 5541-5552. 
Xu, J., Li, Y., Wang, F., Wang, X., Cheng, B., Ye, F., Xie, X., Zhou, C., and Lu, W. (2012). 
Suppressed miR-424 expression via upregulation of target gene Chk1 contributes to the 
progression of cervical cancer. Oncogene 32, 976-987.  
Yagi, Y., Fushida, S., Harada, S., Kinoshita, J., Makino, I., Oyama, K., Tajima, H., Fujita, H., 
Takamura, H., Ninomiya, I., et al. (2010). Effects of valproic acid on the cell cycle and apoptosis 
through acetylation of histone and tubulin in a scirrhous gastric cancer cell line. J. Exp. Clin. 
Cancer Res. 29, 149. 
Yan, L., Nass, S.J., Smith, D., Nelson, W.G., Herman, J.G., Davidson, N.E. (2003). Specific 
inhibition of DNMT1 by antisense oligonucleotides induces re-expression of estrogen receptor α 
(ER) in ER-negative human breast cancer cell lines. Cancer Biol. Ther. 2, 552-556. 
Yang, W.M., Tsai, S.C., Wen, Y.D., Fejer, G., and Seto, E. (2002). Functional domains of 
histone deacetylase-3. J. Biol. Chem. 277, 9447-9454. 
 
Yang, S., Li, Y., Zhang, T., Li, S., Luo, A., Ding, F., Wang, X., and Liu, Z. (2012). MicroRNA-





Yang, P., Zhang, L., Zhang, Y., Zhang, J., and Xu, W. (2013). HDAC6: physiological function 
and its selective inhibitors for cancer treatment. Drug Discov. Ther. 7, 233-242. 
 
Yao, Y.L., and Yang, W.M. (2011). Beyond histone and deacetylase: an overview of cytoplasmic 
histone deacetylases and their nonhistone substrates. J. Biomed. Biotechnol. 2011, 146493. 
 
Yardley, D.A., Ismail-Khan, R.R., Melichar, B., Lichinitser, M., Munster, P.N., Klein, P.M., 
Cruickshank, S., Miller, K.D., Lee, M.J., and Trepel, J.B. (2013). Randomized phase II, double-
blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal 
women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing 
on treatment with a nonsteroidal aromatase inhibitor. J. Clin. Oncol. 31, 2128-2135. 
Younes, A., Oki, Y., Bociek, R.G., Kuruvilla, J., Fanale, M., Neelapu, S., Copeland, A., Buglio, 
D., Galal, A., Besterman, J., et al. (2011). Mocetinostat for relapsed classical Hodgkin's 
lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncol. 12, 1222-1228. 
 
Zawistowski, J.S., Nakamura, K., Parker, J.S., Granger, D.A., Golitz, B.T., and Johnson, G.L. 
(2013). MicroRNA-9-3p targets β1 integrin to sensitise claudin-low breast cancer cells to MEK 
inhibition.  Mol. Cell Biol. 33, 2260-2274. 
 
Zeevaart, J.G., Wang, L., Thakur, V. V, Leung, C.S., Tirado-, J., Bailey, C.M., Domaoal, R.A., 
Anderson, K.S., and William, L. (2009). Histone deacetylase inhibitors equipped with estrogen 
receptor modulation activity. J. Med. Chem. 56, 5782-5796. 
 
Zhang, Z., Yamashita, H., Toyama, T., Sugiura, H., Omoto, Y., Ando, Y., Mita, K., Hamaguchi, 
M., Hayashi, S.I., and Iwase, H. (2004). HDAC6 expression is correlated with better survival in 
breast cancer. Clin. Cancer Res. 10, 6962-6968.  
Zhang, X., Ozawa, Y., Lee, H., Wen, Y., Tan, T., Wadzinski, B.E., and Seto, E. (2005). Histone 
deacetylase 3 (HDAC3) activity is regulated by interaction with protein serine/threonine 
phosphatase 4. Genes Dev. 19, 827-839. 
 
Zhang, Z., Yamashita, H., Toyama, T., Sugiura, H., Ando, Y., Mita, K., Hamaguchi, M., Hara, 
Y., Kobayashi, S., and Iwase, H. (2005). Quantitation of HDAC1 mRNA expression in invasive 
carcinoma of the breast. Breast Cancer Res. Treat, 94, 11-16. 
Zhang, X.H., Wang, Q., Gerald, W., Hudis, C.A., Norton, L., Smid, M., Foekens, J.A., and 
Massague, J. (2009). Latent bone metastasis in breast cancer tied to Src-dependent survival 
signals. Cancer Cell 16, 67-78.  
Zhang, S., Hao, J., Xie, F., Hu, X., Liu, C., Tong, J., Zhou, J., Wu, J., and Shao, C. (2011). 
Downregulation of miR-132 by promoter methylation contributes to pancreatic cancer 
development. Carcinogenesis 32, 1183-1189. 
 
Zhang, J., Ouyang, W., Li, J., Zhang, D., Yu, Y., Wang, Y., Li, X., and Huang, C. (2012). 
Suberoylanilide hydroxamic acid (SAHA) inhibits EGF-induced cell transformation via reduction 




Zhao, Y., Tan, J., Zhuang, L., Jiang, X., Liu, E.T., and Yu, Q. (2005). Inhibitors of histone 
deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of 
proapoptotic protein Bim. Proc. Natl. Acad. Sci. U.S.A. 102, 16090-16095. 
 
Zhao, J.J., Lin, J., Yang, H., Kong, W., He, L., Ma, X., Coppola, D., and Cheng, J.Q. (2008).  
MicroRNA-221/222 negatively regulates estrogen receptor α and is associated with tamoxifen 
resistance in breast cancer. J. Biol. Chem. 283, 31079-31086. 
 
Zhou, Q., Atadja, P., and Davidson, N.E. (2014). Histone deacetylase inhibitor LBH589 
reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA 
hypermethylation. Cancer Biol. Ther. 6, 64-69. 
Zilli, M., Grassadonia, A., Tinari, N., Di Giacobbe, A., Gildetti, S., Giampietro, J., Natoli, C. and 
Iacobelli, S. (2009). Molecular mechanisms of endocrine resistance and their implication in the 
therapy of breast cancer. Biochim. Biophys. Acta 1795, 62-81.  
Zou, H., Wu, Y., Navre, M., and Sang, B.C. (2006). Characterization of the two catalytic 
domains in histone deacetylase 6. Biochem. Biophys. Res. Commun. 341, 45-50. 
Zhu, S., Si, M.L., Wu, H., and Mo, Y.Y. (2007). MicroRNA-21 targets the tumor suppressor 
gene tropomyosin 1 (TPM1). J. Biol. Chem. 282, 14328-14336. 
Zupkovitz, G., Grausenburger, R., Brunmeir, R., Senese, S., Tischler, J., Jurkin, J., Rembold, M., 
Meunier, D., Egger, G., Lagger, S., et al. (2010). The cyclin-dependent kinase inhibitor p21 is a 
crucial target for histone deacetylase 1 as a regulator of cellular proliferation. Mol. Cell. Biol. 30, 
1171-1181.  
 
